

Mass General Brigham Incorporated and Affiliates

**Report on Federal Awards in Accordance with the
OMB Uniform Guidance**

September 30, 2023

EIN 04-3230035

Mass General Brigham Incorporated and Affiliates

Index

September 30, 2023 and 2022

	Page(s)
Part I – Financial Statements	
Report of Independent Auditors	1–3
Mass General Brigham Consolidated Financial Statements and Notes to Consolidated Financial Statements	4–47
Schedule of Expenditures of Federal Awards and Notes to Schedule of Expenditures of Federal Awards.....	48–92
Part II – Reports on Compliance and Internal Controls	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards	94–95
Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance with the OMB Uniform Guidance.....	96–98
Part III – Federal Award Findings and Questioned Costs	
Schedule of Findings and Questioned Costs	100
Summary Schedule of Prior Audit Findings and Status	101



Report of Independent Auditors

To the Board of Directors of
Mass General Brigham Incorporated

Opinion

We have audited the accompanying consolidated financial statements of Mass General Brigham Incorporated (the "Company") and its affiliates, which comprise the consolidated balance sheets as of September 30, 2023 and 2022, and the related consolidated statements of operations, of changes in net assets and of cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Company and its affiliates as of September 30, 2023 and 2022 and the results of its operations, changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Company and its affiliates and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company and its affiliates' ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute



assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS and *Government Auditing Standards*, will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with US GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company and its affiliates' internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company and its affiliates' ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended September 30, 2023 is presented for purposes of additional analysis as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional



procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated December 8, 2023 on our consideration of the Company's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended September 30, 2023. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Company's internal control over financial reporting and compliance.

PricewaterhouseCoopers LLP

Boston, Massachusetts
December 8, 2023

Mass General Brigham Incorporated and Affiliates
Consolidated Balance Sheets
September 30, 2023 and 2022

<i>(in thousands of dollars)</i>	2023	2022
Assets		
Current assets		
Cash and equivalents	\$ 279,459	\$ 193,919
Investments	3,397,634	2,390,217
Current portion of investments limited as to use	3,505,987	4,144,531
Patient accounts receivable, net	1,638,306	1,438,412
Research grants receivable, net	228,117	215,462
Other current assets	946,875	722,486
Total current assets	<u>9,996,378</u>	<u>9,105,027</u>
Investments limited as to use, less current portion	5,440,702	4,961,378
Long-term investments	2,713,547	2,582,271
Property and equipment, net	6,777,363	6,442,260
Right-of-use operating lease assets	1,024,336	1,135,787
Other assets	2,722,977	1,981,608
Total assets	<u>\$ 28,675,303</u>	<u>\$ 26,208,331</u>
Liabilities and Net Assets		
Current liabilities		
Current portion of long-term obligations	\$ 481,130	\$ 519,354
Accounts payable and accrued expenses	1,305,876	1,183,843
Accrued medical claims and related expenses	192,435	119,237
Accrued employee compensation and benefits	1,150,128	1,203,729
Current portion of operating lease obligations	207,671	206,350
Unexpended funds on research grants	377,730	355,934
Total current liabilities	<u>3,714,970</u>	<u>3,588,447</u>
Accrued professional liability	576,038	570,862
Accrued employee benefits	718,087	633,894
Interest rate swaps liability	67,075	156,705
Accrued other	331,166	274,931
Operating lease obligations, less current portion	696,740	801,038
Long-term obligations, less current portion	5,469,626	5,557,177
Total liabilities	<u>11,573,702</u>	<u>11,583,054</u>
Commitments and contingencies		
Net assets		
Without donor restrictions	13,362,445	11,577,802
With donor restrictions	3,739,156	3,047,475
Total net assets	<u>17,101,601</u>	<u>14,625,277</u>
Total liabilities and net assets	<u>\$ 28,675,303</u>	<u>\$ 26,208,331</u>

The accompanying notes are an integral part of these financial statements.

Mass General Brigham Incorporated and Affiliates
Consolidated Statements of Operations
Years Ended September 30, 2023 and 2022

<i>(in thousands of dollars)</i>	2023	2022
Operating revenues		
Net patient service revenue	\$ 12,792,586	\$ 11,869,451
Premium revenue	1,518,556	930,753
Direct academic and research revenue	2,066,518	1,937,738
Indirect academic and research revenue	641,492	569,624
Other revenue	1,807,885	1,402,801
Total operating revenues	<u>18,827,037</u>	<u>16,710,367</u>
Operating expenses		
Employee compensation and benefit expenses	9,659,280	9,144,470
Supplies and other expenses	4,976,156	4,402,993
Medical claims and related expenses	1,086,589	722,212
Direct academic and research expenses	2,066,518	1,937,738
Depreciation and amortization expenses	774,563	769,783
Interest expense	168,765	164,833
Total operating expenses	<u>18,731,871</u>	<u>17,142,029</u>
Income (loss) from operations	<u>95,166</u>	<u>(431,662)</u>
Nonoperating gains (loss)		
Income (loss) from investments	962,128	(2,271,500)
Change in fair value of interest rate swaps	130,393	330,530
Other nonoperating expenses	(115,822)	(109,971)
Net academic and research gifts (expenses)	(68,062)	23,976
Nonservice related pension income	233,827	201,000
Total nonoperating gains (loss), net	<u>1,142,464</u>	<u>(1,825,965)</u>
Excess (deficit) of revenues over expenses	1,237,630	(2,257,627)
Other changes in net assets		
Funds utilized for property and equipment	54,110	44,340
Change in funded status of defined benefit plans	476,211	965,424
Other changes in net assets	16,692	19,337
Increase (decrease) in net assets without donor restrictions	<u>\$ 1,784,643</u>	<u>\$ (1,228,526)</u>

The accompanying notes are an integral part of these financial statements.

Mass General Brigham Incorporated and Affiliates
Consolidated Statements of Changes in Net Assets
Years Ended September 30, 2023 and 2022

<i>(in thousands of dollars)</i>	Without Donor Restrictions	With Donor Restrictions	Total
Net assets at September 30, 2021	<u>\$ 12,806,328</u>	<u>\$ 3,369,175</u>	<u>\$ 16,175,503</u>
Increases (decreases)			
Loss from operations	(431,662)	-	(431,662)
Loss from investments	(2,271,500)	(517,571)	(2,789,071)
Change in fair value of interest rate swaps	330,530	-	330,530
Other nonoperating (expenses) income	(109,971)	218,180	108,209
Academic and research gifts, net of expenses	23,976	-	23,976
Nonservice related pension income	201,000	-	201,000
Funds utilized for property and equipment	44,340	(14,136)	30,204
Change in funded status of defined benefit plans	965,424	-	965,424
Other changes in net assets	19,337	(8,173)	11,164
Change in net assets	<u>(1,228,526)</u>	<u>(321,700)</u>	<u>(1,550,226)</u>
Net assets at September 30, 2022	<u>11,577,802</u>	<u>3,047,475</u>	<u>14,625,277</u>
Increases (decreases)			
Income from operations	95,166	-	95,166
Income from investments	962,128	127,629	1,089,757
Change in fair value of interest rate swaps	130,393	-	130,393
Other nonoperating (expenses) income	(115,822)	589,157	473,335
Net academic and research gifts (expenses)	(68,062)	-	(68,062)
Nonservice related pension income	233,827	-	233,827
Funds utilized for property and equipment	54,110	(28,088)	26,022
Change in funded status of defined benefit plans	476,211	-	476,211
Other changes in net assets	16,692	2,983	19,675
Change in net assets	<u>1,784,643</u>	<u>691,681</u>	<u>2,476,324</u>
Net assets at September 30, 2023	<u>\$ 13,362,445</u>	<u>\$ 3,739,156</u>	<u>\$ 17,101,601</u>

The accompanying notes are an integral part of these financial statements.

Mass General Brigham Incorporated and Affiliates
Consolidated Statements of Cash Flows
Years Ended September 30, 2023 and 2022

<i>(in thousands of dollars)</i>	2023	2022
Cash flows from operating activities		
Change in net assets	\$ 2,476,324	\$ (1,550,226)
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities		
Change in funded status of defined benefit plans	(476,211)	(965,424)
Change in fair value of interest rate swaps	(130,393)	(330,530)
Depreciation and amortization	774,563	769,783
Amortization of bond discount, premium and issuance costs	(10,646)	(11,923)
Gain on disposal of property	(13,086)	(222)
Change in right-of-use operating lease assets	174,612	165,958
Net realized and unrealized change in investments	(1,266,094)	2,580,370
Restricted contributions and investment income	(239,437)	(220,648)
Increases (decreases) in cash resulting from a change in		
Patient accounts receivable	(199,894)	(106,008)
Other assets	(466,316)	6,492
Accounts payable and other accrued expenses	241,617	(202,328)
Accrued medical claims and related expenses	73,198	31,948
Operating lease obligations	(166,138)	(169,438)
Settlements with third-party payers	(13,271)	(45,553)
Medicare accelerated payments	-	(724,469)
Net cash provided by (used in) operating activities	<u>758,828</u>	<u>(772,218)</u>
Cash flows from investing activities		
Purchases of property and equipment	(1,098,913)	(863,717)
Proceeds from sale of property	14,696	436
Purchase of investments	(2,273,363)	(2,281,901)
Proceeds from sales of investments	<u>2,550,984</u>	<u>3,809,183</u>
Net cash (used for) provided by investing activities	<u>(806,596)</u>	<u>664,001</u>
Cash flows from financing activities		
Borrowings under taxable commercial paper	169,885	-
Repayments of borrowings under taxable commercial paper	(50,015)	-
Payments on long-term obligations	(106,306)	(104,771)
Proceeds from long-term obligations	100,230	59,235
Deposits into refunding trusts	(219,923)	(50,235)
Restricted contributions and investment income	<u>239,437</u>	<u>220,648</u>
Net cash provided by financing activities	<u>133,308</u>	<u>124,877</u>
Net increase in cash and equivalents	85,540	16,660
Cash and equivalents		
Beginning of year	<u>193,919</u>	<u>177,259</u>
End of year	<u>\$ 279,459</u>	<u>\$ 193,919</u>
Noncash purchases of property and equipment in accounts payable and accrued expenses	<u>\$ 129,552</u>	<u>\$ 119,196</u>

The accompanying notes are an integral part of these financial statements.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2023 and 2022

(in thousands of dollars)

1. Organization and Community Benefit Commitments

Mass General Brigham Incorporated (the Company) is the parent organization and sole corporate member of numerous organizations whose financial condition and operations are described in these consolidated financial statements. The terms Mass General Brigham, We, Our or Us as used herein, unless otherwise stated or indicated by context, refer collectively to the Company and its affiliated organizations.

Mass General Brigham operates academic medical centers, community acute care hospitals, inpatient and outpatient mental health services facilities, urgent care centers, facilities that provide rehabilitation medicine and long-term care services, physician organizations, home health services, nursing homes and a graduate level program for health professions. Our mission is to provide world class health care services to the local communities in which we operate as well as to patients across the United States and the world. In addition, we are a nonuniversity-based nonprofit private medical research enterprise and a principal teaching affiliate of the medical and dental schools of Harvard University. Our licensed, not-for-profit managed care organization (Mass General Brigham Health Plan, Inc.) and licensed, for-profit insurance company (Mass General Brigham Health Insurance Company) (collectively referred to as MGB Health Plan) provide health insurance products and administrative services to the Massachusetts Medicaid program (MassHealth), ConnectorCare (a state subsidized program for adults who meet income and immigration guidelines) and commercial populations.

Community Health

Through our community health programs we work with community residents and community-based organizations to make measurable, sustainable improvements in the health status of underserved populations with focus on the leading causes of death and premature mortality. In addition, we support and implement initiatives that address social risk factors that contribute to health inequities. Our hospitals and licensed health centers partner with the community to help low-income, vulnerable families overcome barriers to accessing care.

Charity Care

We provide charity care to all emergent patients regardless of their ability to pay. The cost of and reimbursement for providing that care, as reflected in the consolidated statements of operations, is summarized below.

State Programs

Massachusetts

Acute care hospitals in The Commonwealth of Massachusetts (the Commonwealth or Massachusetts) are partially reimbursed for charity care services through the statewide Health Safety Net Trust Fund (HSN). A portion of the funding for the HSN is paid by an assessment on acute care hospitals' charges for private sector payers. The statewide assessment was \$165,313 and \$165,308 in 2023 and 2022, respectively, and the assessment expense on our acute care hospitals was \$57,819 and \$61,696 in 2023 and 2022, respectively.

Acute care hospitals are reimbursed for charity care based on claims for eligible patients and services that are submitted to and adjudicated by the HSN. Payments are based on Medicare rates and payment policies. The Commonwealth reported HSN was under-funded by approximately \$115,828 and \$68,030 as of September 30, 2023 and 2022, respectively. This shortfall is allocated to acute care hospitals based on their share of total statewide patient care

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2023 and 2022

(in thousands of dollars)

costs. We have estimated our share being approximately \$48,547 and \$27,938 as of September 30, 2023 and 2022, respectively. Each hospital's share of the overall state shortfall cannot exceed its total charity care reimbursement. Hospitals with a high proportion of charity care and government funding receive more favorable reimbursement, including limiting their shortfall allocation to no more than 15% of their payments for charity care. In aggregate, our acute care hospitals received charity care funding covering 41% and 53% of the estimated cost of charity care provided in 2023 and 2022, respectively.

The Commonwealth levies an additional assessment on Massachusetts acute care hospitals that is redistributed back to hospitals based on provisions within the 1115 MassHealth Demonstration. A new five-year waiver period began effective October 1, 2022. The value of both the assessment and the redistribution are higher than the prior waiver period. The total assessment was \$709,602 and \$257,500 in 2023 and 2022, respectively, and our assessment expense was \$197,473 and \$95,527 in 2023 and 2022, respectively. The total amount redistributed to hospitals was \$1,387,500 and \$265,000 in 2023 and 2022, respectively, of which we recognized \$188,084 and \$55,338 in 2023 and 2022, respectively.

There is an assessment for our post-acute hospitals which totaled \$5,756 and \$6,045 in 2023 and 2022, respectively.

New Hampshire

The State of New Hampshire (New Hampshire) imposes a Medicaid Enhancement Tax (MET) on hospital net patient service revenue. For both of New Hampshire's fiscal years ended June 30, 2023 and 2022, the MET imposed was 5.4%. We incurred \$25,724 and \$27,046 of MET in 2023 and 2022, respectively.

New Hampshire acute care hospitals receive disproportionate share payments based on a portion of their charity care relative to other acute care hospitals. We received \$14,992 and \$14,634 in 2023 and 2022, respectively.

Medicaid

Medicaid is a health insurance program jointly funded by the states and the federal government. Each state administers its own program and sets rules for eligibility, benefits and provider payments within broad federal guidelines and in some cases, including the Commonwealth and New Hampshire, within a Waiver Agreement between each state and the federal government. The program provides health care coverage to low-income adults and children. Eligibility is determined by a variety of factors which include income relative to the federal poverty line, age, immigrant status and assets.

Medicaid payments to our providers do not cover the full cost of services provided to Medicaid patients. In aggregate, reimbursement from Medicaid covered approximately 70% and 61% of the estimated cost of services provided in 2023 and 2022, respectively.

On April 1, 2023, Mass General Brigham Health Plan, Inc. entered into an Accountable Care Organization (ACO) contract with the Executive Office of Health and Human Services of the Commonwealth (EOHHS) covering over 150,000 MassHealth members whose providers participate in the Mass General Brigham ACO.

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

Federal Program
Medicare

Medicare is a federally sponsored health insurance program for people age 65 or older, under age 65 with certain disabilities and any age with End-Stage Renal Disease. Medicare's payments historically have not kept pace with increases in the cost of care provided at many hospitals. Compounding this shortfall in payments is the continued shift of care from higher paying inpatient services to lower paying outpatient services.

Consequently, Medicare payments to our providers do not cover the full cost of services provided. In aggregate, reimbursement from Medicare covered approximately 68% and 69% of the estimated cost of services provided in 2023 and 2022, respectively.

Mass General Brigham Health Plan, Inc. has been authorized by the Centers for Medicare & Medicaid Services to offer Medicare Advantage products to its eligible members effective January 1, 2023.

Summary

For charity care, Medicaid and Medicare, the estimated cost of services provided is either obtained directly from a costing system or based on an entity specific ratio of cost to gross charges. In the latter case, cost is derived by applying this ratio to gross charges associated with providing care to charity care, Medicaid and Medicare patients. The following summarizes, by program, the cost of services provided, net reimbursement and cost of services in excess of reimbursement for each year:

	Years Ended September 30,	
	2023	2022
Cost of services provided		
Charity care	\$ 113,167	\$ 103,420
Medicaid	1,777,454	1,700,493
Medicare	<u>5,585,749</u>	<u>5,057,826</u>
	<u>\$ 7,476,370</u>	<u>\$ 6,861,739</u>
Net reimbursement		
Charity care	\$ 38,035	\$ 44,683
Medicaid	1,250,916	1,029,883
Medicare	<u>3,790,457</u>	<u>3,502,359</u>
	<u>\$ 5,079,408</u>	<u>\$ 4,576,925</u>
Cost of services in excess of reimbursement		
Charity care	\$ 75,132	\$ 58,737
Medicaid	526,538	670,610
Medicare	<u>1,795,292</u>	<u>1,555,467</u>
	<u>\$ 2,396,962</u>	<u>\$ 2,284,814</u>

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2023 and 2022

(in thousands of dollars)

In addition to charity care and inadequate funding from the Medicaid and Medicare programs, there are significant losses related to self-pay patients who fail to make payment for services rendered or insured patients who fail to remit co-payments and deductibles as required under the applicable health insurance arrangement. The estimated cost of providing these services was approximately \$82,938 and \$73,165 for 2023 and 2022, respectively.

2. Summary of Significant Accounting Policies

Basis of Accounting

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting and include the accounts of the Company and its affiliates. Interaffiliate accounts and transactions have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates are made in the areas of patient accounts receivable, research grants receivable, investments, receivables and accrual for settlements with third-party payers, accrued medical claims and related expenses, accrued employee compensation and benefits, accrued professional liability, interest rate swaps liability and accrued other.

Income Taxes

The Company and substantially all of its affiliates are tax-exempt organizations under Sections 501(c)(3) or 501(c)(4) of the Internal Revenue Code (IRC) or are disregarded entities for tax purposes and therefore are exempt from federal and state income tax except on unrelated business taxable income. No provision for income taxes related to these tax-exempt entities has been made as the effect of any unrelated business income tax is not material to the accompanying consolidated financial statements.

Fair Value of Financial Instruments

The fair value of financial instruments approximates the carrying amount reported in the consolidated balance sheets for cash and equivalents, investments and investments limited as to use, patient accounts receivable, research grants receivable, accounts payable and accrued expenses and interest rate swaps liability.

Cash and Equivalents

Cash and equivalents represent cash, registered money market funds and highly liquid debt instruments with a maturity at the date of purchase of three months or less. Our cash and equivalents are maintained with several national banks, and cash deposits typically exceed federal insurance limits. Our policy is to monitor these banks' financial strength on an ongoing basis, and no losses have been experienced to date.

Investments

Investments in equity securities with readily determinable fair values, debt securities and alternative investments are measured at fair value. Alternative investments, consisting of various hedge funds, private equity funds, private debt funds, other private partnerships and restricted securities

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2023 and 2022

(in thousands of dollars)

of public companies that are not traded on a national securities exchange, are valued based on amounts reported by the fund manager and evaluated by management. Investments in securities sold short or traded on a national securities exchange are valued based on quoted market prices.

Income (loss) from investments (including realized gains and losses, unrealized change in value of investments, interest, dividends and endowment income distributions) is included in excess (deficit) of revenues over expenses unless the income or loss is restricted by donor or law. Income (loss) from investments is reported net of investment-related expenses.

Each year as part of our endowment spending policy, we establish a fixed distribution rate for spending. Distributions will come from either income and/or net accumulated appreciation. Effective July 1, 2023 we changed the endowment spending policy and adopted the Tobin Distribution Rule. The Tobin Distribution rule sets the annual distribution through a quantitative formula that has a stability term (a percentage of the prior year's spending, adjusted for inflation) and a market term (a percentage of the long-term sustainable rate of distribution times the market value of the endowment).

Investments Limited as to Use

Investments limited as to use primarily include assets whose use is contractually limited by external parties as well as assets set aside by the boards (or management) for identified purposes and over which the boards (or management) retain control such that the boards (or management) may, at their discretion, subsequently use such assets for other purposes. Certain investments corresponding to deferred compensation are accounted for such that all income and appreciation (depreciation) is recorded as a direct addition (reduction) to the asset and corresponding liability.

Derivative Instruments

Derivatives are recognized on the balance sheets at fair value with changes in the fair value recorded in excess (deficit) of revenues over expenses.

Patient Accounts Receivable

The payments received for healthcare services rendered from federal and state agencies (under the Medicare and Medicaid programs), managed care payers, commercial insurance companies and patients are subject to explicit and implicit discounts. These discounts are based on contractual agreements, discount policies and management's assessment of historical experiences and are reflected in the period of service.

Research Grants Receivable

Mass General Brigham receives direct and pass through research funding from the National Institutes for Health and other federal agencies, industry, corporate, foundation, nonprofits and other sponsors. Research grants receivable include amounts due from these sponsors of externally funded research. These amounts have been billed or are billable to the sponsor, or in limited circumstances, represent accelerated spending in anticipation of future funding. Research grants receivable are recognized at net realizable value.

As of September 30, 2023, and 2022, we have approximately \$4,408,631 and \$4,239,039, respectively, of conditional research grants for future research to be performed. The timing and amounts of funds received under such grants are subject to continued government funding and may change over time.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2023 and 2022

(in thousands of dollars)

Other Current Assets

Other current assets include prepaid expenses, inventory, nonpatient receivables, current portion of receivable for settlements with third-party payers, current portion of pledges receivable and premiums receivable. Inventory (primarily supplies and pharmaceuticals) is accounted for on a first-in, first-out method basis and is recorded at the lower of average weighted cost or net realizable value.

Property and Equipment

Property and equipment is reported on the basis of cost less accumulated depreciation. Donated items are recorded at fair value at the date of contribution. All research grants received for capital are recorded in the year of expenditure as a change in net assets without donor restrictions. Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. Depreciation of property and equipment is calculated by use of the straight-line method at rates intended to depreciate the cost of assets over their estimated useful lives, which generally range from three to fifty years. Interest costs incurred on borrowed funds during the period of construction of capital assets are capitalized, net of any interest earned, as a component of the cost of acquiring those assets.

Asset Retirement Obligations

Asset retirement obligations, reported in accrued other, are legal obligations associated with the retirement of long-lived assets. These liabilities are initially recorded at fair value and the related asset retirement costs are capitalized by increasing the carrying amount of the related assets by the same amount as the liability. Asset retirement costs are subsequently depreciated over the useful lives of the related assets. Any changes to the liability due either to the passage of time, better information or the settlement of an obligation are reflected in the current period.

Other Assets

Other assets consist of long-term receivables, intangible assets, malpractice insurance receivables, receivable for settlements with third-party payers, investments in healthcare related limited partnerships and long-term pledges and contributions receivable. The carrying value of other assets is evaluated for impairment if the facts and circumstances suggest that the carrying value may not be recoverable.

Compensated Absences

In accordance with formal policies concerning vacation and other compensated absences, accruals of \$422,745 and \$404,123 were recorded as of September 30, 2023 and 2022, respectively.

Unexpended Funds on Research Grants

Research grants received in advance of corresponding grant expenditures are accounted for as a direct addition to investments limited as to use and unexpended funds on research grants.

Self-Insurance Reserves

We are generally self-insured for employee healthcare, disability, workers' compensation and certain other employee benefits. These costs are accounted for on an accrual basis to include estimates of future payments for claims incurred prior to year-end and are included in accrued employee compensation and benefits and long-term accrued employee benefits.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2023 and 2022

(in thousands of dollars)

Net Assets

Net assets with donor restrictions include (a) the historical dollar amounts of contributions and the income and gains on such contributions which are required by donors to be retained and (b) contributions and the income and gains on these contributions which can be expended but for which restrictions have not yet been met. Such restrictions include purpose restrictions where donors have specified the purpose for which the net assets are to be spent, or time restrictions imposed by donors or implied by the nature of the contribution (capital projects, pledges to be paid in the future and life income funds) or by interpretations of law (gains available for appropriation but not appropriated in the current period). All remaining net assets are considered to be without donor restrictions.

Realized gains and losses are classified as net assets without donor restrictions unless they are restricted by the donor or law. Realized gains and net unrealized appreciation on contributions with donor restrictions are classified as net assets with donor restrictions until appropriated for spending in accordance with policies established by Mass General Brigham and applicable provisions of the Uniform Prudent Management of Institutional Funds Acts (UPMIFA). Net losses on donor endowment funds with donor restrictions are classified as a reduction to net assets with donor restrictions.

Contributed Securities

Our policy is to sell securities contributed by donors upon receipt, unless prevented from doing so by donor request. For the years ended September 30, 2023 and 2022, contributed securities of \$58,257 and \$54,254, respectively, were received and liquidated. Donors restricted \$25,545 and \$27,628 of the proceeds received from the sale of these contributed securities for long-term purpose for the years ended September 30, 2023 and 2022, respectively.

Statement of Operations

Activities deemed by management to be ongoing, major and central to the provision of healthcare services, teaching, research activities and health insurance are reported as operating revenues and expenses. Other activities are deemed to be nonoperating and include contributions without donor restrictions (net of fundraising expenses), external community benefit program support, net change in unexpended academic and research contributions, change in fair value of interest rate swaps, substantially all income (loss) from investments, interest on advanced borrowings and nonservice related pension income. Academic and research contributions largely consist of donor contributions (and the related investment income including realized gains and losses) designated to support the clinical, teaching or research efforts of a physician or department as directed by the donor. These contributions are reported as being without donor restrictions, net of related support expenses, when donor restrictions are of a general nature that are inherent in the normal activities of the organization.

The consolidated statements of operations include excess (deficit) of revenues over expenses. Changes in net assets without donor restrictions, which are excluded from excess (deficit) of revenues over expenses, include contributions of long-lived assets (including assets acquired using contributions which by donor restriction were to be used for acquisition of such assets) and change in funded status of defined benefit plans.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2023 and 2022

(in thousands of dollars)

Revenues

To determine the appropriate revenue recognition policy, we first assess whether the transaction is an exchange or nonexchange transaction in accordance with accounting guidance. In general, an exchange transaction consists of an exchange of goods and/or services for commensurate value. Transactions that consist of transferring goods and/or services without receiving commensurate value in return are considered nonexchange transactions.

For exchange transactions, revenue is recognized as goods and/or services are provided and is based on the amount expected to be received in exchange for those goods and/or services. Revenue recognized as exchange transactions include net patient service revenue, premium revenue and other revenue.

Nonexchange transactions include contributions and grants for which the service provider does not receive commensurate value in return for the funding.

Contributions

Contributions are generally reported as other nonoperating gains in the consolidated statements of operations. Unconditional promises to give cash and other assets are reported at fair value at the date the promise is received. Conditional promises to give are recognized when the conditions are substantially met and totaled \$371,648 and \$263,420 as of September 30, 2023 and 2022, respectively. Contributions are reported as support with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. Contributions with donor restrictions whose restrictions are met within the same year as received are reported as contributions without donor restrictions in the consolidated statements of operations.

Contributions of long-lived assets with explicit restrictions that specify use of assets and contributions of cash or other assets that must be used to acquire long-lived assets are reported as additions to net assets with donor restrictions if the assets are not placed in service during the year.

Grants

Grants and contracts normally provide for the recovery of direct and indirect costs, subject to audit. Revenue associated with direct and indirect costs is recognized as direct costs are incurred. The recovery of indirect costs is based on predetermined rates for U.S. Government grants and contracts and negotiated rates for other grants and contracts.

Medical Claims and Related Expenses

MGB Health Plan contracts with various hospitals, community health centers, primary care and specialty physician practices and other health care providers for the delivery of services to its members and compensates these providers on a capitated, fee-for-service, per diem or diagnosis-related group basis.

The cost of contracted health care services is accrued in the period in which services are provided and include certain estimated amounts. The estimated liability for medical claims and related expenses is actuarially determined based on analysis of historical claims-paid experience, modified for changes in enrollment, inflation and benefit coverage. The liability for medical claims and related expenses represents the anticipated cost of claims incurred but unpaid at the balance sheet date. Estimates for claims expense may be more or less than the amounts ultimately paid when claims are settled. Such changes in estimates are reflected in the current period in the consolidated statements of operations.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2023 and 2022

(in thousands of dollars)

In the normal course of business, overpayments are recouped through reductions in future payments made to hospitals and other providers. Such overpayments are the result of, among other things, coordination of benefits and provider claim audits. For the years ended September 30, 2023 and 2022, we recorded a reduction in medical claims expense of \$53,299 and \$37,915, respectively, for such overpayments. As of September 30, 2023 and 2022, respectively, approximately \$2,346 and \$1,812 are recorded as receivables related to such overpayments.

Reinsurance

Reinsurance premiums are reported as reductions of premium revenue in medical claims and related expenses and reinsurance recoveries are reported as reductions in medical claims and related expenses.

Settlements

MGB Health Plan contracts with certain providers at negotiated rates based on historical and anticipated experience. These methods of reimbursement result in settlements based on actual versus anticipated experience which could result in payments due from (to) these providers. Settlements receivable of \$3,647 and \$4,047 were recorded in other current assets as of September 30, 2023 and 2022, respectively. Settlements payable of \$4,633 and \$1,834 were recorded in accrued medical claims and related expenses as of September 30, 2023 and 2022, respectively. The settlements are intended to include both reported and unreported incurred claims as of September 30, 2023 and 2022.

In 2014, the Affordable Care Act introduced new settlements related to a risk adjustment program, a risk corridor program and a reinsurance program designed to mitigate the transitional impact on insurers for new members. The risk corridor program and reinsurance program ended on December 31, 2016 in accordance with the provision of the Affordable Care Act. Our estimated net receivable due from the federal government for the risk adjustment program was \$73,299 and \$73,868 as of September 30, 2023 and 2022, respectively. Similar to the federal program, EOHHS has a risk corridor program, and our estimated net payable due to EOHHS was \$95,619 and \$72,462 as of September 30, 2023 and 2022, respectively.

Premium Deficiency Reserves

Premium deficiency reserves are assessed and recognized on a product line basis based upon expected premium revenue, medical expense and administrative expense levels, and remaining contractual obligations using historical experience. As of September 30, 2023 and 2022, a premium deficiency reserve of \$24,071 and \$21,120, respectively, is included in accrued medical claims and related expenses in the accompanying consolidated financial statements.

Claims Adjustment Expenses

Claims adjustment expenses (CAE) are those costs expected to be incurred in connection with the adjustment and recording of health claims. We have recorded an estimate of unpaid CAE associated with incurred but unpaid claims, which is included in medical claims and related expenses in the accompanying consolidated statements of operations. Management believes the amount of the liability for unpaid CAE as of September 30, 2023, is adequate to cover the cost for the adjustment and recording of unpaid claims; however, actual expenses may differ from those established estimates. Adjustments to the estimates for unpaid CAE are reflected in operating results in the period in which the change in estimate is identified.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2023 and 2022

(in thousands of dollars)

3. Pandemic

On March 11, 2020, the World Health Organization designated COVID-19 as a global pandemic resulting in an extraordinary impact to Mass General Brigham. During certain periods since 2020, the COVID-19 pandemic has continued to impact patient activity and operating expenses. In response to COVID-19, various types of economic support were enacted by federal, state and local authorities to mitigate the financial impact, with the most significant impacts to Mass General Brigham in fiscal 2023 and 2022 summarized below.

Deferred Payment of Employer Payroll Taxes

The Coronavirus Aid Relief and Economic Security (CARES) Act allowed for deferred payments of only the employer share of payroll taxes through December 31, 2020 and required payment of 50% of these deferred taxes by December 31, 2022 and 50% by December 31, 2021. We made repayments of \$121,604 and \$117,862, during 2023 and 2022, respectively. As of September 30, 2023, all amounts have been repaid.

Provider Relief Funds (PRF)

During 2020 and 2021, we received PRF that were used to prevent, prepare for and respond to COVID-19. Based on our interpretation of available information as of September 30, 2023 and 2022, we have deferred \$86,487 of PRF we received.

Federal Emergency Management Agency (FEMA)

During 2023, we submitted applications to FEMA for the reimbursement of COVID-19 expenses and recognized grant revenue totaling \$99,372 as other operating revenue in the consolidated statement of operations. As of September 30, 2023 we have deferred \$35,092 of FEMA payments received.

4. Operating Revenues

Net Patient Service Revenue

Mass General Brigham's providers maintain agreements with The Centers for Medicare and Medicaid Services under the Medicare program, the Commonwealth under the Medicaid program and various managed care payers that govern payment for services rendered to patients covered by these agreements. The agreements generally provide for per case or per diem rates or payments based on discounted charges for inpatient care and discounted charges or fee schedules for outpatient care. Certain contracts also provide for payments that are contingent upon meeting agreed upon quality and efficiency measures.

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

We recognize net patient service revenue for services provided to patients who have third-party payer coverage based on contractual rates for the services rendered. For uninsured patients that do not qualify for charity care, we recognize revenue based on our standard rates (subject to discounts) for services provided. Based on our historical experience, a significant portion of uninsured patients are unable or fail to pay for the services provided. Consequently, we have provided implicit discounts to uninsured patients. These discounts represent the difference between amounts billed to patients and amounts expected to be collected based on historical experience. The following summarizes net patient service revenue, net of contractual adjustments and discounts by significant payer:

	Years Ended September 30,			
	2023		2022	
Net patient service revenue (net of contractual adjustments and discounts)				
Medicare	\$ 2,822,694	22.1 %	\$ 2,677,395	22.6 %
Medicare managed care	967,763	7.6 %	824,964	7.0 %
Medicaid	689,718	5.4 %	730,116	6.2 %
Medicaid managed care	561,198	4.4 %	299,767	2.5 %
Massachusetts managed care organizations	4,569,756	35.7 %	4,306,308	36.3 %
Other commercial	2,729,703	21.3 %	2,493,749	21.0 %
All others	451,754	3.5 %	537,152	4.4 %
Total all payers	<u>\$ 12,792,586</u>	<u>100.0 %</u>	<u>\$ 11,869,451</u>	<u>100.0 %</u>

Net patient service revenue includes estimated retroactive revenue adjustments due to future audits, reviews and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews and investigations. Contracts, laws and regulations governing the Medicare, Medicaid and charity care programs and managed care payer arrangements are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. A portion of the accrual for settlements with third-party payers has been classified as long-term because such amounts, by their nature or by virtue of regulation or legislation, will not be paid within one year.

Third-party payers (accrual) receivable consists of the following:

	Balance Sheet Classification	September 30,	
		2023	2022
Current portion			
Receivable for settlements with third-party payers	Other current assets	\$ 159,813	\$ 136,498
Accrual for settlements with third-party payers	Accounts payable and accrued expenses	(59,584)	(72,765)
		<u>100,229</u>	<u>63,733</u>
Long-term portion			
Receivable for settlements with third-party payers	Other assets	6,700	26,567
Accrual for settlements with third-party payers	Accrued other	(28,526)	(25,168)
		<u>(21,826)</u>	<u>1,399</u>
Third-party payers receivable (accrual)		<u>\$ 78,403</u>	<u>\$ 65,132</u>

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

We recognize changes in third-party payer settlements and other estimates in the year of the change in estimate. For the years ended September 30, 2023 and 2022, adjustments to prior year estimates resulted in an increase to net patient service revenue of \$47,842 and \$13,177, respectively. Subsequent changes to estimated discounts are generally recorded as adjustments to net patient service revenue in the period of change.

We provide either full or partial charity care to patients who cannot afford to pay for their medical services based on income and family size. Charity care is generally available to qualifying patients for medically necessary services. We report certain bad debts related to emergency services as charity care. As there is no expectation of collection, there is no net patient service revenue recorded related to charity care.

Premium Revenue

Premiums are due monthly and are recorded as earned during the period in which members are eligible to receive services. Premiums received prior to the first day of the coverage period are recorded as unearned premiums in accounts payable and accrued expenses.

Academic and Research Revenue

Academic and research revenue is recognized as either an exchange or nonexchange transaction, depending on the contract type. The following table sets forth total academic and research revenue received by funding source:

	Years Ended September 30,			
	2023		2022	
National Institute of Health and other federal agencies	\$ 1,155,306	42.7 %	\$ 1,046,056	41.7 %
Federal subcontracts	260,323	9.6 %	252,503	10.1 %
Industry/corporate	224,821	8.3 %	221,240	8.8 %
Foundations/nonprofits and other sponsors	771,579	28.5 %	697,349	27.8 %
Total research revenue	2,412,029		2,217,148	
Academic revenue	295,981	10.9 %	290,214	11.6 %
Total academic and research revenue	\$ 2,708,010	100.0 %	\$ 2,507,362	100.0 %

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

Other Revenue

Other revenue includes all other operating revenue sources, the most significant being the following:

	Years Ended September 30,	
	2023	2022
Specialty and retail pharmacy operations	\$ 928,501	\$ 652,109
Contract revenue	132,070	111,081
FEMA funding	99,372	-
Parking and office rentals	77,249	71,087
Tuition	62,482	64,885
Outsourced services	58,801	57,082
Blood factor sales	53,308	40,499
Cafeteria sales	36,198	30,644
Contract administrative fees	27,397	32,065
ACO administration fees	24,926	47,135
Consulting services	14,248	14,997
International contracts	10,498	13,415
Intellectual property and royalties	14,916	3,793
Investment income	13,560	12,802
Other	254,359	251,207
Total other revenue	<u>\$ 1,807,885</u>	<u>\$ 1,402,801</u>

5. Liquidity and Availability

Cash and investments are managed centrally under policies developed by the Investment Committee and reviewed by the Finance Committee of the Company's Board of Directors. Wherever possible, funds are commingled and are assigned to one of three investment pools (the Money Market Pool, the Aggregate Bond Pool and the Long-Term Pool, collectively, the Pools) which have been structured to provide a range of investment objectives, risk profiles and rates of return appropriate for our assets. Funds are allocated among the Pools based on expected liquidity needs as determined by multi-year financial plans, restrictions and management judgment.

The tiered time horizon structure of the Pools is designed to meet anticipated and contingent liquidity needs. The following tables set forth the periods within which funds are available to meet liquidity needs and based on redemption provisions with investment managers, the specific Pools from which such funds would be drawn as of:

Investment Pool	September 30, 2023						
	Same Day	1 Week	1 Month	3 Months	1 Year	> 1 Year	Total
Money market	\$ 167,997	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 167,997
Aggregate bond	327,089	2,985	-	-	-	-	330,074
Long-term	364,584	533,078	2,205,916	3,264,619	1,176,742	5,905,179	13,450,118
Total	<u>\$ 859,670</u>	<u>\$ 536,063</u>	<u>\$ 2,205,916</u>	<u>\$ 3,264,619</u>	<u>\$ 1,176,742</u>	<u>\$ 5,905,179</u>	<u>\$ 13,948,189</u>
Cumulative total	<u>\$ 859,670</u>	<u>\$ 1,395,733</u>	<u>\$ 3,601,649</u>	<u>\$ 6,866,268</u>	<u>\$ 8,043,010</u>	<u>\$ 13,948,189</u>	

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

Investment Pool	September 30, 2022						Total
	Same Day	1 Week	1 Month	3 Months	1 Year	> 1 Year	
Money market	\$ 362,668	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 362,668
Aggregate bond	443,584	177,438	-	-	-	-	621,022
Long-term	146,618	1,013,946	1,464,776	2,870,543	907,734	5,803,923	12,207,540
Total	\$ 952,870	\$ 1,191,384	\$ 1,464,776	\$ 2,870,543	\$ 907,734	\$ 5,803,923	\$ 13,191,230
Cumulative total	\$ 952,870	\$ 2,144,254	\$ 3,609,030	\$ 6,479,573	\$ 7,387,307	\$ 13,191,230	

As of September 30, 2023 and 2022, we had cash and equivalents not included in the Pools of \$228,351 and \$129,750, respectively. As of September 30, 2023 and 2022, we had net patient accounts receivable of \$1,638,306 and \$1,438,412, respectively, that would be available for general expenditures within one year of the balance sheet dates.

6. Investments and Investments Limited as to Use

Investments are either invested in the Pools or separately managed. Substantially all affiliates participate in the Pools. Their respective ownership interests are tracked and updated monthly and are accounted for using the fair value method. Income (including realized gains and losses) from the Pools is allocated to each participant on a monthly basis based on its proportionate interest in the Pools.

Oversight of the management of the investable assets, including the Pools and pension assets, is provided by the Investment Committee of the Company's Board of Directors which seeks to achieve incremental returns by manager selection and asset allocation (increasing/decreasing allocations within allowable ranges based on current and projected valuations). The Committee is supported by a professional staff, an outside investment consultant and a pension actuarial consultant.

We utilize a target allocation policy and balance projected returns, correlation and volatility of various asset classes within the overall risk tolerance. Asset allocations are managed based on relative valuations among and within asset classes and the perceived ability of managers to outperform passive benchmarks. Exposure by asset class is the sum of allocation to those managers whose mandates most closely fit the listed asset classes. Asset allocation can and will deviate from target exposures and is regularly monitored for rebalancing.

The Pools invest in a variety of assets which include private partnerships whose assets include equity, fixed income and other investments. The Pools have unfunded commitments as follows:

	September 30,	
	2023	2022
Private equity	\$ 1,702,731	\$ 1,732,382
Private energy	109,042	136,032
Private real estate	49,481	77,402
Timber and agriculture	1,498	1,935
Private alternatives and hedge funds	200,062	345,844
	<u>\$ 2,062,814</u>	<u>\$ 2,293,595</u>

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

The unfunded commitments will be drawn down by the various general partners over the next several years. The maximum annual drawdown is expected to be 3% to 5% of investments and investments limited as to use.

Short-term Investments in Investment Pools

Within the Aggregate Bond Pool and the Long-Term Pool, there are assets that meet the definition of short-term investments. These short-term investments are considered part of the Aggregate Bond Pool and the Long-Term Pool and are not included in cash equivalents on the consolidated balance sheets. Accordingly, transactions within the Aggregate Bond Pool and the Long-Term Pool that result in the purchase of investments or result in proceeds from the sales of investments are excluded from the statement of cash flows purchases of investments and proceeds from the sales of investments. Within the Aggregate Bond Pool, purchases of investments and proceeds from the sales of investments not included in the statement of cash flows were \$100,124 and \$340,979 for the year ended September 30, 2023, and \$159,146 and \$1,536,389 for the year ended September 30, 2022, respectively. Within the Long-Term Pool, purchases of investments and proceeds from the sales of investments not included in the statement of cash flows were \$1,250,769 and \$1,326,573 for the year ended September 30, 2023, and \$1,888,457 and \$1,346,607 for the year ended September 30, 2022, respectively.

Investments limited as to use consist of the following:

	September 30, 2023		September 30, 2022	
	Current Portion	Long-Term Portion	Current Portion	Long-Term Portion
Internally designated funds				
Reserved for capital expenditures	\$ 1,257,712	\$ -	\$ 1,406,275	\$ -
Unexpended academic and research gifts	-	4,363,810	-	3,989,979
Deferred compensation	-	614,318	-	511,439
Other	1,868,784	419,512	2,364,066	420,895
	3,126,496	5,397,640	3,770,341	4,922,313
Externally limited funds				
Unexpended funds on research	377,730	-	355,934	-
Contributions held for others	1,531	-	1,405	-
Professional liability trust fund	-	43,062	-	39,065
Held by trustees under debt and other agreements	230	-	16,851	-
	379,491	43,062	374,190	39,065
	\$ 3,505,987	\$ 5,440,702	\$ 4,144,531	\$ 4,961,378

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

Investment activity included in excess (deficit) of revenues over expenses consists of the following:

	Years Ended September 30,	
	2023	2022
Investment income included in operations and reported in other revenue	\$ 13,560	\$ 12,802
Investment income included in nonoperating gains and reported in		
Income from investments		
Investment income and realized gains on investments	42,213	121,756
Unrealized change in investments	919,915	(2,393,256)
Academic and research gifts, net of expenses	<u>172,738</u>	<u>219,505</u>
Total investment activity included in excess (deficit) of revenues over expenses	<u>\$ 1,148,426</u>	<u>\$ (2,039,193)</u>

7. Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (also referred to as exit price). Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. In determining fair value, the use of various valuation approaches, including market, income and cost approaches, is permitted.

Fair Value Hierarchy

A fair value hierarchy has been established based on whether the inputs to valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the reporting entity's assumptions about the inputs market participants would use. The fair value hierarchy requires the reporting entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. In addition, for hierarchy classification purposes, the reporting entity should not look through the form of an investment to the nature of the underlying securities held by an investee.

The hierarchy is described below

- Level 1 Valuations using quoted prices in active markets for identical assets or liabilities. Valuations of these products do not require a significant degree of judgment. Level 1 assets and liabilities primarily include debt and equity securities that are traded in an active exchange market.

- Level 2 Valuations using observable inputs other than Level 1 prices such as quoted prices in active markets for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; broker or dealer quotations; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities primarily include debt securities with quoted prices that are traded less frequently than exchange-traded instruments as well as debt securities and derivative contracts whose value is determined using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

Level 3 Valuations using unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes assets and liabilities whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the reporting entity's assumptions about the assumptions market participants would use as well as those requiring significant management judgment.

Valuation Techniques

Pooled investments, separately invested short-term investments and debt and equity securities are classified within Level 1 or Level 2 of the fair value hierarchy as they are valued using quoted market prices, broker or dealer quotations, or other observable pricing sources. Certain types of investments are classified within Level 3 of the fair value hierarchy because they have little or no market activity and therefore have little or no observable inputs with which to measure fair value.

The valuation of interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities.

The following tables summarize financial assets and liabilities measured at fair value on a recurring basis as of:

	September 30, 2023				Total
	Fair Value Measurements Using				
	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Investments Valued Using NAV as a Practical Expedient	
Assets					
Pooled investments					
Short-term investments	\$ 324,630	\$ -	\$ -	\$ -	\$ 324,630
Separately managed investments	850,001	197,971	-	-	1,047,972
Mutual funds	2,985	-	-	-	2,985
Private partnerships, commingled funds and other	-	-	-	12,572,601	12,572,601
	<u>1,177,616</u>	<u>197,971</u>	<u>-</u>	<u>12,572,601</u>	<u>13,948,188</u>
Separately invested					
Short-term investments	52,846	-	-	-	52,846
Equities	25,033	-	-	-	25,033
Mutual funds	649,706	64,637	-	-	714,343
Private partnerships, commingled funds and other	-	-	-	187,458	187,458
Beneficial interests in perpetual assets	-	-	51,876	-	51,876
	<u>727,585</u>	<u>64,637</u>	<u>51,876</u>	<u>187,458</u>	<u>1,031,556</u>
	<u>\$ 1,905,201</u>	<u>\$ 262,608</u>	<u>\$ 51,876</u>	<u>\$ 12,760,059</u>	<u>\$ 14,979,744</u>
Interest rate swaps					
Assets		\$ 55,987			\$ 55,987
Liabilities		(67,075)			(67,075)
Net interest rate swaps		<u>\$ (11,088)</u>			<u>\$ (11,088)</u>

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

	September 30, 2022				Total
	Fair Value Measurements Using				
	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Investments Valued Using NAV as a Practical Expedient	
Assets					
Pooled investments					
Short-term investments	\$ 269,086	\$ -	\$ -	\$ -	\$ 269,086
Separately managed investments	755,478	486,044	-	-	1,241,522
Mutual funds	177,438	-	-	-	177,438
Private partnerships, commingled funds and other	-	-	-	11,503,184	11,503,184
	<u>1,202,002</u>	<u>486,044</u>	<u>-</u>	<u>11,503,184</u>	<u>13,191,230</u>
Separately invested					
Short-term investments	55,670	-	-	-	55,670
Equities	30,340	-	-	-	30,340
Mutual funds	632,093	69,015	-	-	701,108
Beneficial interests in perpetual assets	-	-	51,752	-	51,752
	<u>718,103</u>	<u>69,015</u>	<u>51,752</u>	<u>-</u>	<u>838,870</u>
	<u>\$ 1,920,105</u>	<u>\$ 555,059</u>	<u>\$ 51,752</u>	<u>\$ 11,503,184</u>	<u>\$ 14,030,100</u>
Interest rate swaps					
Assets					
		\$ 15,224			\$ 15,224
Liabilities					
		(156,705)			(156,705)
Net interest rate swaps					
		<u>\$ (141,481)</u>			<u>\$ (141,481)</u>

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

8. Pledges and Contributions Receivable

Pledges receivable represent unconditional promises to give and are net of allowances for uncollectible amounts. Pledges are recorded at the present value of their estimated future cash flows. Pledges collectible within one year are classified as other current assets, net of allowances, and total \$255,239 and \$113,916 as of September 30, 2023 and 2022, respectively. Pledges collectible in one year or greater are classified as other assets. Estimated cash flows due after one year are discounted using published treasury bond and note yields that are commensurate with estimated collection risks. The blended discount rate was 4.8% and 4.2% for 2023 and 2022, respectively. Pledges are expected to be collected as follows:

	September 30,	
	2023	2022
Amounts due		
Within one year	\$ 277,559	\$ 136,491
In one to five years	400,728	169,846
In more than five years	118,502	68,247
Total pledges receivable	<u>796,789</u>	<u>374,584</u>
Less: Unamortized discount	69,667	29,837
	<u>727,122</u>	<u>344,747</u>
Less: Allowance for uncollectibles	33,682	28,351
Net pledges receivable	<u>693,440</u>	<u>316,396</u>
Contributions receivable from trusts	49,497	53,481
	<u>\$ 742,937</u>	<u>\$ 369,877</u>

9. Property and Equipment

Property and equipment consists of the following:

	September 30,	
	2023	2022
Land and land improvements	\$ 353,988	\$ 372,508
Buildings and building improvements	9,655,999	9,282,374
Equipment	2,981,003	2,903,484
Construction in progress	1,042,827	702,930
Finance right-of-use lease assets	102,843	92,781
	<u>14,136,660</u>	<u>13,354,077</u>
Less: Accumulated depreciation	7,359,297	6,911,817
Property and equipment, net	<u>\$ 6,777,363</u>	<u>\$ 6,442,260</u>

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2023 and 2022

(in thousands of dollars)

Depreciation expense for the years ended September 30, 2023 and 2022 was \$772,556 and \$767,158, respectively. Interest costs, net of interest earned, aggregating \$2,720 and \$417 were capitalized in 2023 and 2022, respectively.

For the years ended September 30, 2023 and 2022, fully depreciated assets with an original cost of \$325,076 and \$268,623, respectively, were written off.

10. Levels of Capital and Surplus

Risk-based capital (RBC) is a methodology adopted by the National Association of Insurance Commissioners for determining the minimum level of capital and surplus deemed necessary for an insurer based upon the types of assets held and business written. The Company has guaranteed to the Massachusetts Division of Insurance (DOI) (the RBC Guaranty) to maintain MGB Health Plan's capital and surplus at a specified minimum level, measured quarterly in accordance with an RBC methodology permitted by DOI. The RBC Guaranty may be enforced by the DOI. The Company provided capital to MGB Health Plan of \$75,000 and \$11,000 in 2023 and 2022, respectively. Mass General Brigham Health Plan, Inc.'s current contract with EOHHS requires it to maintain a minimum net worth and/or financial insolvency insurance in an amount equal to the Minimum Net Worth calculation as defined in Massachusetts General Law 176G, Section 25. At December 31, 2022 and 2021 (Mass General Brigham Health Plan, Inc.'s statutory year end), the minimum net worth requirement, as determined in accordance with EOHHS guidelines, was \$50,357 and \$47,718, respectively. Mass General Brigham Health Plan, Inc.'s GAAP net worth was \$124,286 and \$158,853 at December 31, 2022 and 2021, respectively, and thus exceeded the EOHHS requirements by \$73,929 and \$111,135, respectively.

11. Accrued Medical Claims and Related Expenses

Accrued medical claims and related expenses include estimates of expected trends in claims severity, frequency, and other factors, which could vary as the claims are ultimately settled and are based principally upon historical experience. For the years ended September 30, 2023 and 2022, changes in estimates resulted in a decrease of accrued medical claims and related expense of \$38,421 and \$14,564, respectively. Decreases of this nature occur as the result of claim settlements and recoveries during the current year and as additional information is received regarding individual claims, causing changes from the original estimates of the cost of these claims. Ongoing analysis of the recent loss development trends is also taken into account in evaluating the overall adequacy of the reserves.

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

Changes in accrued medical claims and related expenses are as follows:

	2023	2022
Balance at beginning of year	\$ 119,237	\$ 87,289
Less:		
Premium deficiency reserve	(21,120)	-
Accrual for claims adjustment expenses	(1,608)	(1,602)
Accrued medical payables - other	(16,818)	(17,281)
Plus: Settlements payable, net	91,230	61,687
Net balance at beginning of year	<u>170,921</u>	<u>130,093</u>
Incurring related to		
Current year	1,125,010	736,776
Prior years	(38,421)	(14,564)
Total incurred	<u>1,086,589</u>	<u>722,212</u>
Paid related to		
Current year	928,975	591,660
Prior years	47,016	89,724
Total paid	<u>975,991</u>	<u>681,384</u>
Net balance at end of year	281,519	170,921
Plus:		
Premium deficiency reserve	24,071	21,120
Accrual for claims adjustment expenses	2,962	1,608
Accrued medical payables - other	19,646	16,818
Less: Settlements payable, net	(135,763)	(91,230)
Balance at end of year	<u>\$ 192,435</u>	<u>\$ 119,237</u>

Medical claims and related expenses in the accompanying consolidated statements of operations include other nonclaims related costs. These nonclaims related expenses were for directly delivered services and medical cost risk sharing and incentives.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2023 and 2022

(in thousands of dollars)

12. Long-Term Obligations

Mass General Brigham's long-term obligations consist of the following:

	Final Maturity	September 30,	
		2023	2022
Massachusetts Health and Educational Facilities Authority Revenue Bonds			
Series 1997 P*, variable interest rate of 4.03% and 2.38%	2027	\$ 120,000	\$ 150,000
Series 2005 F*, variable interest rate of 3.99% and 2.48%	2040	224,250	226,150
Series 2007 G*, variable interest rate of 4.00% and 2.10%	2042	75,000	75,000
Series 2008 H*, variable interest rate of 3.43% and 1.64%	2042	156,780	159,785
Massachusetts Development Finance Agency (Agency) Revenue Bonds			
Series 2011 K*, variable interest rate of 3.90% and 2.54%	2046	100,000	100,000
Series 2014 M*, average fixed interest rate of 4.10%	2026	9,335	16,835
Series 2014 N*, variable interest rate of 4.94% and 2.60%	2044	124,250	126,150
Series 2015 O*, average fixed interest rate of 4.37%	2045	169,830	176,930
Series 2016 Q*, average fixed interest rate of 4.81%	2047	394,920	406,260
Series 2016 R*, variable interest rate of n/a and 2.29%	n/a	-	100,000
Series 2017 S*, average fixed interest rate of 4.59%, variable interest rate of n/a and 2.96%	2047	740,480	823,485
Series 2019 T*, variable interest rate of 4.54% and 3.01%	2049	123,250	138,250
Series 2020 A*, average fixed interest rate of 4.82%	2050	276,530	286,325
Series 2022 B*, variable interest rate of 4.74% and n/a	2052	100,230	-
New Hampshire Health and Education Facilities Authority Revenue Bonds			
Series 2017, average fixed interest rate of 5.00%	2041	87,830	90,390
MGB Taxable Debt			
Series 2007 Bonds, fixed interest rate of 6.26%	2037	100,000	100,000
2012 Senior Notes, fixed interest rate of 4.11%	2052	400,000	400,000
2014 Senior Notes, fixed interest rate of 4.73%	2044	150,000	150,000
Series 2015 Bonds, fixed interest rate of 4.12%	2055	300,000	300,000
2016 Senior Notes, fixed interest rate of 3.89%	2046	225,000	225,000
Series 2017 Bonds, fixed interest rate of 3.77%	2048	303,644	303,644
2018 Senior Notes, fixed interest rate of 4.60%	2049	400,000	400,000
Series 2020 Bonds, average fixed interest rate of 3.29%	2060	1,017,135	1,017,135
Series B-1 Commercial Paper Notes, variable interest rate of 5.40% and 2.65%	2023	119,870	50,230
Other obligations		2,452	14,341
Total long-term obligations, par value		5,720,786	5,835,910
Net unamortized bond premiums		252,112	264,135
Deferred financing costs		(22,142)	(23,514)
Total long-term obligations, net		5,950,756	6,076,531
Less:			
Current portion		481,130	519,354
		<u>\$ 5,469,626</u>	<u>\$ 5,557,177</u>

* Denotes series is issued in multiple subseries

Variable interest rates are presented at September 30, 2023 and 2022, respectively

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

Scheduled maturities of long-term obligations (including the impact of net unamortized bond premiums and deferred financing costs) during the next five years and thereafter and other amounts classified as current liabilities, are as follows:

	Scheduled Maturities	Bonds Supported by Self Liquidity	Bonds Supported by Bank Facilities	Total
2024	\$ 230,705	\$ 222,925	\$ 27,500	\$ 481,130
2025	121,446	-	-	121,446
2026	93,686	-	-	93,686
2027	86,148	-	-	86,148
2028	91,996	-	-	91,996
Thereafter	<u>5,076,350</u>	<u>-</u>	<u>-</u>	<u>5,076,350</u>
	<u>\$ 5,700,331</u>	<u>\$ 222,925</u>	<u>\$ 27,500</u>	<u>\$ 5,950,756</u>

The scheduled maturities represent annual payments as required under debt repayment schedules. The current portion of long-term obligations includes the payments scheduled to be made in 2024, bonds supported by self-liquidity that can be tendered prior to September 30, 2024, and bonds supported by bank facilities with financial institutions (standby bond purchase agreements or letters of credit) that expire prior to September 30, 2024 or have potential principal amortization under bank facilities' term out provisions due during 2024. The bonds supported by self-liquidity provide the bondholder with an option to tender the bonds to the Company. Accordingly, these bonds are classified as a current liability. The bonds supported by bank facilities provide the bondholder with an option to tender the bonds to the liquidity provider. Generally accepted accounting principles require bonds backed by bank facilities expiring within one year of the balance sheet date as well as potential principal amortization under bank facilities' term out provisions due within one year of the balance sheet date to be classified as a current liability.

If bonds supported by bank facilities cannot be remarketed, the repayment terms of those bank facilities would result in repayments of \$57,500 in 2024, \$126,417 in 2025, \$81,417 in 2026 and \$28,917 in 2027. If the bonds supported by self-liquidity cannot be remarketed, the bonds would be tendered to the Company on their respective earliest tender dates, which differ from scheduled maturity dates, and would result in payments of \$222,925 in 2024, \$61,935 in 2025, \$80,000 in 2026, \$0 in 2027, \$0 in 2028 and \$239,515 thereafter.

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

Scheduled payments of long-term debt (excluding the impact of net unamortized bond premiums and deferred financing costs) for each of the next five years, assuming bonds backed by bank facilities are remarketed and the standby purchase agreements are renewed and bonds supported by self-liquidity are remarketed, are as follows:

2024	\$ 110,835
2025	124,751
2026	93,686
2027	101,148
2028	99,032
Thereafter	<u>5,191,334</u>
	<u>\$ 5,720,786</u>

Interest expense paid during the years ended September 30, 2023 and 2022 was \$244,096 and \$237,384, respectively.

In October 2022, we issued \$100,230 of Mass General Brigham Series 2022 B Revenue Bonds. The bond proceeds were used to refund Partners HealthCare System Series 2016 R-1 Revenue Bonds (\$50,000) and Taxable Commercial Paper Notes (\$50,230) that refinanced, on an interim basis, Partners HealthCare System Series 2017 S-5 Revenue Bonds.

Mass General Brigham bonds are general obligations of the Company supported by guarantees from Brigham, Inc., The Brigham and Women's Hospital, Inc., The Massachusetts General Hospital and The General Hospital Corporation (the General) which may be suspended under certain conditions.

Our debt agreements contain certain covenants, including a minimum debt service coverage ratio and limitations on additional indebtedness and asset transfers.

Lines of Credit

The Company maintains two lines of credit aggregating \$375,000 that provide access to same day funds. Advances under the lines of credit bear a variable rate of interest based on the Bloomberg Short-Term Bank Yield Index rate (BSBY) for the \$250,000 line of credit and the Secured Overnight Financing Rate (SOFR) for the \$125,000 line of credit. As of September 30, 2023 and 2022, there were no amounts outstanding under the lines of credit. The lines of credit expire in July 2025.

Taxable Commercial Paper

The Company maintains a \$500,000 Taxable Commercial Paper (CP) program. As of September 30, 2023 and 2022, there was \$119,870 and \$50,230, respectively, outstanding under the CP program.

13. Derivatives

Interest Rate Swaps

We utilize swap contracts to lock-in long-term synthetic fixed rates and manage fluctuations in cash flows resulting from interest rate risk on certain of our variable rate bonds. These bonds expose us to variability in interest payments due to changes in interest rates. Management believes that it is prudent to limit this variability. To meet this objective and to take advantage of low interest rates,

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

we have entered into various swap contracts involving the exchange of fixed rate payments by us for variable rate payments from several counterparties. These variable rate payments are currently based on a percentage of SOFR (based on compound average of daily SOFR in arrears) plus a spread.

By using swap contracts to manage the risk of changes in interest rates, we expose ourselves to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the swap contracts. When the fair value of a swap contract is positive, the counterparty has a liability to us, which creates credit risk. We minimize our credit risk by entering into swap contracts with several counterparties and requiring the counterparty to post collateral for our benefit based on the credit rating of the counterparty and the fair value of the swap contract. Conversely, when the fair value of a swap contract is negative, we have a liability to the counterparty and, therefore, we do not have credit risk. Under certain circumstances, we may be required to post collateral for the benefit of the counterparty. Market risk is the adverse effect on the value of a financial instrument that results from a change in interest rates. The market risk associated with interest rate changes is managed by establishing and monitoring parameters that limit the types and degree of market risk that we may undertake.

The following is a summary of the outstanding positions under our swap contracts as of September 30, 2023:

Effective Date	Notional Amount	Maturity	Rate Paid	Rate Received
5/1/03	\$ 144,229	7/1/45	3.36%	67% 1M SOFR + 0.0767%
10/15/03	9,480	1/1/31	3.85%	70% 1M SOFR + 0.08014%
7/1/05	150,000	7/1/50	3.09%	67% 1M SOFR + 0.0767%
7/1/05	8,300	7/1/25	5.11%	67% 6M SOFR + 0.28693%
7/1/07	50,000	7/1/52	3.00%	67% 1M SOFR + 0.0767%
7/1/07	100,000	7/1/52	2.95%	67% 1M SOFR + 0.083%
7/1/09	100,000	7/1/50	3.58%	67% 1M SOFR + 0.0767%
7/1/11	100,000	7/1/50	3.66%	67% 1M SOFR + 0.0767%
7/1/13	100,000	7/1/48	3.80%	67% 1M SOFR + 0.0767%
7/1/15	50,000	7/1/50	3.80%	67% 1M SOFR + 0.0767%
4/1/16	100,000	7/1/52	3.76%	67% 1M SOFR + 0.0767%
7/1/17	50,000	7/1/52	3.74%	67% 1M SOFR + 0.083%
7/1/19	50,000	7/1/49	1.85%	67% 1M SOFR + 0.0767%
7/1/21	50,000	7/1/51	1.84%	67% 1M SOFR + 0.0767%
7/1/23	50,000	7/1/53	1.80%	67% 1M SOFR + 0.0767%
7/1/24	100,000	7/1/54	1.81%	67% 1M SOFR + 0.0767%
7/1/25	50,000	7/1/55	1.77%	67% 1M SOFR + 0.083%
7/1/26	100,000	7/1/56	1.78%	67% 1M SOFR + 0.0767%
7/1/27	50,000	7/1/57	1.80%	67% 1M SOFR + 0.0767%
7/1/27	50,000	7/1/57	1.77%	67% 1M SOFR + 0.083%
	<u>\$ 1,462,009</u>			

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

Our swap contracts contain provisions that require collateral to be posted if the fair value of the swap exceeds certain thresholds. The collateral thresholds reflect the current credit ratings issued by major credit rating agencies on our and the counterparty's debt. Declines in our or the counterparty's credit ratings would result in lower collateral thresholds and, consequently, the potential for additional collateral postings by us or the counterparty. As of September 30, 2023, we held collateral of \$7,350 and as of September 30, 2022, we have posted collateral \$16,397. We have established procedures to ensure that liquidity and securities are available to meet collateral posting requirements.

Upon the occurrence of certain events of default or termination events identified in the swap contracts, either the Company or the counterparty could terminate the contracts in accordance with their respective terms. Termination results in the payment of a termination amount by one party that attempts to compensate the other party for its economic losses. If interest rates at the time of termination are lower than those specified in the swap contract, we would make a payment to the counterparty. Conversely, if interest rates at such time are higher, the counterparty would make a payment to us.

14. Leases

We lease property and equipment under both finance and operating lease agreements. We recognize leases with a term greater than twelve months on the balance sheets.

Some lease agreements require us to pay variable costs including property taxes, insurance, maintenance and repairs. Variable costs are excluded from the right-of-use asset and liability. Lease and nonlease components of agreements are not separated. Some leases contain rental escalation clauses and renewal options that are included in lease payment calculations when appropriate. The estimated incremental borrowing rate is used to discount the lease payment amounts.

The components of lease expense consist of the following:

	Year Ended September 30, 2023		
	Supplies and Other Expenses	Academic and Research Gifts, Net of Expenses	Total
Operating lease expense	\$ 225,101	\$ 3,357	\$ 228,458
Short-term lease expense	14,026	1,001	15,027
Variable lease expense	87,866	1,252	89,118
Finance lease expense			
Amortization of leased assets	14,874	167	15,041
Interest on lease liabilities	3,650	22	3,672
Total lease expense	<u>\$ 345,517</u>	<u>\$ 5,799</u>	<u>\$ 351,316</u>

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

	Year Ended September 30, 2022		
	Supplies and Other Expenses	Academic and Research Gifts, Net of Expenses	Total
Operating lease expense	\$ 216,064	\$ 7,639	\$ 223,703
Short-term lease expense	12,964	183	13,147
Variable lease expense	77,112	2,545	79,657
Finance lease expense			
Amortization of leased assets	13,012	204	13,216
Interest on lease liabilities	3,871	36	3,907
Total lease expense	<u>\$ 323,023</u>	<u>\$ 10,607</u>	<u>\$ 333,630</u>

Lease related assets and liabilities are as follows:

		September 30,	
		2023	2022
	Balance Sheet Classification		
Operating lease assets	Right-of-use operating lease assets	\$ 1,024,336	\$ 1,135,787
Finance lease assets	Property and equipment, net	68,194	72,401
Total lease assets		<u>\$ 1,092,530</u>	<u>\$ 1,208,188</u>
Current operating lease liability	Current portion of operating lease obligations	\$ 207,671	\$ 206,350
Current finance lease liability	Accounts payable and accrued expenses	16,939	15,864
Noncurrent operating lease liability	Operating lease obligation, less current portion	696,740	801,038
Noncurrent finance lease liability	Accrued other	73,318	77,274
Total lease liabilities		<u>\$ 994,668</u>	<u>\$ 1,100,526</u>

Supplemental cash flow and other information related to leases are as follows:

	Years Ended September 30,	
	2023	2022
Cash paid for amounts included in the measurement of lease liabilities		
Operating cash flow for operating leases	\$ 222,040	\$ 216,762
Operating cash flow for finance leases	3,630	3,556
Financing cash flows for finance leases	13,461	9,744
Weighted-average remaining term (years)		
Operating leases	7.0	7.4
Finance leases	16.0	15.9
Weighted-average discount rate		
Operating leases	4.05 %	4.00 %
Finance leases	4.05 %	4.00 %

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

Commitments related to noncancelable operating and finance leases for each of the next five years and thereafter are as follows:

	Operating Leases	Finance Leases
2024	\$ 207,671	\$ 16,939
2025	190,206	14,041
2026	174,964	8,882
2027	141,599	5,178
2028	114,645	3,552
Thereafter	<u>245,691</u>	<u>98,158</u>
Total minimum future payments	1,074,776	146,750
Less: Amount representing interest	<u>(170,365)</u>	<u>(56,493)</u>
Present value of minimum future payments	904,411	90,257
Less: Current portion	<u>(207,671)</u>	<u>(16,939)</u>
Long-term lease obligations	<u>\$ 696,740</u>	<u>\$ 73,318</u>

We are also a lessor and sublessor of real estate under operating leases. Lease income for the years ended September 30, 2023 and 2022 was \$16,425 and \$15,604, respectively, and is included in other revenue in the consolidated statements of operations. Some of these leases include expenses such as utilities and maintenance costs in rent charges, however, this variable lease income is not considered material. We do not separate lease and nonlease components by class of underlying asset for all asset classes. The underlying real estate assets are included in property and equipment, net in the consolidated balance sheets.

The future undiscounted cash flows to be received from these leases for each of the next five years and thereafter is as follows:

2024	\$ 4,265
2025	3,795
2026	2,787
2027	2,840
2028	2,483
Thereafter	<u>159,350</u>
	<u>\$ 175,520</u>

15. Construction Projects

The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University (collectively, the Ragon Institute) is constructing a new research facility at Kendall Square in Cambridge, Massachusetts. This new 318,000 square foot building (including 120 spaces of sub-level parking) is being built to meet both the current and future needs of the Ragon Institute, facilitating the important work that lies ahead in harnessing the power of the human immune systems to prevent and cure disease. It will include three floors of state-of-the-art

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

laboratories supporting 60-open lab modules and 60-support lab modules, a vivarium, a translational research clinic and administrative space (including colloquium and case study seminar rooms). Accumulated costs incurred related to this project were approximately \$265,953 and \$93,530 for 2023 and 2022, respectively, with approximately \$84,368 in outstanding commitments at September 30, 2023. The total cost of the project is expected to be approximately \$412,000 with occupancy scheduled in June of 2024. The General, an affiliate of the Company, serves as the administrative home of Ragon Institute, and therefore the construction costs are carried on the books of the General.

The General is constructing a new clinical building, the Phillip and Susan Ragon Building, that will occupy approximately one million square feet and will contain 482 private medical/surgical and intensive care unit beds, exam and infusion bays associated with a relocated and expanded outpatient oncology service, hybrid and conventional cardiovascular operating rooms, and associated imaging modalities as well as below-grade parking. As of September 30, 2023, accumulated costs incurred related to the new clinical building are approximately \$352,504 with approximately \$736,052 in outstanding construction project contracts. The total cost of the project is expected to be approximately \$3,311,000 with occupancy scheduled for 2027 for Phase 1 and 2030 for Phase 2.

The Brigham and Women's Faulkner Hospital, Inc. is constructing a five-story inpatient addition and a 941 space garage that will replace a garage that is at its end-of-life use. The inpatient addition will include 78 new beds and will expand patient care for observation, imaging and endoscopy services. As of September 30, 2023, accumulated cost incurred related to the construction are approximately \$82,617 with approximately \$160,458 in outstanding construction project contracts. The total cost of the project is expected to be approximately \$294,000 with occupancy scheduled for December 2024 for the garage and June 2025 for the inpatient addition.

16. Pension and Postretirement Healthcare Benefit Plans

Substantially all Mass General Brigham employees are covered under noncontributory defined benefit pension plans and various defined contribution pension plans. In addition, certain affiliates provide subsidized healthcare benefits for retired employees on a self-insured basis, with the benefit obligation being partially funded. These retiree healthcare benefits are administered through a third-party administrator and are accounted for on the accrual basis, which includes an estimate of future payments for claims incurred.

Total (income) expense for Mass General Brigham plans consists of the following:

	Years Ended September 30,	
	2023	2022
Defined benefit plans	\$ 106,708	\$ 304,026
Defined contribution plans	181,814	184,227
Postretirement healthcare benefit plans	422	(4,038)
	<u>\$ 288,944</u>	<u>\$ 484,215</u>

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

Information regarding benefit obligations, plan assets, funded status, expected cash flows and net periodic benefit cost is as follows:

Benefit Obligations

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2023	2022	2023	2022
Change in benefit obligations				
Benefit obligations at beginning of year	\$ 7,391,402	\$ 9,945,227	\$ 202,696	\$ 237,224
Service cost	338,035	503,193	2,922	4,250
Interest cost	435,026	322,521	11,295	6,541
Plan amendments loss	7,928	-	-	-
Actuarial gain	(384,256)	(2,970,410)	(5,882)	(47,457)
Benefits paid	(343,062)	(397,884)	(9,065)	(8,731)
Expenses paid	(11,494)	(11,347)	(1,115)	(683)
Employee contributions	97	102	12,192	11,552
Benefit obligations at end of year	\$ 7,433,676	\$ 7,391,402	\$ 213,043	\$ 202,696

The estimated actuarial gain in the change in benefit obligation for 2023 and 2022 is due primarily to the change in discount rate, respectively.

The accumulated benefit obligation for all defined benefit pension plans at the end of 2023 and 2022 was \$7,140,057 and \$7,096,333, respectively.

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2023	2022	2023	2022
Weighted-average assumptions used to determine end of year benefit obligation				
Discount rate	6.22%	5.76%	6.07% - 6.10%	5.71% - 5.72%
Rate of compensation increase	3.00% - 5.00%	3.00% - 5.00%	N/A	N/A
Postretirement healthcare cost trend rate for next year	N/A	N/A	6.75%	7.00%
Rate to which the cost trend rate is to decline	N/A	N/A	5.00%	5.00%
Year that rate reaches the ultimate trend rate	N/A	N/A	2031	2031

Plan Assets

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2023	2022	2023	2022
Change in plan assets				
Fair value of plan assets at beginning of year	\$ 8,570,585	\$ 10,163,079	\$ 151,424	\$ 171,053
Actual return on plan assets	752,199	(1,491,419)	21,950	(24,489)
Employer contributions	106,995	308,054	2,704	2,585
Employee contributions	97	102	12,192	11,552
Benefits paid	(343,062)	(397,884)	(9,065)	(8,594)
Expenses paid	(11,494)	(11,347)	(1,115)	(683)
Fair value of plan assets at end of year	\$ 9,075,320	\$ 8,570,585	\$ 178,090	\$ 151,424

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2023 and 2022

(in thousands of dollars)

The assets of the defined benefit pension plans are aggregated in a single master trust (Master Trust) and managed as one asset pool. The investment objective for the Master Trust is to achieve the highest reasonable total return after considering (i) plan liabilities, (ii) funding status and projected cash flows, (iii) projected market returns, valuations and correlations for various asset classes and (iv) ability and willingness to incur market risk.

Within the Master Trust, assets are allocated to managers with investment mandates that may range from a single sub-asset class to very broad mandates; with restrictions that range from long-only to unconstrained; and with management structures ranging from separately managed funds to mutual/commingled funds to private partnerships. Less market sensitive managers employ long/short equity and diversified strategies. Investment risks (concentration, correlation, valuation, liquidity, leverage, mandate compliance, etc.) are monitored at the manager level as well as the pool level.

The following table presents the capital allocations and reported exposures by manager mandate within the Master Trust. Some managers, particularly less market sensitive managers, invest capital among multiple asset classes. The Long-Term Policy Benchmark is 70% Morgan Stanley Capital International All Country World Index and 30% Barclays Global Aggregate Bond.

	September 30, 2023		September 30, 2022	
	Dollars	Reported Exposures	Dollars	Reported Exposures
Global equity	\$ 1,171,312	12.9 %	\$ 1,132,182	13.2 %
Traditional U.S. equity	1,124,628	12.4 %	929,068	10.8 %
Traditional foreign developed equity	313,409	3.4 %	310,468	3.6 %
Traditional emerging markets equity	449,983	5.0 %	560,912	6.5 %
Private equity	2,313,451	25.4 %	2,158,992	25.2 %
Real assets	558,524	6.2 %	609,123	7.1 %
Less Market Sensitive managers	2,783,007	30.7 %	2,564,880	29.9 %
Fixed income managers	361,006	4.0 %	304,960	3.7 %
	<u>\$ 9,075,320</u>	<u>100.0 %</u>	<u>\$ 8,570,585</u>	<u>100.0 %</u>

The postretirement healthcare benefit plans' assets are invested in commingled funds with the objective of achieving returns to satisfy plan obligations and with a level of volatility commensurate with our overall financial profile.

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

The following tables summarize plan assets measured at fair value on a recurring basis (using the fair value hierarchy defined in Note 7) as of:

	September 30, 2023			Total
	Fair Value Measurements Using			
	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Investments Valued Using NAV as a Practical Expedient	
Defined benefit pension plans				
Short-term investments	\$ 175,053	\$ -	\$ -	\$ 175,053
Separately managed investments	370,293	155,452	-	525,745
Private partnerships and commingled funds	-	-	8,374,522	8,374,522
	<u>545,346</u>	<u>155,452</u>	<u>8,374,522</u>	<u>9,075,320</u>
Postretirement healthcare benefit plans				
Commingled funds	49,615	-	128,475	178,090
Total plan assets	<u>\$ 594,961</u>	<u>\$ 155,452</u>	<u>\$ 8,502,997</u>	<u>\$ 9,253,410</u>

	September 30, 2022			Total
	Fair Value Measurements Using			
	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Investments Valued Using NAV as a Practical Expedient	
Defined benefit pension plans				
Short-term investments	\$ 143,631	\$ -	\$ -	\$ 143,631
Separately managed investments	336,538	144,062	-	480,600
Private partnerships and commingled funds	-	-	7,946,354	7,946,354
	<u>480,169</u>	<u>144,062</u>	<u>7,946,354</u>	<u>8,570,585</u>
Postretirement healthcare benefit plans				
Commingled funds	42,540	-	108,884	151,424
Total plan assets	<u>\$ 522,709</u>	<u>\$ 144,062</u>	<u>\$ 8,055,238</u>	<u>\$ 8,722,009</u>

In evaluating the Level at which private partnerships have been classified within the fair value hierarchy, management has assessed factors including but not limited to price transparency, the ability to redeem these investments at net asset value at the measurement date and the existence or absence of certain restrictions at the measurement date. Investments in private partnerships generally have limited redemption options for investors and, subsequent to final closing, may or may not permit subscriptions by new or existing investors. These entities may also have the ability to impose gates, lockups and other restrictions on an investor's ability to readily redeem out of their investment interest in the fund. As of September 30, 2023 and 2022, we have excluded all assets from the fair value hierarchy for which fair value is measured using net asset value per share as a practical expedient.

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

Funded Status

The funded status of the plans recognized in the balance sheet and the amounts recognized in net assets without donor restrictions is as follows:

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2023	2022	2023	2022
End of year				
Fair value of plan assets at measurement date	\$ 9,075,320	\$ 8,570,585	\$ 178,090	\$ 151,424
Benefit obligations at measurement date	<u>(7,433,676)</u>	<u>(7,391,402)</u>	<u>(213,043)</u>	<u>(202,696)</u>
Funded status	<u>\$ 1,641,644</u>	<u>\$ 1,179,183</u>	<u>\$ (34,953)</u>	<u>\$ (51,272)</u>
Amounts recognized in the balance sheet consist of				
Noncurrent asset	\$ 1,663,197	\$ 1,202,435	\$ 319	\$ 408
Current liabilities	(1,620)	(1,705)	(1,248)	(1,470)
Long-term liabilities	<u>(19,933)</u>	<u>(21,547)</u>	<u>(34,024)</u>	<u>(50,210)</u>
	<u>\$ 1,641,644</u>	<u>\$ 1,179,183</u>	<u>\$ (34,953)</u>	<u>\$ (51,272)</u>
Amounts not yet recognized in net periodic benefit cost and included in net assets without donor restrictions consist of				
Actuarial net loss (gain)	\$ (615,642)	\$ (117,642)	\$ (9,901)	\$ 7,199
Prior service credit	<u>(60,127)</u>	<u>(95,953)</u>	<u>-</u>	<u>(3,064)</u>
	<u>\$ (675,769)</u>	<u>\$ (213,595)</u>	<u>\$ (9,901)</u>	<u>\$ 4,135</u>
Amounts recognized in net assets without donor restrictions consist of				
Current year actuarial loss	\$ (498,000)	\$ (871,080)	\$ (19,070)	\$ (12,960)
Amortization of actuarial loss (gain)	-	(114,122)	1,969	(470)
Current year prior service cost	7,928	-	-	-
Amortization of prior service credit	<u>27,899</u>	<u>27,899</u>	<u>3,064</u>	<u>5,289</u>
	<u>\$ (462,173)</u>	<u>\$ (957,303)</u>	<u>\$ (14,037)</u>	<u>\$ (8,141)</u>

As of September 30, 2023 and 2022, the projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with an accumulated benefit obligation in excess of plan assets were as follows:

	September 30,	
	2023	2022
Accumulated benefit obligation in excess of, or below plan assets		
Projected benefit obligation	\$ 7,433,676	\$ 7,391,402
Accumulated benefit obligation	7,140,057	7,096,333
Fair value of plan assets	9,075,320	8,570,585

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

Expected Cash Flows

Information about the expected cash flows for the defined benefit and postretirement healthcare benefit plans is as follows:

	Defined Benefit Pension Plans	Postretirement Healthcare Benefit Plans	
Expected employer contributions			
2024	\$ 98,969	\$ 4,660	Medicare Subsidy
Expected benefit payments (receipts)			
2024	368,734	17,906	(15)
2025	400,822	17,943	(13)
2026	426,239	18,138	(11)
2027	449,475	18,391	(9)
2028	477,562	18,576	(7)
2029-2032	2,757,116	90,319	(21)

Net Periodic Benefit Cost

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2023	2022	2023	2022
Service cost	\$ 338,035	\$ 503,193	\$ 2,922	\$ 4,250
Interest cost	435,026	322,521	11,295	6,541
Expected return on plan assets	(638,454)	(607,911)	(8,762)	(10,010)
Amortization of				
Prior service credit	(27,899)	(27,899)	(3,064)	(5,289)
Actuarial net loss (gain)	-	114,122	(1,969)	470
Nonservice related pension income	(231,327)	(199,167)	(2,500)	(8,288)
Net periodic benefit cost	<u>\$ 106,708</u>	<u>\$ 304,026</u>	<u>\$ 422</u>	<u>\$ (4,038)</u>
	2023	2022	2023	2022

**Weighted-average assumptions used
to determine net periodic pension and
postretirement cost**

Discount rate	5.76 %	3.15 %	5.71% - 5.72%	2.75% - 3.00%
Expected return on plan assets	7.00 %	7.00 %	6.00 %	6.00 %
Rate of compensation increase	3.00% - 5.00%	3.00% - 5.00%	N/A	N/A
Healthcare cost trend rate for this year	N/A	N/A	7.00 %	6.25 %
Rate to which the cost trend rate is to decline	N/A	N/A	5.00 %	5.00 %
Year that rate reaches the ultimate trend rate	N/A	N/A	2031	2027

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2023 and 2022

(in thousands of dollars)

We use a long-term return assumption which is validated annually by obtaining long-term asset return, volatility and correlation projections for relevant asset class indexes; modifying volatility and correlations to reflect the actual historical experience of the active managers; calculating the expected return using benchmark weights and indexes; and comparing the return assumption to the sum of the expected return and the historical outperformance of the actual return versus the benchmark. We regularly monitor the active risk of the Master Trust by a statistical regression of the return series of the actual portfolio to that of the policy benchmark.

17. Professional Liability Insurance

We insure substantially all of our professional and general liability risk on a claims-made basis in cooperation with other healthcare organizations in the Greater Boston area through a captive insurance company, Controlled Risk Insurance Company Ltd. (CRICO). The Company owns 11% of CRICO. The policies cover claims made during their respective terms, but not those occurrences for which claims may be made after expiration of the policy. Management intends to renew its coverage on a claims-made basis and has no reason to believe that it will be prevented from such renewal. During 2022, CRICO announced and paid a dividend to member organizations. As a result, we recorded dividend income of \$58,453 in other nonoperating (expenses) income.

We follow the accounting policy of establishing reserves to cover the ultimate costs of medical malpractice claims, which include costs associated with litigating or settling claims. The liability also includes an estimated tail liability, established to cover all malpractice claims incurred but not reported to the insurance company as of the end of the year. The total malpractice liability of \$576,038 and \$570,862 as of September 30, 2023 and 2022, respectively, is presented as an accrued professional liability in the consolidated balance sheets. These reserves have been recorded on a discounted basis using an interest rate of 6.04% and 5.6% as of September 30, 2023 and 2022, respectively.

We also recognize an insurance receivable from CRICO at the same time that it recognizes the liability, measured on the same basis as the liability, subject to the need for a valuation allowance for uncollectible amounts. The insurance receivable of \$441,834 and \$432,704 as of September 30, 2023 and 2022, respectively, is reported as a component of other assets in the consolidated balance sheets.

Management is not aware of any claims against us or factors affecting CRICO that would cause the expense for professional liability risks to vary materially from the amount provided.

18. Concentration of Credit Risk

Financial instruments that potentially subject us to concentration of credit risk consist of patient accounts receivable, research grants receivable, pledges receivable, premiums receivable, certain investments and interest rate swaps.

Mass General Brigham provider organizations receive a significant portion of payments for services rendered from a limited number of government and commercial third-party payers, including Medicare, Medicaid, Blue Cross and Blue Shield of Massachusetts, Harvard Pilgrim Health Care and Tufts Health Plan. Research funding is provided through many government and private sponsors. MGB Health Plan receives a portion of premium revenue from the Commonwealth.

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

Pledges receivable are due from multiple donors. We assess the credit risk for pledges based on history and the financial wherewithal of donors, most of which are individuals or organizations well known to us.

Investments, which include government and agency securities, stocks and corporate bonds, private partnerships and other investments, are not concentrated in any corporation or industry or with any single counterparty. Alternative investments are less liquid than other investments. The reported values of the alternative investments may differ significantly from the values that would have been used had a ready market for those securities existed. These instruments may contain elements of both credit and market risk. Such risks include, but are not limited to, limited liquidity, absence of oversight, dependence upon key individuals, emphasis on speculative investments and nondisclosure of portfolio composition.

We minimize our credit risk exposure under interest rate swap agreements by utilizing several counterparties and requiring the counterparties to post collateral for our benefit when the fair value of the swap is positive. We minimize our counterparty risk by contracting with nine counterparties, none of which accounts for more than 20% of the aggregate notional amount of the swap contracts.

19. Net Assets

Net assets with donor restrictions are available for the following purposes:

	September 30,	
	2023	2022
Net assets with donor restrictions		
Charity care	\$ 193,671	\$ 183,758
Buildings and equipment	851,037	470,888
Clinical care, research and academic	2,694,448	2,392,829
	<u>\$ 3,739,156</u>	<u>\$ 3,047,475</u>

Endowment

Our endowment consists of numerous individual funds established for a variety of purposes and includes both endowment funds with donor restrictions and funds designated by boards to function as endowment. We have interpreted UPMIFA as requiring the preservation of the value of the original contribution of the endowment funds with donor restrictions absent explicit donor stipulations to the contrary. As a result of this interpretation, we classify net assets with donor restrictions, the original value of all contributions with donor stipulations to maintain in perpetuity, accumulated gains required to be maintained in perpetuity by explicit donor stipulation or accumulated gains which have been appropriated for expenditure in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, we consider several factors in making a determination to appropriate or accumulate endowment funds with donor restrictions. These factors include: the duration and preservation of the fund; the purposes of the organization and the endowment fund with donor restrictions; general economic conditions; the possible effect of inflation and deflation; the expected total return from income and the appreciation of investments; other resources of the organization; and the investment policies of the organization.

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

Endowment Funds with Deficits

From time to time, the value of assets associated with individual endowment funds with donor restrictions may fall below the value of the initial and subsequent donor contribution amounts. These deficits generally result from unfavorable market fluctuations that occurred after the investment of new contributions with donor restrictions or subsequent endowment additions. When such endowment deficits exist, they are classified as a reduction to net assets with donor restrictions.

The following presents the endowment net asset composition by type of fund as of September 30, 2023 and 2022 and the changes in endowment assets for the years ended September 30, 2023 and 2022:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net asset composition by type of fund as of September 30, 2023			
Endowment funds with donor restrictions	\$ -	\$ 2,441,991	\$ 2,441,991
Endowment funds with board designations	1,368,005	-	1,368,005
Total funds	<u>\$ 1,368,005</u>	<u>\$ 2,441,991</u>	<u>\$ 3,809,996</u>
	Without Donor Restrictions	With Donor Restrictions	Total
Changes in endowment net assets			
Endowment net assets at September 30, 2022			
	<u>\$ 1,285,916</u>	<u>\$ 2,167,346</u>	<u>\$ 3,453,262</u>
Investment return			
Investment loss	(296)	(498)	(794)
Net realized and unrealized appreciation	129,862	216,938	346,800
Total investment return	129,566	216,440	346,006
Contributions	9,396	151,356	160,752
Appropriation of endowment assets for expenditure	(59,336)	(101,597)	(160,933)
Other changes	2,463	8,446	10,909
Total changes	<u>82,089</u>	<u>274,645</u>	<u>356,734</u>
Endowment net assets at September 30, 2023	<u>\$ 1,368,005</u>	<u>\$ 2,441,991</u>	<u>\$ 3,809,996</u>

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2023 and 2022

(in thousands of dollars)

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net asset composition by type of fund as of September 30, 2022			
Endowment funds with donor restrictions	\$ -	\$ 2,167,346	\$ 2,167,346
Endowment funds with board designations	1,285,916	-	1,285,916
Total funds	<u>\$ 1,285,916</u>	<u>\$ 2,167,346</u>	<u>\$ 3,453,262</u>
	Without Donor Restrictions	With Donor Restrictions	Total
Changes in endowment net assets			
Endowment net assets at September 30, 2021			
	<u>\$ 1,582,262</u>	<u>\$ 2,543,776</u>	<u>\$ 4,126,038</u>
Investment return			
Investment income	902	1,484	2,386
Net realized and unrealized appreciation	(262,195)	(428,389)	(690,584)
Total investment return	(261,293)	(426,905)	(688,198)
Contributions	7,855	141,343	149,198
Appropriation of endowment assets for expenditure	(54,754)	(90,550)	(145,304)
Other changes	11,846	(318)	11,528
Total changes	(296,346)	(376,430)	(672,776)
Endowment net assets at September 30, 2022			
	<u>\$ 1,285,916</u>	<u>\$ 2,167,346</u>	<u>\$ 3,453,262</u>

20. Functional Expenses

Expenses by functional classification are allocated based on management's judgement, the nature of the expense and historical experience. Such classifications and allocations are as follows:

	Healthcare Services	Research and Academic	Insurance	General and Administrative	Year Ended September 30, 2023
Operating expenses					
Employee compensation and benefit expense	\$ 8,296,219	\$ -	\$ 72,326	\$ 1,290,735	\$ 9,659,280
Supplies and other expenses	4,644,283	-	80,980	250,893	4,976,156
Medical claims and related expenses	-	-	1,086,589	-	1,086,589
Direct academic and research expenses	-	2,066,518	-	-	2,066,518
Depreciation and amortization expenses	687,592	-	-	86,971	774,563
Interest expense	104,199	-	-	64,566	168,765
Total operating expenses	<u>\$ 13,732,293</u>	<u>\$ 2,066,518</u>	<u>\$ 1,239,895</u>	<u>\$ 1,693,165</u>	<u>\$ 18,731,871</u>

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2023 and 2022

(in thousands of dollars)

Direct academic and research expenses include \$1,228,043 of employee compensation and benefit expense and \$838,475 of supplies and other expenses for the year ended September 30, 2023.

	Healthcare Services	Research and Academic	Insurance	General and Administrative	Year Ended September 30, 2023
Nonoperating expenses					
Employee compensation and benefit expense	\$ -	\$ -	\$ -	\$ 78,209	\$ 78,209
Supplies and other expenses	-	-	-	37,363	37,363
Interest expense	-	-	-	63,720	63,720
Pension related interest costs	341,062	49,229	-	56,030	446,321
Total nonoperating expenses	\$ 341,062	\$ 49,229	\$ -	\$ 235,322	\$ 625,613

	Healthcare Services	Research and Academic	Insurance	General and Administrative	Year Ended September 30, 2022
Operating expenses					
Employee compensation and benefit expense	\$ 7,766,887	\$ -	\$ 60,507	\$ 1,317,076	\$ 9,144,470
Supplies and other expenses	4,274,806	-	66,741	61,446	4,402,993
Medical claims and related expenses	-	-	722,212	-	722,212
Direct academic and research expenses	-	1,937,738	-	-	1,937,738
Depreciation and amortization expenses	662,229	-	-	107,554	769,783
Interest expense	103,964	-	-	60,869	164,833
Total operating expenses	\$ 12,807,886	\$ 1,937,738	\$ 849,460	\$ 1,546,945	\$ 17,142,029

Direct academic and research expenses include \$1,147,460 of employee compensation and benefit expense and \$790,278 of supplies and other expenses for the year ended September 30, 2022.

	Healthcare Services	Research and Academic	Insurance	General and Administrative	Year Ended September 30, 2022
Nonoperating expenses					
Employee compensation and benefit expense	\$ -	\$ -	\$ -	\$ 76,262	\$ 76,262
Supplies and other expenses	-	-	-	44,607	44,607
Interest expense	-	-	-	63,599	63,599
Pension related interest cost	239,690	37,184	-	52,188	329,062
Total nonoperating expenses	\$ 239,690	\$ 37,184	\$ -	\$ 236,656	\$ 513,530

21. Contingencies

We are subject to complaints, claims and litigation which arise in the normal course of business. In addition, we are subject to reviews and investigations by various federal and state government agencies to assure compliance with applicable laws, some of which are subject to different interpretations. Governmental review of compliance by healthcare organizations has increased.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2023 and 2022

(in thousands of dollars)

22. Subsequent Events

We have assessed the impact of subsequent events through December 8, 2023, the date the audited financial statements were issued. During this period, there were no subsequent events that require adjustment to the audited financial statements. On November 2, 2023, the Centers for Medicare & Medicaid Services (CMS) published a final rule to remedy underpayments associated with 340B-acquired pharmaceuticals in 2018-2022. CMS will be making a one-time payment to impacted hospitals in 2024 and has estimated Mass General Brigham's payment to be \$97,500. Other than this contract, there were no other events that require disclosure in the notes to the audited financials.

Schedule of Expenditures of Federal Awards

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development and Research Training					
Research and Development					
Administration for Children and Families, Health and Human Services, Department of					
Assistance for Torture Victims	93.604	Center for Victims of Torture	90ZT0187-01-00	\$ 25,743	\$ -
Assistance for Torture Victims	93.604	Center for Victims of Torture	90ZT0214-01-00	116,967	-
			Subtotal	142,710	-
Administration for Community Living (ACL), Health and Human Services, Department of					
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Craig Hospital	90DPTB0017-04-00	13,587	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Direct		1,718,992	195,003
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Spaulding Rehabilitation Hospital	90DPCP0008-04-00	19,199	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Spaulding Rehabilitation Hospital	90DPTB0027-01-00	32,441	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Spaulding Rehabilitation Hospital	90SIMS0017-01-00	15,762	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Spaulding Rehabilitation Hospital	90DPBU0008-01-00	60,769	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Trustees of Indiana University	90DPHF0006-01-00	9,686	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	University of Alabama, Birmingham	90REGE0019-01-00	8,655	-
			Subtotal	1,879,091	195,003
Agency for Healthcare Research and Quality, Health and Human Services, Department of					
Agency for Healthcare Research and Quality Contracts	93.RD9	Abt Associates, Inc.	HHSP2332015000131	14,247	-
Agency for Healthcare Research and Quality Contracts	93.RD9	Direct		2,017	-
Agency for Healthcare Research and Quality Contracts	93.RD9	President and Fellows of Harvard College	51349	55,680	-
COVID-19 Research on Healthcare Costs, Quality and Outcomes	93.226	COVID-19 President and Fellows of Harvard College	5R01HS028240-02	18,152	-
COVID-19 Research on Healthcare Costs, Quality and Outcomes	93.226	COVID-19 RAND Corporation	R18HS026432	(11,541)	-
Research on Healthcare Costs, Quality and Outcomes	93.226	American College of Surgeons	5R18HS026189-03	90,993	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Beth Israel Deaconess Medical Center	5R01HS025702-03	(5,338)	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Boston Medical Center	1R13HS028936-01A1	2,753	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Cincinnati Children's Hospital Medical Center	5R01HS028976-02	15,948	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Direct		4,165,937	520,725
Research on Healthcare Costs, Quality and Outcomes	93.226	Harvard Pilgrim Health Care	R01HS027170	69,143	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Oregon Health & Science University (OHSU)	1R18HS029345-01	171,592	-
Research on Healthcare Costs, Quality and Outcomes	93.226	President and Fellows of Harvard College	1R01HS026753-05	45,231	-
Research on Healthcare Costs, Quality and Outcomes	93.226	President and Fellows of Harvard College	5R18HS027282-04	53,017	-
Research on Healthcare Costs, Quality and Outcomes	93.226	RAND Corporation	5R18HS026432-03	51,683	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Regents of the University of California, San Francisco	1R18HS029366-01	176,078	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Regents of the University of California, San Francisco	5R01HS027369-03	11,276	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Trustees of Columbia University in the City of New York (The)	5R01HS024713-04	(1)	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Tufts Medical Center, Inc.	1R01HS029319-01	62,780	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Utah	1R18HS027960-01	41,851	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Yale University	1U18HS029307-01	146,374	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Yale University	5U18HS016978-15	5,783	-
			Subtotal	5,183,655	520,725
Bureau of Democracy, Human Rights and Labor, State, Department of					
International Programs to Support Democracy, Human Rights and Labor	19.345	International Coalition of Sites of Conscience	S-LMAQM-19-CA-2383	82,728	-
			Subtotal	82,728	-
Centers for Disease Control and Prevention, Health and Human Services, Department of					
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	Children's Hospital Corporation dba Boston Children's Hospital	NU27DD000020-04-00	11,223	-
Centers for Disease Control and Prevention Investigations and Technical Assistance	93.283	Trustees of Columbia University in the City of New York (The)	6U01DP006436-01-02	13,215	-
Centers for Diseases Control and Prevention Contracts	93.RD7	Abt Associates, Inc.	53100	17,018	-
Centers for Diseases Control and Prevention Contracts	93.RD7	Broad Institute, Inc.	75D30122C15113	598,207	-
Centers for Diseases Control and Prevention Contracts	93.RD7	Direct		146,425	-
Centers for Diseases Control and Prevention Contracts	93.RD7	Harvard Pilgrim Health Care	200-2016-91779/75D30121F00002	3,115	-
Centers for Diseases Control and Prevention Contracts	93.RD7	President and Fellows of Harvard College	200-2016-91779/75D30121F003	(7,886)	-
Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.135	Emory University	5U48DP006377-04-00	72,423	-
Chronic Diseases: Research, Control, and Prevention	93.068	American College of Rheumatology (REF)	5NU58DP006908-02-00	1,324	-
COVID-19 Centers for Diseases Control and Prevention Contracts	93.RD7	COVID-19 Broad Institute, Inc.	75D30120C09605	313,858	-
COVID-19 Centers for Diseases Control and Prevention Contracts	93.RD7	COVID-19 Direct		76,917	-
COVID-19 Centers for Diseases Control and Prevention Contracts	93.RD7	COVID-19 NTouchStrategies	75D30121C12802	70,489	80,951
COVID-19 Centers for Diseases Control and Prevention Contracts	93.RD7	COVID-19 Brown University	200-2016-91773-T.O.2	190,886	-
COVID-19 Centers for Diseases Control and Prevention Contracts	93.RD7	COVID-19 Wayne State University	75D30121C11813	205,673	-
COVID-19 Emerging Infections Sentinel Networks	93.860	COVID-19 OliveView/UCLA Education and Research Institute, Inc.	6U01CK000480-05-01	9,675	-
COVID-19 Emerging Infections Sentinel Networks	93.860	COVID-19 OliveView/UCLA Education and Research Institute, Inc.	6U01CK000480-05-05	7,739	-
COVID-19 Emerging Infections Sentinel Networks	93.860	COVID-19 OliveView/UCLA Education and Research Institute, Inc.	U01CK000643-01-02	29,394	-
COVID-19 PPHF: Racial and Ethnic Approaches to Community Health Program financed solely by Public Prevention and Health Funds	93.738	COVID-19 Partners in Health	6NU58DP006594-03-01	266,515	-
COVID-19 Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	COVID-19 Direct		1,243,115	359,140
COVID-19 Strengthening Public Health Systems and Services through					

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
National Partnerships to Improve and Protect the Nation's Health	93.421	COVID-19 University of Vermont Medical Center, The	6NU38OT000280-04-00	13,631	-
COVID-19 Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention	93.326	COVID-19 Direct		530,123	135,692
Global AIDS	93.067	Beth Israel Deaconess Medical Center	5NU2ZGGH002212-02-00	65,379	-
Global AIDS	93.067	Beth Israel Deaconess Medical Center	5NU2ZGGH002212-03-00	(20,043)	-
Injury Prevention and Control Research and State and Community Based Programs	93.136	Boston Medical Center	1R01CE003529-01	32,828	-
Injury Prevention and Control Research and State and Community Based Programs	93.136	Direct		366,785	62,624
NON-ACA/PPHF—Building Capacity of the Public Health System to Improve Population Health through National Nonprofit Organizations	93.424	Broad Institute, inc.	7R01MH123451-02	18,561	-
Occupational Safety and Health Program	93.262	Direct		247,938	-
Occupational Safety and Health Program	93.262	Icahn School of Medicine at Mount Sinai	5U01OH010401-10	78,572	-
Occupational Safety and Health Program	93.262	President and Fellows of Harvard College	5R01OH002421-26	25,771	-
Occupational Safety and Health Program	93.262	President and Fellows of Harvard College	5U19OH008861-17	14,867	-
Occupational Safety and Health Program	93.262	President and Fellows of Harvard College	5U19OH008861-17-00	179,772	-
Packaging and Spreading Proven Pediatric Weight Management Interventions for Use by Low-Income Families	93.349	Direct		571,623	191,693
PPHF: Racial and Ethnic Approaches to Community Health Program					
financed solely by Public Prevention and Health Funds	93.738	Partners in Health	NU58DP006594-02-00	187,383	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Direct		1,331,925	252,048
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Harvard Pilgrim Health Care	5U54CK000611-02-00	17,226	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Harvard Pilgrim Health Care	5U54CK000611-02	79,518	-
Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention	93.326	Direct		568,571	102,925
Tuberculosis Demonstration, Research, Public and Professional Education	93.947	New York University Grossman School of Medicine	5R01DK108803-07	57,507	-
				<u>Subtotal</u>	<u>1,185,073</u>
Centers for Medicare and Medicaid Services, Health and Human Services, Department of Medicare Access and CHIP Reauthorization Act (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program	93.986	Direct		(19,750)	-
				<u>Subtotal</u>	<u>-</u>
Consumer Product Safety Commission, Consumer Product Safety Commission Consumer Product Safety Commission Contracts	93.RD5	Direct		54,686	-
				<u>Subtotal</u>	<u>-</u>
Defense Advanced Research Projects Agency (DARPA), Dept of Defense					
COVID-19 Research and Technology Development	12.910	COVID-19 Charles Stark Draper Laboratory, Inc (The)	75N95010C00035	225	-
Research and Technology Development	12.910	Broad Institute, inc.	HR00112120010	40,802	-
Research and Technology Development	12.910	Charles Stark Draper Laboratory, Inc (The)	N66001-23-C-4018	161,774	-
Research and Technology Development	12.910	Direct		(141,975)	-
Research and Technology Development	12.910	President and Fellows of Harvard College	HR00111920022	110,242	-
				<u>Subtotal</u>	<u>-</u>
Defense Threat Reduction Agency (DTRA), Dept of Defense					
Scientific Research - Combating Weapons of Mass Destruction	12.351	Direct		701,673	73,109
				<u>Subtotal</u>	<u>73,109</u>
Department of Defense, Dept of Defense					
COVID-19 Department of Defense Contracts	93.RD10	COVID-19 Mitre Corporation	1160555	745,509	-
COVID-19 Department of Defense Contracts	93.RD10	COVID-19 Advanced Technology International	2017-605	480,173	-
COVID-19 Department of Defense Contracts	93.RD10	COVID-19 Geneva Foundation, The	W81XWH1590001	170,048	-
COVID-19 Department of Defense Contracts	93.RD10	COVID-19 Nihon Kohden OrangeMed, Inc.	W81XWH159001	38,800	-
Department of Defense Contracts	93.RD10	Direct		1,933,746	609,328
Department of Defense Contracts	93.RD10	Geneva Foundation, The	HU00011920056	806,383	-
Department of Defense Contracts	93.RD10	Geneva Foundation, The	00011920056	2,425,826	116,477
Department of Defense Contracts	93.RD10	Henry M Jackson Foundation for the Advancement of Military Medicine, Inc.	47QFWA20C0012	35,009	-
Department of Defense Contracts	93.RD10	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	FA8650-21-2-7120	29,818	-
Department of Defense Contracts	93.RD10	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	FA8702-15-D-0001	115,332	-
Department of Defense Contracts	93.RD10	Massachusetts Institute of Technology Lincoln Laboratories	FA8702-15-D-0001	629,629	-
Department of Defense Contracts	93.RD10	Massachusetts Institute of Technology Lincoln Laboratories	7000561749	53,487	-
Department of Defense Contracts	93.RD10	Metro International Biotech, LLC	H924051890002	423,585	-
Department of Defense Contracts	93.RD10	President and Fellows of Harvard College	W81XWH22C0128	329,207	-
Department of Defense Contracts	93.RD10	Regents of the University of California, San Francisco	W81XWH1590001	126,094	-
Department of Defense Contracts	93.RD10	Triton Systems, Inc.	W81XWH21C0023	43,974	-
Department of Defense Contracts	93.RD10	Triton Systems, Inc.	W81XWH21C0024	146,416	-
Department of Defense Contracts	93.RD10	Triton Systems, Inc.	HT942523C0012	17,651	-
Department of Defense Contracts	93.RD10	Triton Systems, Inc.	W81XWH22P0042	20,599	-
Department of Defense Contracts	93.RD10	University of Houston	W81XWH2010755	24,829	-
Department of Defense Contracts	93.RD10	University of North Carolina at Chapel Hill, The	W81XWH22C0122	107,466	-
Department of Defense Contracts	93.RD10	University of Pittsburgh Of the Commonwealth System of Higher Education	W81XWH2110542	21,461	-
Department of Defense Contracts	93.RD10	Sylvatica Biotech, Inc	W81XWH21C0060	117,560	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Department of Defense Contracts	93.RD10	University of South Florida	H9240520D0001	1,145,515	-
Department of Defense Contracts	93.RD10	Citizens United for Research in Epilepsy (CURE)	W81XWH1520069	1,566	-
Department of Defense Contracts	93.RD10	Arsenal Medical, Inc.	W81XWH15C0147	8,112	-
Department of Defense Contracts	93.RD10	Real-Time Analyzers, Inc.	W81XWH20C0037	13,326	-
Department of Defense Contracts	93.RD10	Luna Innovations	W81XWH20C0094	43,671	-
Department of Defense Contracts	93.RD10	Coalesenz, Inc	W81XWH20C0119	7,338	-
Department of Defense Contracts	93.RD10	Medical Technology Enterprise Consortium (MTEC)	W81XWH2290004	790,142	-
Department of Defense Contracts	93.RD10	QLEDcures, LLC	W911NF22P0018	37,663	-
				Subtotal	725,805
Dept of The Air Force, Dept of Defense				183,630	-
Air Force Defense Research Sciences Program	12.800	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	FA8702-15-D-0001		-
				Subtotal	183,630
Dept of The Army, Dept of Defense					
Basic Scientific Research	12.431	University of Southern California	W911NF1810434	(1,824)	-
COVID-19 Military Medical Research and Development	12.420	COVID-19 Direct		314,535	-
COVID-19 Military Medical Research and Development	12.420	COVID-19 Dana Farber Cancer Institute	W81XWH2110080	(41,999)	-
COVID-19 Military Medical Research and Development	12.420	COVID-19 Trustees of the University of Pennsylvania	W81XWH2110422	22,253	-
Military Medical Research and Development	12.420	Beth Israel Deaconess Medical Center	W81XWH2210349	11,282	-
Military Medical Research and Development	12.420	Beth Israel Deaconess Medical Center	W81XWH2020023	29,920	-
Military Medical Research and Development	12.420	Beth Israel Deaconess Medical Center	W81XWH20PCRPPRA2	110,076	-
Military Medical Research and Development	12.420	Board of Trustees of the Leland Stanford Junior University, The	W81XWH2010855	365,882	-
Military Medical Research and Development	12.420	Board of Trustees of the University of Alabama for the University of Alabama	W81XWH1510705	(59,063)	-
Military Medical Research and Development	12.420	Board of Trustees of the University of Illinois, The	W81XWH1810661	53,430	-
Military Medical Research and Development	12.420	Boston University School of Medicine	W81XWH2110980	20,533	-
Military Medical Research and Development	12.420	Boston VA Research Institute Inc	W81XWH1710217	(149)	-
Military Medical Research and Development	12.420	Boston VA Research Institute Inc	W81XWH2210568	28,538	-
Military Medical Research and Development	12.420	Boston VA Research Institute Inc	W81XWH1910057	100,722	-
Military Medical Research and Development	12.420	Brigham and Women's Hospital, Inc.	W81XWH1820058	3,633	-
Military Medical Research and Development	12.420	Brigham and Women's Hospital, Inc.	W81XWH1910316	7,097	-
Military Medical Research and Development	12.420	Brigham and Women's Hospital, Inc.	W81XWH1910517	(67)	-
Military Medical Research and Development	12.420	Brigham and Women's Hospital, Inc.	W81XWH1910708	2,354	-
Military Medical Research and Development	12.420	Children's Hospital Corporation dba Boston Children's Hospital	W81XWH1910219	12,314	-
Military Medical Research and Development	12.420	Children's Hospital Corporation dba Boston Children's Hospital	W81XWH1910560	(387)	-
Military Medical Research and Development	12.420	Children's Hospital Los Angeles	W81XWH2110257	13,904	-
Military Medical Research and Development	12.420	Dana Farber Cancer Institute	W81XWH2010057	5,565	-
Military Medical Research and Development	12.420	Dana Farber Cancer Institute	W81XWH2110482	58,868	-
Military Medical Research and Development	12.420	Dana Farber Cancer Institute	W81XWH2210705	34,900	-
Military Medical Research and Development	12.420	Dana Farber Cancer Institute	W81XWH1910780	119,184	-
Military Medical Research and Development	12.420	Dana Farber Cancer Institute	W81XWH2110981	91,513	-
Military Medical Research and Development	12.420	Dartmouth-Hitchcock Clinic	W81XWH2010319	582	-
Military Medical Research and Development	12.420	Direct		38,934,906	2,854,409
Military Medical Research and Development	12.420	Geneva Foundation, The	W81XWH2010833	9,626	-
Military Medical Research and Development	12.420	Henry M Jackson Foundation for the Advancement of Military Medicine, Inc.	W81XWH2020061	1,928	-
Military Medical Research and Development	12.420	Icahn School of Medicine at Mount Sinai	W81XWH2210999	145,384	-
Military Medical Research and Development	12.420	Joan & Sanford I. Weill Medical College of Cornell University	W81XWH1810667	488,220	-
Military Medical Research and Development	12.420	Johns Hopkins University	10054547-01	13,168	-
Military Medical Research and Development	12.420	Johns Hopkins University	W81XWH1620060	5,496	-
Military Medical Research and Development	12.420	Massachusetts Eye and Ear Infirmary	HT94252310284	33,307	-
Military Medical Research and Development	12.420	Massachusetts General Hospital	243076	14,809	-
Military Medical Research and Development	12.420	Massachusetts General Hospital	W81XWH2010293	49,202	-
Military Medical Research and Development	12.420	Massachusetts General Hospital	W81XWH2210293	15,051	-
Military Medical Research and Development	12.420	Massachusetts General Hospital	W81XWH2211053	16,856	-
Military Medical Research and Development	12.420	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	W81XWH1910151	5,351	-
Military Medical Research and Development	12.420	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	W81XWH2110235	34,706	-
Military Medical Research and Development	12.420	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	W81XWH1820010	73,386	-
Military Medical Research and Development	12.420	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	W81XWH2110245	23,018	-
Military Medical Research and Development	12.420	Mayo Clinic	W81XWH1510293	33	-
Military Medical Research and Development	12.420	Michigan State University	W81XWH2110744	27,871	-
Military Medical Research and Development	12.420	New York University Grossman School of Medicine	W81XWH2220078	312,264	-
Military Medical Research and Development	12.420	Northwestern University	W81XWH2210166	24,828	-
Military Medical Research and Development	12.420	President and Fellows of Harvard College	W81XWH1910696	(2,349)	-
Military Medical Research and Development	12.420	President and Fellows of Harvard College	W81XWH1920011	11,513	-
Military Medical Research and Development	12.420	President and Fellows of Harvard College	W81XWH2010303	58,863	-
Military Medical Research and Development	12.420	President and Fellows of Harvard College	W81XWH2110326	20,273	-
Military Medical Research and Development	12.420	Regents of the University of California, Los Angeles, The	W81XWH2110869	89,841	-
Military Medical Research and Development	12.420	Regents of the University of California, San Diego	W81XWH1710671	97,530	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Military Medical Research and Development	12.420	Regents of the University of California, San Francisco	W81XWH1820042	44,902	-
Military Medical Research and Development	12.420	Trustees of Boston University	W81XWH2110980	32,203	-
Military Medical Research and Development	12.420	Trustees of Boston University	W81XWH1910765	5,033	-
Military Medical Research and Development	12.420	Trustees of the University of Pennsylvania	W81XWH1810861	13,092	-
Military Medical Research and Development	12.420	University of Alabama, Birmingham	W81XWH1720037	13,668	-
Military Medical Research and Development	12.420	University of Texas Health Science Center at San Antonio	W81XWH2120044	51,475	-
Military Medical Research and Development	12.420	Regents of the University of California, Davis	HT94252310153	92,689	-
Military Medical Research and Development	12.420	Axogen Corporation	W81XWH18PRORPCTRA	102,877	-
Military Medical Research and Development	12.420	Moberg Research, Inc.	W81XWH1920013	154,570	-
Military Medical Research and Development	12.420	Melanoma Research Alliance	W81XWH2110819	15,263	-
Military Medical Research and Development	12.420	MD Anderson Cancer Center	W81XWH2210890	57,120	-
Military Medical Research and Development	12.420	Trustees of Tufts College	W81XWH2211065	20,578	-
Military Medical Research and Development	12.420	American University	W81XWH2220012	120,798	-
				Subtotal	2,854,409
Energy, Department of, Energy, Department of					
Advanced Research Projects Agency - Energy	81.135	Texas A&M University	DE-AR0000823	248,265	-
Office of Science Financial Assistance Program	81.049	North Carolina State University	DE-SC0023334	47,085	-
U.S. Department of Energy Contracts	93.RD4	Broad Institute, inc.	2F-60037Rev,1	(337)	-
				Subtotal	295,013
Federal Aviation Administration, Transportation, Department of					
Federal Aviation Administration Contracts	93.RD14	Boston University School of Public Health	13-C-AJFE-BU-027	101,177	-
Federal Aviation Administration Contracts	93.RD14	Direct		923,977	-
				Subtotal	1,025,154
Federal Communications Commission, Federal Communications Commission					
Federal Communications Commission Contracts	93.RD11	Direct		168,686	-
				Subtotal	168,686
Food and Drug Administration, Health and Human Services, Department of					
COVID-19 U.S. Food & Drug Administration Contracts	93.RD8	COVID-19 American College of Medical Toxicology, Inc.	75F40122D00028	2,695	-
Food and Drug Administration Research	93.103	Direct		2,161,094	197,567
Food and Drug Administration Research	93.103	President and Fellows of Harvard College	1R43DP006690-01	1,423	-
Food and Drug Administration Research	93.103	Regents of the University of California, San Diego	1U01FD007773-01	52,552	-
Food and Drug Administration Research	93.103	Regents of the University of Minnesota	1R01FD007630-01	13,338	-
Food and Drug Administration Research	93.103	Vanderbilt University Medical Center	1R01FD007627-01	8,503	-
Food and Drug Administration Research	93.103	Perspectum Ltd	U01FD006880	(3,085)	-
U.S. Food & Drug Administration Contracts	93.RD8	Direct		2,149,796	12,290
U.S. Food & Drug Administration Contracts	93.RD8	Harvard Pilgrim Health Care	75F40119D10037	1,495,512	-
U.S. Food & Drug Administration Contracts	93.RD8	Regents of the University of Michigan	75F40121C00148	75,251	-
U.S. Food & Drug Administration Contracts	93.RD8	American College of Radiology	75F40120C00093	6,895	-
				Subtotal	209,857
Health Resources and Services Administration, Health and Human Services, Department of					
COVID-19 Mental and Behavioral Health Education and Training Grants	93.732	COVID-19 Massachusetts League of Community Health Centers, Inc.	1U3MHP45385-01-00	330,904	-
Health Systems Strengthening and HIV/AIDS Prevention, Care and Treatment under the President's Emergency Plan for AIDS Relief	93.266	Boston Medical Center	5R18HS026177-05	18,746	-
HIV Emergency Relief Project Grants	93.914	Fenway Community Health Center	U69HA31067	5,591	-
HIV-Related Training and Technical Assistance	93.145	Fenway Community Health Center	5U28HA376440100	11,144	-
HIV-Related Training and Technical Assistance	93.145	Fenway Community Health Center	6U1OHA29294-08	2,615	-
HIV-Related Training and Technical Assistance	93.145	Fenway Community Health Center	U1OHA29294	6,622	-
Maternal and Child Health Federal Consolidated Programs	93.110	Direct		149,360	-
Maternal and Child Health Federal Consolidated Programs	93.110	Education Development Center, Inc.	2UF4MC26525	78,365	-
Maternal and Child Health Federal Consolidated Programs	93.110	Education Development Center, Inc.	UF4MC26525	(56)	-
Maternal and Child Health Federal Consolidated Programs	93.110	Ichahn School of Medicine at Mount Sinai	5H30MC24048-12	3,553	-
Maternal and Child Health Federal Consolidated Programs	93.110	President and Fellows of Harvard College	RS20210327-01	29,039	-
Maternal and Child Health Federal Consolidated Programs	93.110	University of Colorado at Denver	SUMA6MC31101-05-00	(10,838)	-
Maternal and Child Health Federal Consolidated Programs	93.110	HHT Foundation International Inc.	1UP4MC46404-01-00	98,849	-
Special Projects of National Significance	93.928	Fenway Community Health Center	5U90HA42153-02	30,090	-
Technical and Non-Financial Assistance to Health Centers	93.129	Fenway Community Health Center	5U30CS22742-12	16,485	-
Technical and Non-Financial Assistance to Health Centers	93.129	Fenway Community Health Center	U30CS22742	22,273	-
Technical and Non-Financial Assistance to Health Centers	93.129	Fenway Community Health Center	U3FCS41777	6,685	-
Telehealth Programs	93.211	President and Fellows of Harvard College	5U3IRI143510	62,704	-
				Subtotal	862,131
Immed Office of The Secretary Of Health and Human Services, Health and Human Services, Department of					
Biomedical Advanced Research and Development Authority	93.RD13	Mitre Corporation	OVH001.FINA.201.A2TO:1163811	122,161	-
COVID-19 Biomedical Advanced Research and Development Authority	93.RD13	COVID-19 Beckman Coulter, Inc.	75A0120C00189	26,549	21,000

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
COVID-19 Biomedical Advanced Research and Development Authority	93.RD13	COVID-19 Beckman Coulter, Inc.	75A50122C00036	345,173	45,603
COVID-19 Biomedical Advanced Research and Development Authority	93.RD13	COVID-19 Battelle Memorial Institute	75A50121P00058	16,774	-
COVID-19 National Ebola Training and Education Center (NETEC)	93.825	COVID-19 Emory University	6U3REP150549-05-16	115,867	-
COVID-19 National Ebola Training and Education Center (NETEC)	93.825	COVID-19 New York City Health and Hospitals Corporation	6NU38CK000482-01-05	66,211	-
COVID-19 National Ebola Training and Education Center (NETEC)	93.825	COVID-19 New York City Health and Hospitals Corporation	6NU38CK000482-01-06	(21,796)	-
National Ebola Training and Education Center (NETEC)	93.825	Emory University	6U3REP170552-04-05	(9)	-
National Ebola Training and Education Center (NETEC)	93.825	New York City Health and Hospitals Corporation	6NU38CK000482-01-10	157,053	-
				<u>827,893</u>	<u>66,603</u>
Institute of Education Sciences, Education, Department of Education Research, Development and Dissemination	84.305	Regents of the University of Minnesota	R305A180265	(669)	-
				<u>(669)</u>	<u>-</u>
National Aeronautics and Space Administration, National Aeronautics and Space Administration					
Exploration	43.003	Baylor College of Medicine	80NSSC21K0757	15,971	-
Exploration	43.003	Direct		1,372,488	277,867
Exploration	43.003	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	7000000324/NNX16A069A	227,564	-
Exploration	43.003	Thomas Jefferson University	NNX15AC14G	2,292	-
Exploration	43.003	Trustees of the University of Pennsylvania	NNX15AK76A	67,428	-
National Aeronautics and Space Administration Contracts	93.RD17	Direct		247,026	-
National Aeronautics and Space Administration Contracts	93.RD17	KBRWyle	NNJ15HK11B	65,225	7,370
National Aeronautics and Space Administration Contracts	93.RD17	Wake Forest University Health Sciences	80ARC022CA008	53,408	-
Science	43.001	Direct		9,221	-
Science	43.001	Georgia Institute of Technology	80NSSC21K0234	75,040	-
				<u>2,135,663</u>	<u>285,237</u>
National Institute of Food and Agriculture, Agriculture, Department of COVID-19 Food Insecurity Nutrition Incentive Grants Program	10.331	COVID-19 Community Outreachand Patient Empowerment Program, Inc.	2021-70034-34991	(2,462)	-
Food Insecurity Nutrition Incentive Grants Program	10.331	Community Outreachand Patient Empowerment Program, Inc.	2019-70030-30407	(3,106)	-
				<u>(5,568)</u>	<u>-</u>
National Institute of Standards and Technology, Commerce, Department of Measurement and Engineering Research and Standards	11.609	Direct		137,841	-
				<u>137,841</u>	<u>-</u>
National Institutes of Health, Health and Human Services, Department of					
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Broad Institute, inc.	1U2CCA252974-01	20,361	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Broad Institute, inc.	1206405	8,687	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Broad Institute, inc.	5U2CCA33195-03	1,838	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Broad Institute, inc.	U01DE029188-01	14,756	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Broad Institute, inc.	U2CCA233238	1,929	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana Farber Cancer Institute	1U01CA250549-01	3,649	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana Farber Cancer Institute	1U01CA274276-01	12,597	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana Farber Cancer Institute	1U01DE029188-01	203,047	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana Farber Cancer Institute	1U2CCA233195-01	(218)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana Farber Cancer Institute	1U2CCA233195-03	5,039	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana Farber Cancer Institute	1U2CCA233195-04	5,039	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana Farber Cancer Institute	2P01CA163222	15,282	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana Farber Cancer Institute	5P01CA154303-09	9	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana Farber Cancer Institute	5U2CCA233195-05	159,525	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana Farber Cancer Institute	R33CA246455-02	5,081	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana Farber Cancer Institute	U24CA224331	20,564	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana Farber Cancer Institute	1U54CA231637-01	316,701	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Direct		1,668,727	323,499
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5U01CA250554-03	44,034	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	1U2CCA233262-01	1,096,118	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	1U2CCA233280	26,492	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	5U2CCA233280-05	8,124	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	3P50CA244433-04S1	175,558	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	3U01CA253912-03S2	29,105	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	5P50CA244433-03	59,909	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	5P50CA244433-04	117,739	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	P50CA244433-03S3	(2,674)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	P50CA244433-04	372,192	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Yale University	5U2CCA252979-02	155,181	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Wys Institute at Harvard University	1U54CA244726-01	386,732	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	University of Texas - Southwestern Medical Center	3UM1CA221940-05S1	49,502	-
21st Century Cures Act - Precision Medicine Initiative	93.368	Broad Institute, inc.	1OT2OD002750-01	49,072	-
21st Century Cures Act - Precision Medicine Initiative	93.368	Broad Institute, inc.	3OT2OD002750-01S3	187,143	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
21st Century Cures Act - Precision Medicine Initiative	93.868	Broad Institute, inc.	OT20D002750	47,316	-
Aging Research	93.866	Albert Einstein College of Medicine	5R01AG062622-04	16,703	-
Aging Research	93.866	Allec, Inc.	1R43AG072991-01	(926)	-
Aging Research	93.866	Beth Israel Deaconess Medical Center	1R56AG075017-01A1	27,697	-
Aging Research	93.866	Beth Israel Deaconess Medical Center	5R01AG052282-05	47,675	-
Aging Research	93.866	Beth Israel Deaconess Medical Center	5R01AG065554-04	86,787	-
Aging Research	93.866	Beth Israel Deaconess Medical Center	5R01AG055559-05	11,773	-
Aging Research	93.866	BioSensics LLC	5R42AG059491	9,723	-
Aging Research	93.866	BioSensics LLC	5R42AG059491-03	48,458	-
Aging Research	93.866	BioSensics LLC	1R44AG080861-01	198,103	-
Aging Research	93.866	Board of Regents of the University of Wisconsin System, The	WEI2990-10	47,253	-
Aging Research	93.866	Boston Medical Center	5R01AG066892-03	(36,484)	-
Aging Research	93.866	Boston University School of Medicine	5R01AG066914-04	54,489	-
Aging Research	93.866	Boston University School of Medicine	7R01AG069917-02	52,918	-
Aging Research	93.866	Boston University School of Medicine	1RF1AG061706-01	142,378	-
Aging Research	93.866	Boston University School of Medicine	SU19AG073172-02	627,593	-
Aging Research	93.866	Boston VA Research Institute Inc	7RF1AG061774-02	199,403	-
Aging Research	93.866	Brandeis University	5P30AG048785-09	19,164	-
Aging Research	93.866	Brandeis University	5R01AG074330-02	715,678	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	1P01AG071463-01A1	729,640	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG066921-04	138,477	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	1R01AG080429-01	11,232	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	1RF1AG063381-01	5,807	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	1RF1AG064312-01	(2,317)	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	2P01AG015379-25	562,033	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5P01AG015379-25	291,884	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5P30AG064199-03	(706)	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5P30AG064199-04	24,918	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG042512-10	53,304	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG053184-05	266,938	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG054029-05	184,577	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG058825-04	433,957	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG061083-05	365,000	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG063689-04	220,621	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG067507-04	200,020	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG070252-03	17,725	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG077489-02	27,487	-
Aging Research	93.866	Broad Institute, inc.	DP2AG058488	21	-
Aging Research	93.866	Brown University	5P01AG027296-14	36,223	-
Aging Research	93.866	Brown University	5U54AG063546-03	(8,593)	-
Aging Research	93.866	Brown University	5U54AG063546-04	37,353	-
Aging Research	93.866	Cedar-Sinai Medical Center	5R01AG058911-05	175,704	-
Aging Research	93.866	Cedar-Sinai Medical Center	5U54AG065141-03	21,533	-
Aging Research	93.866	Children's Hospital Corporation dba Boston Children's Hospital	1R01AG078929-01	33,048	-
Aging Research	93.866	Children's Hospital Corporation dba Boston Children's Hospital	5R01AG070921-02	10,931	-
Aging Research	93.866	Columbia University Medical Center	SU01AG051412-05	28,944	-
Aging Research	93.866	Dana Farber Cancer Institute	5UH3AG060626-05	290,018	-
Aging Research	93.866	Direct		122,175,050	33,739,683
Aging Research	93.866	Duke University	1RF1AG059093-01	201,885	-
Aging Research	93.866	Emory University	5R01AG058704-05	18,417	-
Aging Research	93.866	Emory University	5R01AG066956-03	97,089	-
Aging Research	93.866	Emory University	5R01AG070704-03	59,106	-
Aging Research	93.866	ExQor Technologies Inc	2R44AG058343-04	142,645	-
Aging Research	93.866	ExQor Technologies Inc	4R44AG05834302	(1,560)	-
Aging Research	93.866	Function Promoting Therapies, LLC	1R33AG068234-01	41,522	-
Aging Research	93.866	Function Promoting Therapies, LLC	2R44AG045011-04	126,417	-
Aging Research	93.866	General Biophysics LLC	R41AG073059	194,554	-
Aging Research	93.866	Hebrew Rehabilitation Center for Aged	5P01AG031720-10	151,818	-
Aging Research	93.866	Hebrew Rehabilitation Center for Aged	5R03AG075434-02	39,532	-
Aging Research	93.866	Hebrew Rehabilitation Center for Aged	90083	37,078	-
Aging Research	93.866	Hebrew Rehabilitation Center for Aged	1R01AG059099	18,324	-
Aging Research	93.866	Hebrew Rehabilitation Center for Aged	1R01AG076708-01	48,444	-
Aging Research	93.866	Hebrew Senior Life	5P01AG031720-10	109,160	-
Aging Research	93.866	Hebrew Senior Life	P01AG031720	2,218	-
Aging Research	93.866	Highland Instruments	1R44AG055360-01	74,383	-
Aging Research	93.866	Icahn School of Medicine at Mount Sinai	5P01AG066605-03	49,433	-
Aging Research	93.866	Icahn School of Medicine at Mount Sinai	5R01AG053509-05	5	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Aging Research	93.866	Johns Hopkins University School of Medicine	5R01AG050515-05	303,373	-
Aging Research	93.866	Massachusetts General Hospital	1R01AG089678-01	171,391	-
Aging Research	93.866	Massachusetts General Hospital	1RF1AG067744-01	69,479	-
Aging Research	93.866	Massachusetts General Hospital	1RF1AG074008-01	77,502	-
Aging Research	93.866	Massachusetts General Hospital	5R01AG054081-05	(18)	-
Aging Research	93.866	Massachusetts General Hospital	5R01AG062667-04	113,678	-
Aging Research	93.866	Massachusetts General Hospital	5R01AG065254-03	44,046	-
Aging Research	93.866	Massachusetts General Hospital	5R01AG067019-05	33,606	-
Aging Research	93.866	Massachusetts General Hospital	5R01AG071865-03	5,455	-
Aging Research	93.866	Massachusetts General Hospital	7R01AG065254-02	20,386	-
Aging Research	93.866	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	1R01AG081017-01	52,415	-
Aging Research	93.866	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	1R56AG069192-01	(579)	-
Aging Research	93.866	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5R01AG058002-04	22,488	-
Aging Research	93.866	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	P30AG064190-03	54,940	-
Aging Research	93.866	Mayo Clinic	5U19AG063911-04	219,926	-
Aging Research	93.866	Mayo Clinic	5U19AG063911-05	129,816	-
Aging Research	93.866	MelaxTechnologies	1R44AG081006-01	27,466	-
Aging Research	93.866	Michigan State University	1RF1AG072449-01	446,478	-
Aging Research	93.866	Northern California Institute for Research and Education	5U19AG024904-17	70,415	-
Aging Research	93.866	Northwestern University	3RF1AG064006-01S1	285,663	-
Aging Research	93.866	Northwestern University	SU2CAG057441-03S1	39,473	-
Aging Research	93.866	Northwestern University	SU2CAG060426-04S1	62,053	-
Aging Research	93.866	Ohio State University	5R01AG073113-03	35,606	-
Aging Research	93.866	Ohio State University	1R01AG050801-05	5,914	-
Aging Research	93.866	Ohio State University	5R01AG058822-05	24,055	-
Aging Research	93.866	Oregon Health & Science University (OHSU)	1RF1AG069782-01	17,635	-
Aging Research	93.866	Oregon Health & Science University (OHSU)	5R01AG056102-05	292,933	-
Aging Research	93.866	Pennsylvania State University	SU2CAG060408-05	197,159	-
Aging Research	93.866	Pennsylvania State University	5R01AG077016-02	32,612	-
Aging Research	93.866	President and Fellows of Harvard College	2R01AG011085-30	86,600	-
Aging Research	93.866	President and Fellows of Harvard College	3R01AG048917-05	171	-
Aging Research	93.866	President and Fellows of Harvard College	5P01AG041710-08	59,301	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG011085-29	146,071	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG060935-03	25,778	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG066793-02	14,443	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG068122-03	51,412	-
Aging Research	93.866	President and Fellows of Harvard College	1R21AG072516-01	155,256	-
Aging Research	93.866	President and Fellows of Harvard College	1RF1AG061774-01	(2,665)	-
Aging Research	93.866	President and Fellows of Harvard College	1RF1AG074372-01A1	297,337	-
Aging Research	93.866	President and Fellows of Harvard College	1RF1AG078377-01	450,105	-
Aging Research	93.866	President and Fellows of Harvard College	1RF1AG081475-01	9,878	-
Aging Research	93.866	President and Fellows of Harvard College	2P01AG032952-13	91,096	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG066793-03	18,054	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG067420-04	57,805	-
Aging Research	93.866	President and Fellows of Harvard College	R01HS026753	52,473	-
Aging Research	93.866	Regents of the University of California, Los Angeles, The	5R01AG054366-05	5,370	-
Aging Research	93.866	Regents of the University of California, San Diego	5R01AG075758-02	83,087	-
Aging Research	93.866	Regents of the University of California, San Diego	7R56AG069107-02	(7)	-
Aging Research	93.866	Regents of the University of California, San Francisco	5R01AG066137-05	111,107	-
Aging Research	93.866	Research Foundation for Mental Hygiene, Inc.	5R01AG066828-04	32,164	-
Aging Research	93.866	Research Foundation for The SUNY Stony Brook University, The	5R21AG074707-02	18,799	-
Aging Research	93.866	RetiSpecnc.	1R01AG053184-01	1,654	-
Aging Research	93.866	Rush University Medical Center	5R01AG017917-19	175,735	-
Aging Research	93.866	Rush University Medical Center	5R01AG052583-05	471,587	-
Aging Research	93.866	Rush University Medical Center	5R01AG061798-03	8,697	-
Aging Research	93.866	Rush University Medical Center	5R01AG062637-03	322,555	-
Aging Research	93.866	Rush University Medical Center	1RF1AG052621	44,600	-
Aging Research	93.866	Seattle Institute for Biomedical and Clinical Research	5R01AG061558-04	331,317	-
Aging Research	93.866	Translational Genomics Research Institute	SUH3AG064706-04	159,033	-
Aging Research	93.866	Translational Genomics Research Institute	SU19AG073153-02	22,420	-
Aging Research	93.866	Trustees of Boston University	1RF1AG068121-01	73,140	-
Aging Research	93.866	Trustees of Boston University	5R01AG066010-04	95,877	-
Aging Research	93.866	Trustees of Boston University	5R01AG067394-04	86,510	-
Aging Research	93.866	Trustees of Boston University	1R01AG073179-01	50,794	-
Aging Research	93.866	Trustees of Boston University	1U01AG068221-01A1	(31,123)	-
Aging Research	93.866	Trustees of Boston University	5R01AG070135-03	40,282	-
Aging Research	93.866	Trustees of Boston University	5U19AG068753-03	453,650	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Aging Research	93.866	Trustees of Boston University	SU19AG073172-02	466,347	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The	1R21AG080464-01	11,486	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The	1RF1AG072167-01A1	548,864	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The	SU01AG061356-03S1	172,503	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The	SU01AG061356-05	140,971	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The	SU01AG072572-03	524,311	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The	5P30AG064198-03	(472)	-
Aging Research	93.866	Trustees of Indiana University	SU01AG057195-03S1	480	-
Aging Research	93.866	Trustees of Indiana University	SU01AG057195-05	809,419	-
Aging Research	93.866	Trustees of the University of Pennsylvania	1R01AG072796-01A1	201,057	-
Aging Research	93.866	Trustees of the University of Pennsylvania	SU01AG032984-14	18,927	-
Aging Research	93.866	Tufts Medical Center, Inc.	5R01AG064064-03	9,623	-
Aging Research	93.866	Tufts University	1R56AG065236	(558)	-
Aging Research	93.866	Tufts University	5R01AG059011-05	91,175	-
Aging Research	93.866	University of California at Davis	RF1AG054548	(69,872)	-
Aging Research	93.866	University of California at Davis	5R01AG052132-04	24,432	-
Aging Research	93.866	University of Cincinnati	5R01AG072087-04	172,892	-
Aging Research	93.866	University of Colorado at Denver	5R01AG054366-05	(4,867)	-
Aging Research	93.866	University of Massachusetts Amherst	2R01AG051600-05	45,740	-
Aging Research	93.866	University of Massachusetts Amherst	5P30AG073107-02	325,761	-
Aging Research	93.866	University of Massachusetts Amherst	5P30AG073107-03	230,480	-
Aging Research	93.866	University of Massachusetts Amherst	P30AG073107	76,511	-
Aging Research	93.866	University of Massachusetts at Lowell	R21AG068890	(58,628)	-
Aging Research	93.866	University of Massachusetts Medical School	7U01AG068221-02	134,413	-
Aging Research	93.866	University of Miami	5R01AG067568-03	182,613	-
Aging Research	93.866	University of North Carolina at Chapel Hill, The	3R01AG065394-03S1	28,607	-
Aging Research	93.866	University of North Carolina at Chapel Hill, The	5R01AG065394-02	103,148	-
Aging Research	93.866	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01AG066198-04	415,276	-
Aging Research	93.866	University of Pittsburgh Of the Commonwealth System of Higher Education	1R01AG068567	(5,672)	-
Aging Research	93.866	University of Pittsburgh Of the Commonwealth System of Higher Education	1U19AG063720-01A1	712,151	-
Aging Research	93.866	University of Pittsburgh Of the Commonwealth System of Higher Education	3U19AG063720-02S2	20,047	-
Aging Research	93.866	University of Pittsburgh Of the Commonwealth System of Higher Education	3U19AG068054-03S3	132,754	-
Aging Research	93.866	University of Pittsburgh Of the Commonwealth System of Higher Education	U19AG068054	1,308,005	-
Aging Research	93.866	University of Rochester	5P01AG047200-09	316,641	-
Aging Research	93.866	University of Southern California	1R01AG061848-01	28,192	-
Aging Research	93.866	University of Southern California	3R01AG051125-07S1	8,660	-
Aging Research	93.866	University of Southern California	3U24AG057437-04S1	83,668	-
Aging Research	93.866	University of Southern California	4U19AG010483-25	497,214	-
Aging Research	93.866	University of Southern California	5R01AG053798-04	41,531	-
Aging Research	93.866	University of Southern California	5R01AG053798-05	181,786	-
Aging Research	93.866	University of Southern California	5R01AG054029-02	78,289	-
Aging Research	93.866	University of Southern California	5R01AG063689-02	486,991	-
Aging Research	93.866	University of Southern California	SU19AG024904-14	5,642	-
Aging Research	93.866	University of Southern California	SU24AG057437-02	125,151	-
Aging Research	93.866	University of Southern California	SU24AG057437-05	736,920	-
Aging Research	93.866	University of Southern California	1RF1AG057892-01A1	43,113	-
Aging Research	93.866	University of Southern California	5R01AG061848-03	310,551	-
Aging Research	93.866	University of Tennessee Medical Center	A22-1001-S001	44,709	-
Aging Research	93.866	University of Texas Health Science Center at San Antonio	5R01AG062531-03	203,582	-
Aging Research	93.866	University of Texas Health Science Center at San Antonio	5R01AG066524-02	169,101	-
Aging Research	93.866	University of Texas Health Science Center at San Antonio	5R01AG054078-05	885,325	-
Aging Research	93.866	University of Texas Southwestern Medical Center	5R01AG056426-05	164,171	-
Aging Research	93.866	University of Texas Southwestern Medical Center	5R01AG062770-05	25,313	-
Aging Research	93.866	University of Washington	5R33AG067069-03	(1,956)	-
Aging Research	93.866	University of Washington	1R03AG073990-01A1	11,230	-
Aging Research	93.866	University of Washington - Seattle	5R21AG070576-02	(4,380)	-
Aging Research	93.866	University of Washington - Seattle	SU24AG072122-02	23,965	-
Aging Research	93.866	Vanderbilt University Medical Center	5R01AG062499-05	23,128	-
Aging Research	93.866	Vanderbilt University Medical Center	5R01AG073439-03	48,035	-
Aging Research	93.866	Virginia Commonwealth University	R01AG076360-02	111,650	-
Aging Research	93.866	Virginia Commonwealth University	1RF1AG076912-01A1	40,646	-
Aging Research	93.866	Virginia Commonwealth University	1U01AG076481-01	282,782	-
Aging Research	93.866	Wake Forest University Health Sciences	5R01AG064440-04	93,283	-
Aging Research	93.866	Wake Forest University Health Sciences	5R01AG074562-03	113,939	-
Aging Research	93.866	Wake Forest University Health Sciences	5R01AG075959-02	97,983	-
Aging Research	93.866	Washington University, The	2RF1AG047644-06	332,241	-
Aging Research	93.866	Washington University, The	SU01AG052564-04	111	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Aging Research	93.866	Washington University, The	5U19AG032438-11	100,131	-
Aging Research	93.866	Washington University, The	5U19AG071754-02	265,660	-
Aging Research	93.866	Washington University, The	5U19AG073585-02	1,544,396	-
Aging Research	93.866	WellSImBioMedicalTechnologies,Inc.	1R41AG076098-01	55,325	-
Aging Research	93.866	Yale University	5R01AG065403-04	268,944	-
Aging Research	93.866	Yale University	5R01AG071528-02	70,800	-
Aging Research	93.866	George Washington University	1U19AG078568-01	420,023	-
Aging Research	93.866	Hennepin Healthcare Research Institute	3U19AG062682-02S1	13,998	-
Aging Research	93.866	Hennepin Healthcare Research Institute	3U19AG062682-03S1	70,297	-
Aging Research	93.866	Hennepin Healthcare Research Institute	5U19AG062682-04	173,638	-
Aging Research	93.866	PASCALL Systems, Inc.	4R42AG066325-02	233,852	-
Aging Research	93.866	Collagen Medical, LLC	R44AG059524	448,212	-
Aging Research	93.866	University of Maryland, Baltimore	1RF1AG073236-01	227,750	-
Aging Research	93.866	The Methodist Hospital Research Institute	5R01AG057635-05	137,091	-
Aging Research	93.866	Advanced Brain Monitoring, Inc.	1R44AG050326-01A1	(22,157)	-
Aging Research	93.866	Advanced Brain Monitoring, Inc.	2R44AG050326-03A1	79,441	-
Aging Research	93.866	CND Life Sciences	1R44AG076072-01	785	-
Aging Research	93.866	Aromha Inc	2R42AG062130-04	125,760	-
Aging Research	93.866	National Bureau of Economic Research (NBER)	5P30AG034532-14	73,443	-
Aging Research	93.866	University of California at San Francisco	5R01AG038791-10	(14,945)	-
Aging Research	93.866	Banner Alzheimer's Institute	5R01AG055444-05	23,244	-
Aging Research	93.866	Banner Alzheimer's Institute	5R01AG058468-03	662,452	-
Aging Research	93.866	NYU Langone Health	5R01AG068248-04	483,944	-
Aging Research	93.866	Methodist Hospital Research Institute dba Houston Methodist Research Institute	5R01AG071496-03	427,417	-
Aging Research	93.866	Columbia University	5U01AG051412-05	(7,307)	-
Aging Research	93.866	Cortico Metrics, LLC	R42AG062026	(15,363)	-
Aging Research	93.866	Seer Biosciences, Inc.	R44AG065051	290,375	-
Aging Research	93.866	Einsenca, Inc.	R44AG079734	154,854	-
Aging Research	93.273	Clintech, Inc.	2R44AA026123-02	21,008	-
Alcohol Research Programs	93.273	Direct		712,245	84,599
Alcohol Research Programs	93.273	Fenway Community Health Center	5P01AA029544-02	46,389	-
Alcohol Research Programs	93.273	Planned Parenthood League of Massachusetts ,Inc.	1R01AA030529-01	13,544	-
Alcohol Research Programs	93.273	President and Fellows of Harvard College	5R01AA029267-03	29,825	-
Alcohol Research Programs	93.273	Seton Hall University	1R21AA029925-01A1	114,458	-
Alcohol Research Programs	93.273	University of Texas at Austin	5R01AA029090-02	116,509	-
Allergy and Infectious Diseases Research	93.855	Africa Health Research Institute (AHRI)	5R01AI138546-05	12,700	-
Allergy and Infectious Diseases Research	93.855	Africa Health Research Institute (AHRI)	5R01AI145305-05	37,333	-
Allergy and Infectious Diseases Research	93.855	Arkansas Children's Hospital Research Institute	R01AI139032	6,747	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute at Virginia Mason	2UM1AI109565-09	44,500	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute at Virginia Mason	5UM1AI109565-10	2,041,592	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute at Virginia Mason	5UM1AI109565-07	(18,551)	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute at Virginia Mason	5UM1AI109565-09	274	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	5R01AI129797-05	290	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	5R01AI149670-04	427,581	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	5U01AI145801-04	81,977	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	5U19AI128751-05	109,239	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	5U19AI128751-05	39,045	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	5UM1AI164556-03	473,965	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	5UM1AI126603-05	(5,623)	-
Allergy and Infectious Diseases Research	93.855	Board of Regents of the University of Wisconsin System, The	1R01AI168370-01A1	36,954	-
Allergy and Infectious Diseases Research	93.855	Board of Regents of the University of Wisconsin System, The	2U01AI102456-06	252,376	-
Allergy and Infectious Diseases Research	93.855	Board of Trustees of the Leland Stanford Junior University, The	5U19AI057229-20	30,992	-
Allergy and Infectious Diseases Research	93.855	Board of Trustees of the University of Alabama for the University of Alabama	5R01AI147727-04	200,526	-
Allergy and Infectious Diseases Research	93.855	Boston University School of Public Health	1R01AI168424-01A1	76,028	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5R01AI138900-05	25,438	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5R01AI138801-03	(1,787)	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5R01AI138999-04	126,407	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5R01AI150235-04	210,639	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5R21AI154830-02	(191)	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5U01AI117841-06	1,063,215	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5U01AI148306-04	10,173	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5U01AI170056-02	20,545	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5UM1AI069412-17	811,241	-
Allergy and Infectious Diseases Research	93.855	Broad Institute, inc.	5R21AI154099-02	21,333	-
Allergy and Infectious Diseases Research	93.855	Broad Institute, inc.	CNVA000599421316161	4,715	-
Allergy and Infectious Diseases Research	93.855	Broad Institute, inc.	1R01AI153405	134,561	-
Allergy and Infectious Diseases Research	93.855	Broad Institute, inc.	1R01AI158495-01A1	26,892	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Allergy and Infectious Diseases Research	93.855	Broad Institute, inc.	1R01AI172147-01	34,053	-
Allergy and Infectious Diseases Research	93.855	Broad Institute, inc.	1U19AI142780-04	721,343	-
Allergy and Infectious Diseases Research	93.855	Broad Institute, inc.	5P01AI148102-02	44,447	-
Allergy and Infectious Diseases Research	93.855	Broad Institute, inc.	5U19AI110816-09	19,843	-
Allergy and Infectious Diseases Research	93.855	Broad Institute, inc.	5U19AI142784-04	6,256	-
Allergy and Infectious Diseases Research	93.855	Broad Institute, inc.	A265499	1,619	-
Allergy and Infectious Diseases Research	93.855	Broad Institute, inc.	GMO1904409	4,326	-
Allergy and Infectious Diseases Research	93.855	Broad Institute, inc.	R01AI132300	30,724	-
Allergy and Infectious Diseases Research	93.855	Broad Institute, inc.	U19AI082630	7,380	-
Allergy and Infectious Diseases Research	93.855	Broad Institute, inc.	U19AI142780	30,287	-
Allergy and Infectious Diseases Research	93.855	Brown University	1R01AI167694-01	16,970	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	1R01AI175556-01	46,357	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	1U19AI168643-01	44,634	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5U01AI126614-07	53,491	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5U01AI143514-05	101,115	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5U01AI163072-02	252,097	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5U19AI168643-02	199,902	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	2P01AI089618-10	210,110	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	2P01AI089618-11A1	146,681	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5R01AI151180-03	11,848	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5U01AI163072-03	67,716	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Medical Center	5R01AI148276-04	56,664	-
Allergy and Infectious Diseases Research	93.855	Dana Farber Cancer Institute	5U01AI165442-02	245,143	-
Allergy and Infectious Diseases Research	93.855	Dana Farber Cancer Institute	5U01AI165442-02	78,984	-
Allergy and Infectious Diseases Research	93.855	Direct		102,735,560	22,255,559
Allergy and Infectious Diseases Research	93.855	Duke University	5R01AI139425-04	19,434	-
Allergy and Infectious Diseases Research	93.855	Emory University	5UM1AI164562-02	107,805	-
Allergy and Infectious Diseases Research	93.855	Emory University	1R01AI166988-01A1	59,225	-
Allergy and Infectious Diseases Research	93.855	Emory University	5R01AI051231-21	235,249	-
Allergy and Infectious Diseases Research	93.855	Emory University	5U01AI131295-06	145	-
Allergy and Infectious Diseases Research	93.855	Emory University	5U19AI110483-10	30,378	-
Allergy and Infectious Diseases Research	93.855	Emory University	5U19AI110483-10	270,347	-
Allergy and Infectious Diseases Research	93.855	Erasmus uUniversity Medical Center	1R01AI147330-01	363,012	-
Allergy and Infectious Diseases Research	93.855	Fenway Community Health Center	5UM1AI068619-17	11,144	-
Allergy and Infectious Diseases Research	93.855	FHI 360	UM1AI068619	30,799	-
Allergy and Infectious Diseases Research	93.855	FHI 360	5UM1AI1068619-16	26,763	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Center	5UM1AI068614-18	421,128	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Center	6UM1AI068614-17	111,055	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Center	6UM1AI068617-18	121,157	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Research Center	5UM1AI068614-14	179	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Research Center	5UM1AI068614-16	68,844	-
Allergy and Infectious Diseases Research	93.855	GHEKIO Centers	4UM1AI069421-17	54,577	-
Allergy and Infectious Diseases Research	93.855	Icahn School of Medicine at Mount Sinai	1P01AI168258-01A1	6,776	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	2UM1AI068632-15	23,494	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5R01AI172092-02	65,819	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5UMAI164566-03	299,960	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	UH3AI133669	42,356	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	2UM1AI068632-17	33,676	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5U01AI134591-05	9,649	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5U01AI138897-05	2,368	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5U19AI159822-02	414,744	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5UM1AI164566-03	105,031	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5UM2AI130836-07	1,330,304	-
Allergy and Infectious Diseases Research	93.855	Massachusetts Eye and Ear Infirmary	5P01AI083214-13	(31,640)	-
Allergy and Infectious Diseases Research	93.855	Massachusetts Eye and Ear Infirmary	5P01AI083214-15	471,655	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	1R01AI155171-02	287,487	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	2R01AI042006-24	59,433	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	2R01AI042006-25	37,490	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5R01AI155662-03	48,203	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5R37AI058736-18	15,746	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5U01AI163086-03	23,479	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5U01AI136816-04	19,826	-
Allergy and Infectious Diseases Research	93.855	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5U19AI167899-02	219,793	-
Allergy and Infectious Diseases Research	93.855	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5R61AI161805-02	265	-
Allergy and Infectious Diseases Research	93.855	Oregon Health & Science University (OHSU)	5R01AI157807-03	79,581	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	2P30AI060354-19	23,922	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	2P30AI060354-20	54,566	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	2UM1AI069456-16	4,579	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	4U01AI114235-06	1,632	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	4U01AI135940-06	25,568	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5P01AI056299-19	504,444	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5P30AI060354-18	21,144	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5P30AI060354-20	647,747	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5U01AI135940-04	290,342	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5U01AI135940-05	406,731	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5U19AI133524-05	(9,006)	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5U19AI142793-05	399,930	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	UM1AI069456-17	9,249	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	2P30AI060354-18	(4,037)	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5P30AI060354-19	995,677	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5R01AI143723-04	292,236	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5R01AI148338-04	368,210	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	CFAR-MGH-22-3-CIARANELLO	23,178	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	2UM1AI068636-16	174,637	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	3UM1AI068636-14S2	(127)	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	3UM1AI068636-15S3	11,877	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	3UM1AI068636-16S1	51,708	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	3UM1AI068636-16S2	66,169	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	5UM1AI068636-16	43,885	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	5UM1AI106701-10	321,025	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	2UM1AI068636-17	139,954	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	3UM1AI068636-16S4	32,951	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	5R01AI166313-02	204,352	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	5UM1AI068636-17	492,747	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, San Diego	2U19AI070535-16	43,467	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, San Diego	5U19AI070535-17	125,805	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, San Francisco	5UM1AI164560-03	278,841	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of Minnesota	1U01AI169587-01	632,050	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of Minnesota	5R01AI084913-12	3,415	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5R01AI147826-05	203,100	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5R61AI161818-03	240,146	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5U19AI135995-05	149,625	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5UM1AI144462-04	244,109	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5UM1AI144462-05	1,284,309	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5UM1AI144462-05	88,032	-
Allergy and Infectious Diseases Research	93.855	Trustees of Boston University	5R01AI162850-02	80,618	-
Allergy and Infectious Diseases Research	93.855	Trustees of Columbia University in the City of New York (The)	4U54AI138370-06	37,618	-
Allergy and Infectious Diseases Research	93.855	Trustees of the University of Pennsylvania	5U01AI163087-03	113,821	-
Allergy and Infectious Diseases Research	93.855	Trustees of the University of Pennsylvania	5U19AI149680-04	435,097	-
Allergy and Infectious Diseases Research	93.855	Tufts University	1R01AI169786	156,820	-
Allergy and Infectious Diseases Research	93.855	University of Alabama, Birmingham	5U19AI142737-04	105,070	-
Allergy and Infectious Diseases Research	93.855	University of Connecticut	1R01AI167884-01A1	3,096	-
Allergy and Infectious Diseases Research	93.855	University of Georgia Research Foundation, Inc. (UGARF)	U01AI148114	56,850	-
Allergy and Infectious Diseases Research	93.855	University of Maryland	5R01AI155716-03	73,782	-
Allergy and Infectious Diseases Research	93.855	University of Massachusetts Medical School	1U01AI165524-01	49,243	-
Allergy and Infectious Diseases Research	93.855	University of Massachusetts Medical School	5R01AI159159-02	(43,932)	-
Allergy and Infectious Diseases Research	93.855	University of North Carolina at Chapel Hill, The	5U01AI131310-05	(20,906)	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh Of the Commonwealth System of Higher Education	1R01AI150255-02	(1,414)	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh Of the Commonwealth System of Higher Education	2P01AI08545-06	146,732	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh Of the Commonwealth System of Higher Education	5P01AI129880-05	340,893	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01AI155345-03	137,682	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01AI164970-02	59,611	-
Allergy and Infectious Diseases Research	93.855	University of Texas Southwestern Medical Center	1R34AI134569-01A1	57,353	-
Allergy and Infectious Diseases Research	93.855	University of Texas Southwestern Medical Center	5U19AI142784-05	654,559	-
Allergy and Infectious Diseases Research	93.855	University of Utah	R01AI135115	26,182	-
Allergy and Infectious Diseases Research	93.855	Volatylx, Inc.	5R44AI141264-03	432,918	-
Allergy and Infectious Diseases Research	93.855	Wistar Institute of Anatomy and Biology	5UM1AI164570-02	295,053	-
Allergy and Infectious Diseases Research	93.855	Wistar Institute of Anatomy and Biology	5UM1AI164570-03	22,488	-
Allergy and Infectious Diseases Research	93.855	Yale University	5P01AI039671-24	(12,176)	-
Allergy and Infectious Diseases Research	93.855	Yale University	5R01AI104824-10	32,209	-
Allergy and Infectious Diseases Research	93.855	University of Iowa	5UH2AI144434-02	32,371	-
Allergy and Infectious Diseases Research	93.855	University of California at Berkeley	1R01AI155634-03	32,278	-
Allergy and Infectious Diseases Research	93.855	University of Maryland, Baltimore	1R01AI167367-01A1	260,437	-
Allergy and Infectious Diseases Research	93.855	University of Maryland, Baltimore	5U19AI145825-03	251,813	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Allergy and Infectious Diseases Research	93.855	Regents of the University of Colorado	R01AI141452	210,052	-
Allergy and Infectious Diseases Research	93.855	Sylvatica Biotech, Inc	2R44AI124835-02	238	-
Allergy and Infectious Diseases Research	93.855	Sylvatica Biotech, Inc	R44AI145782	61,949	-
Allergy and Infectious Diseases Research	93.855	La Jolla Institute for Immunology	5U19AI142790-04	3,989	-
Allergy and Infectious Diseases Research	93.855	La Jolla Institute for Immunology	5U19AI142790-05	130,884	-
Allergy and Infectious Diseases Research	93.855	Sanaria Inc	U01AI156354	33,691	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Baylor College of Medicine	5U54AR068069-09	53,081	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Beth Israel Deaconess Medical Center	3R01AR075964-03S1	125,204	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Beth Israel Deaconess Medical Center	5R01AR075964-03	111,096	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Board of Trustees of the University of Alabama for the University of Alabama	5P50AR060772-10	(7,143)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital, Inc.	1R01AR080193-01	14,762	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital, Inc.	5R01AR065807-25	212,593	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital, Inc.	5R01AR074797-04	16,541	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital, Inc.	5R01AR077607-03	89,521	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital, Inc.	5U01AR068043-05	8,460	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital, Inc.	5U01AR070498-04	632,933	161,697
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Broad Institute, inc.	5UH2AR067677-03	1,123	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Broad Institute, inc.	1UC2AR081031-01	23,399	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Children's Hospital Corporation dba Boston Children's Hospital	1R01AR080079-01	40,227	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Children's Hospital Corporation dba Boston Children's Hospital	5R01AR065538-09	191,685	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Cleveland Clinic Foundation Group Return, The	5R01AR074131-04	4,259	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Columbia University Medical Center	5R01AR068425-05	40,096	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Dartmouth-Hitchcock Clinic	R01AR077157	502	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Direct		26,683,086	3,853,711
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Feinstein Institutes for Medical Research	3UH2AR067694-05S5	(2,297)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Highland Instruments	1R44AR076885-01	5,375	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Highland Instruments	4R44AR076885-02	31,129	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Johns Hopkins University	5UH3AR077360-03	18,741	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	5R01AR065944-07	119,604	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	5R01AR077023-04	10,810	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	5R34AR076077-02	(6,420)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Oregon Health & Science University (OHSU)	5R01AR073186-04	44,641	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Regents of the University of California, Irvine	5R01AR078340-03	44,668	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Regents of the University of Michigan	1U24AR076730-01	42,972	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Terasaki Family Foundation	5R01AR073135-06	80,619	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Boston University	1R01AR078299-01A1	19,849	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Boston University	5P30AR072571-04	20,557	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Boston University	5R01AR080950-02	27,764	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Columbia University in the City of New York (The)	1R56AR077187-01	(78,945)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Columbia University in the City of New York (The)	5R01AR050026-16	127,075	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Columbia University in the City of New York (The)	5R01AR077187-02	11,201	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Columbia University in the City of New York (The)	1R01AR077187-01A1	292,589	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of the University of Pennsylvania	1U01AR079752-01	49,371	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Tufts Medical Center, Inc.	R01AR077146	16,327	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Arizona	3R01AR078187-01S1	295,631	111,497
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Arizona	5R01AR080742-02	136,867	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Colorado at Denver	5R01AR075033-04	37,307	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Connecticut	5R01AR073822-06	142,862	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Massachusetts Medical School	5R01AR078230-02	217,141	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of North Carolina at Chapel Hill, The	1U24AR076730-01	381,963	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pittsburgh Of the Commonwealth System of Higher Education	5UH3AR076568-04	385,340	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pittsburgh Of the Commonwealth System of Higher Education	5P50AR060780-10	(84)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Rochester	1UC2AR081025-01	60,728	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Texas Health Science Center at San Antonio	7R01AR077445-02	18,445	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Vanderbilt University Medical Center	5R01AR060846-09	26,235	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	WakeForesUniversity	R34AR077361	211	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Regents of the University of Colorado	2R01AR069060-04A1	12,754	-
Biomedical Research and Research Training	93.859	Brigham and Women's Hospital, Inc.	5R01GM132825-04	3,615	-
Biomedical Research and Research Training	93.859	Broad Institute, inc.	1R01GM137606-01A1	41,154	-
Biomedical Research and Research Training	93.859	Direct		20,981,778	1,355,443
Biomedical Research and Research Training	93.859	President and Fellows of Harvard College	5R01GM129026-04	(3,436)	-
Biomedical Research and Research Training	93.859	President and Fellows of Harvard College	5R01GM131401-04	29,495	-
Biomedical Research and Research Training	93.859	President and Fellows of Harvard College	1R01GM148494-01	34,973	-
Biomedical Research and Research Training	93.859	Regents of the University of California, Los Angeles, The	5P01GM099134-10	(842)	-
Biomedical Research and Research Training	93.859	Regents of the University of California, San Francisco	5R01GM130900-04	4,779	-
Biomedical Research and Research Training	93.859	Regents of the University of California, San Francisco	R01GM117163	308,850	-
Biomedical Research and Research Training	93.859	Trustees of Dartmouth College	5R35GM128745-05	25,169	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Biomedical Research and Research Training	93.859	Trustees of the University of Pennsylvania	5R01GM132668-05	101,292	-
Biomedical Research and Research Training	93.859	University of Utah	R01GM134069	246,096	-
Biomedical Research and Research Training	93.859	Wake Forest University Health Sciences	3P01GM113852-05S1	(18)	-
Biomedical Research and Research Training	93.859	Wake Forest University Health Sciences	P01GM113852	(10)	-
Biomedical Research and Research Training	93.859	Trustees of Tufts College	5R21GM141683-02	134,259	-
Blood Diseases and Resources Research	93.839	Broad Institute, inc.	996106	(11)	-
Blood Diseases and Resources Research	93.839	Broad Institute, inc.	1P01HL158505-01	3,028	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	5P01HL046925-25	212,713	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	5P01HL095489-10	23,206	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	1OT2HL154984-01	5,682	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL095791-13	101,853	-
Blood Diseases and Resources Research	93.839	Cleveland Clinic Lerner College of Medicine	UH3HL140097-04	3,025	-
Blood Diseases and Resources Research	93.839	Cleveland Clinic Lerner College of Medicine	UH3HL140097-05	227,942	-
Blood Diseases and Resources Research	93.839	Dana Farber Cancer Institute	5UG1HL069249-23	13,396	-
Blood Diseases and Resources Research	93.839	Direct		6,361,471	1,016,364
Blood Diseases and Resources Research	93.839	Emory University	1R01HL138714-01A1	(23,622)	-
Blood Diseases and Resources Research	93.839	Emory University	3R01HL138714-02S1	5,245	-
Blood Diseases and Resources Research	93.839	Emory University	5U54HL141981-04	109,243	-
Blood Diseases and Resources Research	93.839	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	1R01HL158102-01	275,249	-
Blood Diseases and Resources Research	93.839	New York University Grossman School of Medicine	1UG3HL155798-01A1	51,747	-
Blood Diseases and Resources Research	93.839	Rector and Visitors of the University of Virginia, The	5P01HL132819-04	(13,247)	-
Blood Diseases and Resources Research	93.839	University of Massachusetts at Lowell	5R01HL143020-05	3,703	-
Blood Diseases and Resources Research	93.839	University of Massachusetts at Lowell	7R01HL143020-04	5,816	-
Blood Diseases and Resources Research	93.839	University of Miami	R01HL156958	28,361	-
Blood Diseases and Resources Research	93.839	University of Michigan Medical School	5R01HL144550-04	113,989	-
Blood Diseases and Resources Research	93.839	University of Southern California	5U19HL156247-04	534,361	-
Blood Diseases and Resources Research	93.839	University of Washington	5R01HL154385-03	13,620	-
Blood Diseases and Resources Research	93.839	University of Washington - Seattle	1R01HL147894-03	39,733	-
Blood Diseases and Resources Research	93.839	Washington University, The	4UH3HL138325-03	(45)	-
Blood Diseases and Resources Research	93.839	Washington University, The	5UH3HL138325-05	92,212	-
Blood Diseases and Resources Research	93.839	University of Minnesota	5R01HL132906-07	300,099	-
Blood Diseases and Resources Research	93.839	Phenocia Biosciences, Inc.	5R33HL147845-02	44,209	-
Cancer Biology Research	93.396	Brigham and Women's Hospital, Inc.	1U19CA264504-02	123,428	-
Cancer Biology Research	93.396	Brigham and Women's Hospital, Inc.	5P01CA120964-15	25,657	-
Cancer Biology Research	93.396	Brigham and Women's Hospital, Inc.	5U01CA214411-05	(20)	-
Cancer Biology Research	93.396	Broad Institute, inc.	1R35CA263817-01A1	2,651	-
Cancer Biology Research	93.396	Brown University	1R01CA263324-01A1	25,897	-
Cancer Biology Research	93.396	Cincinnati Children's Hospital Medical Center	1R01CA240317-03	48,097	-
Cancer Biology Research	93.396	Dana Farber Cancer Institute	2R01CA181217-09	69,379	-
Cancer Biology Research	93.396	Dana Farber Cancer Institute	5P01CA233412-04	221,627	-
Cancer Biology Research	93.396	Dana Farber Cancer Institute	5R01CA238039-05	63,160	-
Cancer Biology Research	93.396	Dana Farber Cancer Institute	5R01CA246653-04	128,094	-
Cancer Biology Research	93.396	Dana Farber Cancer Institute	5R01CA251589-03	6,282	-
Cancer Biology Research	93.396	Dana Farber Cancer Institute	5R01CA251589-03	6,799	-
Cancer Biology Research	93.396	Dana Farber Cancer Institute	5U01CA232161-04	(1,001)	-
Cancer Biology Research	93.396	Dana Farber Cancer Institute	5U01CA232161-05	216,506	-
Cancer Biology Research	93.396	Dana Farber Cancer Institute	P01CA250959	186,027	-
Cancer Biology Research	93.396	Direct		18,348,547	4,148,899
Cancer Biology Research	93.396	Florida International University	7U01CA225644-03	17,805	-
Cancer Biology Research	93.396	Joan & Sanford I. Weill Medical College of Cornell University	1U01CA275301-01	482,762	-
Cancer Biology Research	93.396	Kaiser Permanente Division of Research	R01CA251589	384,376	-
Cancer Biology Research	93.396	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	1UG3CA275687-01	303,413	-
Cancer Biology Research	93.396	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5U01CA215798-05	(9,540)	-
Cancer Biology Research	93.396	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	7R01CA248280-03	18,968	-
Cancer Biology Research	93.396	Memorial Sloan-Kettering Institute Cancer Center	5U01CA228963-03	408,959	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	1R01CA273461-02	132,628	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	5R35CA220523-05	63,956	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	5U01CA267827-02	45,987	-
Cancer Biology Research	93.396	Tufts Medical Center, Inc.	R01CA243542	34,809	-
Cancer Biology Research	93.396	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01CA256068-03	39,567	-
Cancer Biology Research	93.396	University of Texas Southwestern Medical Center	SUM1CA221940-06	425,600	-
Cancer Biology Research	93.396	University of Texas Southwestern Medical Center	SUM1CA221940-05	70,209	-
Cancer Biology Research	93.396	Wistar Institute of Anatomy and Biology	1P01CA269043-01A1	401,639	-
Cancer Biology Research	93.396	Yale University	5R01CA230275-05	62,204	-
Cancer Biology Research	93.396	MD Anderson Cancer Center	5P01CA117969-18	274,192	-
Cancer Cause and Prevention Research	93.393	Baylor College of Medicine	1P01CA263025-01A1	230,198	-
Cancer Cause and Prevention Research	93.393	Beckman Research Institute of the City of Hope	5R01CA202712-05	90,466	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Cancer Cause and Prevention Research	93.393	Beth Israel Deaconess Medical Center	5R01CA242747-04	73,706	-
Cancer Cause and Prevention Research	93.393	Broad Institute, Inc.	5R01CA231264-04	3,795	-
Cancer Cause and Prevention Research	93.393	Broad Institute, Inc.	U01CA176058	(16,980)	-
Cancer Cause and Prevention Research	93.393	Dana Farber Cancer Institute	1R01CA256877-01A1	28,905	-
Cancer Cause and Prevention Research	93.393	Dana Farber Cancer Institute	8310051	35,747	-
Cancer Cause and Prevention Research	93.393	Dana Farber Cancer Institute	R01CA248857-01	49,405	-
Cancer Cause and Prevention Research	93.393	Dana Farber Cancer Institute	UNASSIGNED	12,102	-
Cancer Cause and Prevention Research	93.393	Dana Farber Cancer Institute	5R01CA204954-05	(2,553)	-
Cancer Cause and Prevention Research	93.393	Dana Farber Cancer Institute	5R01CA258924-03	141,813	-
Cancer Cause and Prevention Research	93.393	Direct		20,405,064	5,579,906
Cancer Cause and Prevention Research	93.393	Duke University	1U54CA231630-01A1	94,621	-
Cancer Cause and Prevention Research	93.393	Duke University	5R01CA235677-04	59,208	-
Cancer Cause and Prevention Research	93.393	Fred Hutchinson Cancer Center	5R01CA248857-04	205,997	-
Cancer Cause and Prevention Research	93.393	Fred Hutchinson Cancer Center	6R01CA215134-06	7,450	-
Cancer Cause and Prevention Research	93.393	Fred Hutchinson Cancer Research Center	1R01CA248857-01	(257)	-
Cancer Cause and Prevention Research	93.393	Icahn School of Medicine at Mount Sinai	5R01CA260889-02	61,111	-
Cancer Cause and Prevention Research	93.393	Joan & Sanford I. Weill Medical College of Cornell University	5R01CA260352-02	44,188	-
Cancer Cause and Prevention Research	93.393	Massachusetts General Hospital	5R01CA218123-05	11,188	-
Cancer Cause and Prevention Research	93.393	Massachusetts General Hospital	5U01CA225451-05	35,334	-
Cancer Cause and Prevention Research	93.393	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5R21CA256081-02	8,626	-
Cancer Cause and Prevention Research	93.393	Mayo Clinic	5R01CA248288-03	61,352	-
Cancer Cause and Prevention Research	93.393	Memorial Sloan-Kettering Institute Cancer Center	1R21CA263489-01A1	33,002	-
Cancer Cause and Prevention Research	93.393	Memorial Sloan-Kettering Institute Cancer Center	5R01CA244185-03	96,018	-
Cancer Cause and Prevention Research	93.393	Memorial Sloan-Kettering Institute Cancer Center	5U01CA253913-02	(5,729)	-
Cancer Cause and Prevention Research	93.393	Memorial Sloan-Kettering Institute Cancer Center	5U01CA253913-03	135,164	-
Cancer Cause and Prevention Research	93.393	Northeastern University	5R01CA252966-03	87,134	-
Cancer Cause and Prevention Research	93.393	Ohio State University	5R01CA266402-02	140,470	-
Cancer Cause and Prevention Research	93.393	Physical Sciences, Inc.	4R44CA224853-02	8,289	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	2U01CA167552-11	80,052	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	2U01CA209414-07	111,928	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA167552-10	(3,249)	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA176726-10	1,293,143	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA209414-06	363,504	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	2U01CA167552-12	8,128	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	3R01CA255035-03S1	308,095	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	3U01CA253912-02S2	(3,008)	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5P01CA228696-03	2,394	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5R00CA215314-04	(3,621)	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5R01CA240299-04	22,801	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA253912-03	185,310	-
Cancer Cause and Prevention Research	93.393	Regents of the University of California, Irvine	5R37CA252081-03	19,435	-
Cancer Cause and Prevention Research	93.393	Regents of the University of Michigan	5U01CA253858-02	(12,804)	-
Cancer Cause and Prevention Research	93.393	Research Foundation of the City University of New York	5U24CA180996-10	181,775	-
Cancer Cause and Prevention Research	93.393	Seattle Institute for Biomedical and Clinical Research	5R01CA239208-04	238,562	25,030
Cancer Cause and Prevention Research	93.393	Trustees of Columbia University in the City of New York (The)	7R01CA240080-04	219,405	-
Cancer Cause and Prevention Research	93.393	Trustees of Indiana University	2R01CA157823	23,420	-
Cancer Cause and Prevention Research	93.393	University of Alabama, Birmingham	5R01CA229197-05	43,381	-
Cancer Cause and Prevention Research	93.393	University of Florida Board of Trustees	5R01CA240341-04	119,670	-
Cancer Cause and Prevention Research	93.393	University of Massachusetts Amherst	5R01CA207369-05	103,902	-
Cancer Cause and Prevention Research	93.393	University of North Carolina at Chapel Hill, The	1R01CA227122-04S1	72,028	-
Cancer Cause and Prevention Research	93.393	University of Texas Southwestern Medical Center	3U01CA253912-02S2	(2,112)	-
Cancer Cause and Prevention Research	93.393	University of Texas Southwestern Medical Center	5R01CA233794-04	137,004	-
Cancer Cause and Prevention Research	93.393	University of Utah	R01CA242729	35,014	-
Cancer Cause and Prevention Research	93.393	University of Washington - Seattle	5R01CA194393-07	88,062	-
Cancer Cause and Prevention Research	93.393	Washington University, The	5R37CA246175-03	87,208	-
Cancer Cause and Prevention Research	93.393	Washington University, The	5R01CA248526-04	100,810	-
Cancer Cause and Prevention Research	93.393	ECOG-ACRIN Medical Research Foundation, Inc.	1U01CA274926-01	67,618	-
Cancer Cause and Prevention Research	93.393	Dimagi, Inc	2R44CA265301-02	5,361	-
Cancer Cause and Prevention Research	93.393	Cambridge Hospital	5R01CA229355-02	14,977	-
Cancer Cause and Prevention Research	93.393	Dartmouth Hitchcock Medical Center	5R01CA243449-03	39,389	-
Cancer Cause and Prevention Research	93.393	HealthPartners Institute	5R01CA263542-02	20,881	-
Cancer Cause and Prevention Research	93.393	BC Cancer, a part of the Provincial Health Services Authority	7U01CA253858-04	168,575	-
Cancer Cause and Prevention Research	93.393	Kaiser Foundation Research Institute	R01CA241623-04	32,223	-
Cancer Centers Support Grants	93.397	Beth Israel Deaconess Medical Center	2P50CA101942-16	31,921	-
Cancer Centers Support Grants	93.397	Beth Israel Deaconess Medical Center	2P50CA101942-18	529,524	-
Cancer Centers Support Grants	93.397	Beth Israel Deaconess Medical Center	5P50CA101942-18	122,817	-
Cancer Centers Support Grants	93.397	Brigham and Women's Hospital, Inc.	2P50CA165962-08	156,334	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Cancer Centers Support Grants	93.397	Brigham and Women's Hospital, Inc.	2P50CA165962-09	134,434	-
Cancer Centers Support Grants	93.397	Brigham and Women's Hospital, Inc.	5P50CA165962-09	137,031	-
Cancer Centers Support Grants	93.397	Broad Institute, inc.	2P50CA127003-11A1	5,148	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	1P50CA240243-03	129,274	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	1P50CA265826-01A1	1,199,589	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	2P30CA006516-57	1,365,918	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	2P50CA127003-12	15,424	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	2P50CA127003-14	30,707	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	2P50CA168504-07	185,972	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	2P50CA168504-7	22,229	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	5P30CA006516-58	1,708,523	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	5P50CA100707-18	(1,132)	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	5P50CA100707-19	164,382	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	5P50CA168504-07	19,698	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	5P50CA168504-09	66,945	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	5P50CA168504-10	79,450	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	5P50CA206963-06	63,411	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	5P50CA240243-03	498,418	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	2P30CA006516-58	15,231	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	5P30CA006516-56	(5,600)	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	5P30CA006516-57	48,095	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	5P50CA127003-13	(22,423)	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	5P50CA127003-14	264,936	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	5P50CA127003-15	624,105	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	5P50CA168504-08	(2,517)	-
Cancer Centers Support Grants	93.397	Dana Farber Cancer Institute	5U54CA156732-12	23,865	-
Cancer Centers Support Grants	93.397	Direct		3,042,478	2,011,136
Cancer Centers Support Grants	93.397	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5U54CA210180-03	(6,260)	-
Cancer Centers Support Grants	93.397	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5U54CA210180-05	(16,703)	-
Cancer Centers Support Grants	93.397	President and Fellows of Harvard College	5U54CA225088-04	45,610	-
Cancer Centers Support Grants	93.397	President and Fellows of Harvard College	5U54CA225088-05	125,864	-
Cancer Centers Support Grants	93.397	Regents of the University of Michigan	1P50CA272170-01	590,281	-
Cancer Centers Support Grants	93.397	Trustees of Dartmouth College	3P30CA023108-42S1	(2,980)	-
Cancer Centers Support Grants	93.397	Washington University, The	5P50CA171963-10	130,725	-
Cancer Control	93.399	Broad Institute, inc.	U54CA272688	2,907	-
Cancer Control	93.399	Dana Farber Cancer Institute	5UG1CA233180-05	18,566	-
Cancer Control	93.399	Dana Farber Cancer Institute	5UG1CA233180-04	19,008	-
Cancer Control	93.399	Direct		139,116	26,209
Cancer Control	93.399	Medical University of South Carolina	7R01CA232888-05	15,013	-
Cancer Control	93.399	The University of Texas Health Science Center at Houston	51R01CA232888-04	(954)	-
Cancer Control	93.399	ECOG-ACRIN Medical Research Foundation, Inc.	5UG1CA189828-09	47,431	-
Cancer Control	93.394	Board of Trustees of the Leland Stanford Junior University, The	501CA242879-03	(6,309)	-
Cancer Detection and Diagnosis Research	93.394	Brigham and Women's Hospital, Inc.	5R01CA235589-05	135,552	-
Cancer Detection and Diagnosis Research	93.394	Broad Institute, inc.	1U01CA271492-01	2,689	-
Cancer Detection and Diagnosis Research	93.394	Broad Institute, inc.	1U24CA264024-01	53,349	-
Cancer Detection and Diagnosis Research	93.394	Broad Institute, inc.	1U24CA264029-01	2,611	-
Cancer Detection and Diagnosis Research	93.394	Broad Institute, inc.	1U24CA270823-01	71,675	-
Cancer Detection and Diagnosis Research	93.394	Broad Institute, inc.	1U24CA271075-01	35,838	-
Cancer Detection and Diagnosis Research	93.394	Broad Institute, inc.	5U24CA210999-05	79	-
Cancer Detection and Diagnosis Research	93.394	Broad Institute, inc.	U24CA264024-02	118,583	-
Cancer Detection and Diagnosis Research	93.394	Broad Institute, inc.	U24CA271075	52,190	-
Cancer Detection and Diagnosis Research	93.394	Broad Institute, inc.	WU-23-0056	71,675	-
Cancer Detection and Diagnosis Research	93.394	Cedar-Sinai Medical Center	5R01CA201709-05	29,166	-
Cancer Detection and Diagnosis Research	93.394	Cedars-Sinai Health System	5R01CA260955-02	29,859	-
Cancer Detection and Diagnosis Research	93.394	Dana Farber Cancer Institute	1R01CA255184-01A1	13,661	-
Cancer Detection and Diagnosis Research	93.394	Dana Farber Cancer Institute	1R01CA266424-01A1	165,362	-
Cancer Detection and Diagnosis Research	93.394	Dana Farber Cancer Institute	1R21CA249875-01A1	28,070	-
Cancer Detection and Diagnosis Research	93.394	Dana Farber Cancer Institute	2U01CA210171-06	35,605	-
Cancer Detection and Diagnosis Research	93.394	Dana Farber Cancer Institute	5R01CA188446-08	39,422	-
Cancer Detection and Diagnosis Research	93.394	Dana Farber Cancer Institute	5R01CA214385-05	28,059	-
Cancer Detection and Diagnosis Research	93.394	Dana Farber Cancer Institute	5R01CA240592-04	30,386	-
Cancer Detection and Diagnosis Research	93.394	Dana Farber Cancer Institute	5U01CA210171-05S1	(4)	-
Cancer Detection and Diagnosis Research	93.394	Dana Farber Cancer Institute	R01CA240582-03	57,172	-
Cancer Detection and Diagnosis Research	93.394	Dana Farber Cancer Institute	3U01CA210171-05S1	(2,308)	-
Cancer Detection and Diagnosis Research	93.394	Direct		18,798,952	2,386,677
Cancer Detection and Diagnosis Research	93.394	Fred Hutchinson Cancer Center	6U01CA214114-06	24,481	-
Cancer Detection and Diagnosis Research	93.394	Fred Hutchinson Cancer Research Center	3U01CA214172-05S1	2	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Cancer Detection and Diagnosis Research	93.394	Glyciome,LLC	1R41CA254543-01A1	53,339	-
Cancer Detection and Diagnosis Research	93.394	Massachusetts General Hospital	5R01CA203873-05	(12,509)	-
Cancer Detection and Diagnosis Research	93.394	Massachusetts General Hospital	5R01CA215431-05	101,890	-
Cancer Detection and Diagnosis Research	93.394	Massachusetts General Hospital	5R01CA227156-04	37,226	-
Cancer Detection and Diagnosis Research	93.394	Massachusetts General Hospital	5R01CA265742-03	209,815	-
Cancer Detection and Diagnosis Research	93.394	Massachusetts General Hospital	5U01CA233360-05	179,343	-
Cancer Detection and Diagnosis Research	93.394	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	1R21CA236685-02	12,998	-
Cancer Detection and Diagnosis Research	93.394	Navigation Sciences, Inc.	R41CA261420	65,535	-
Cancer Detection and Diagnosis Research	93.394	New York University Grossman School of Medicine	5U01CA214195-05	(316)	-
Cancer Detection and Diagnosis Research	93.394	Northeastern University	5R01CA204443-05	36	-
Cancer Detection and Diagnosis Research	93.394	Ohio State University	7R01CA237133-04	253,481	-
Cancer Detection and Diagnosis Research	93.394	Trustees of Boston University	5R01CA232056-04	141,567	-
Cancer Detection and Diagnosis Research	93.394	University of Kentucky	5R21CA267152-02	226,837	-
Cancer Detection and Diagnosis Research	93.394	University of Texas Southwestern Medical Center	1R01CA258524-01A1	13,022	-
Cancer Detection and Diagnosis Research	93.394	University of Texas Southwestern Medical Center	1R37CA242070-01A1	(27,802)	-
Cancer Detection and Diagnosis Research	93.394	University of Washington	5R01CA251803-02	75,941	-
Cancer Detection and Diagnosis Research	93.394	University of Washington	5U24CA264044-02	33,259	-
Cancer Detection and Diagnosis Research	93.394	Washington University, The	5U24CA196171-09	96,698	-
Cancer Detection and Diagnosis Research	93.394	Yale University	5U01CA233364-05	198,385	-
Cancer Detection and Diagnosis Research	93.394	ECOG-ACRIN Medical Research Foundation, Inc.	5U24CA196172-08	5,040	-
Cancer Detection and Diagnosis Research	93.394	Memorial Sloan Kettering Institute	1R37CA262662-01A1	43,311	-
Cancer Detection and Diagnosis Research	93.394	Collagen Medical, LLC	1R44CA250771-01	190,367	-
Cancer Detection and Diagnosis Research	93.394	AIQ Solutions, Inc.	2R44CA257253-02	99,222	-
Cancer Detection and Diagnosis Research	93.394	University of Texas, MD Anderson Cancer Center	3U01CA200462-05S1	15,273	-
Cancer Detection and Diagnosis Research	93.394	Washington University in St. Louis	5U24CA253531-03	9,077	-
Cancer Detection and Diagnosis Research	93.394	Reveal Pharmaceuticals	R44CA239935	10,116	-
Cancer Detection and Diagnosis Research	93.394	Imagine Scientific, Inc.	R44CA268468	112,114	-
Cancer Research Manpower	93.398	Brown University	5R01CA201262-05	(1,408)	-
Cancer Research Manpower	93.398	Direct		57,090	-
Cancer Treatment Research	93.395	Alliance Data Innovations Lab, LLC	U10CA180821	20,130	-
Cancer Treatment Research	93.395	Beth Israel Deaconess Medical Center	5U01CA236489-04	32,414	-
Cancer Treatment Research	93.395	Brandeis University	2R01CA142746-11A1	36,860	-
Cancer Treatment Research	93.395	Brigham and Women's Hospital, Inc.	1R01CA272637-01	281,495	-
Cancer Treatment Research	93.395	Brigham and Women's Hospital, Inc.	3U10CA180821-09S2	4,826	-
Cancer Treatment Research	93.395	Brigham and Women's Hospital, Inc.	5P01CA236749-03	448,983	-
Cancer Treatment Research	93.395	Brigham and Women's Hospital, Inc.	5R01CA207982-06	(3,640)	-
Cancer Treatment Research	93.395	Brigham and Women's Hospital, Inc.	5U10CA031946-32	712	-
Cancer Treatment Research	93.395	Broad Institute, inc.	1P01CA229092	13,031	-
Cancer Treatment Research	93.395	Broad Institute, inc.	1R21CA267607-01	12,297	-
Cancer Treatment Research	93.395	Broad Institute, inc.	2R01CA155010-11	8,881	-
Cancer Treatment Research	93.395	Broad Institute, inc.	P01CA206978	42,083	-
Cancer Treatment Research	93.395	Broad Institute, inc.	UG1CA189955	2,750	-
Cancer Treatment Research	93.395	Brown University	7R01CA237063-04	42,798	-
Cancer Treatment Research	93.395	Cedar-Sinai Medical Center	5U01CA232859-04	(44,901)	-
Cancer Treatment Research	93.395	Children's Hospital of Philadelphia (The)	2U10CA180886	(265)	-
Cancer Treatment Research	93.395	Curer,Inc	1R42CA268629-01A1	8,641	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	1P01CA229092-02	52,768	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	1R01CA267726-01	29,073	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	1R01CA272982-01	48,556	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	1R21CA263130	13,529	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	1R21CA277316-01	31,499	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	1R37CA269990-01A1	26,133	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	1U01CA260369-02	4,533	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	2R01CA205406-06	26,382	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	3U10CA186709-08	54,493	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	5P01CA066986-16A1	(138)	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	5R01CA240804-04	85,147	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	5R01CA258698-03	66,710	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	5UG1CA242609-04	2,276	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	R01CA244936	2,750	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	R01CA272657	44,814	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	U10CA180886	21,139	-
Cancer Treatment Research	93.395	Dana Farber Cancer Institute	U10CA180886-09	10,569	-
Cancer Treatment Research	93.395	Direct		43,315,352	17,719,105
Cancer Treatment Research	93.395	HackensackUniversityMedicalCenter	5R01CA212639-05	(381)	-
Cancer Treatment Research	93.395	Health Research, Inc.-Roswell Park Cancer Institute Division	1R01CA267690-01A1	40,040	-
Cancer Treatment Research	93.395	Joan & Sanford I. Weill Medical College of Cornell University	1R01CA270245-01	57,022	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Cancer Treatment Research	93.395	Massachusetts General Hospital	5P01CA069246-24	(5,297)	-
Cancer Treatment Research	93.395	Massachusetts General Hospital	5R01CA227821-05	44,428	-
Cancer Treatment Research	93.395	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5R01CA247632	19,270	-
Cancer Treatment Research	93.395	Mayo Clinic	SU19CA264362-02	109,607	-
Cancer Treatment Research	93.395	Mayo Clinic	SUG1CA189823-05	(554)	-
Cancer Treatment Research	93.395	Memorial Sloan-Kettering Institute Cancer Center	5P01CA190174-05	(4,329)	-
Cancer Treatment Research	93.395	Michigan State University	5R01CA221771-05	288,785	-
Cancer Treatment Research	93.395	New York University Medical Center	5U01CA213333-04	(439)	-
Cancer Treatment Research	93.395	Northeastern University	5R01CA226855-03	150,694	-
Cancer Treatment Research	93.395	President and Fellows of Harvard College	5R01CA263776-02	220,310	-
Cancer Treatment Research	93.395	Stanford University Medical Center	2R01CA177684-06A2	85,132	-
Cancer Treatment Research	93.395	StratagenBio	1R43CA261401-1A1	(17,321)	-
Cancer Treatment Research	93.395	Temalys Therapeutics, Inc.	R41CA278074	90,941	-
Cancer Treatment Research	93.395	Trustees of Boston University	5R01CA227433-05	61,307	-
Cancer Treatment Research	93.395	Trustees of Boston University	5R01CA232708-04	200,655	-
Cancer Treatment Research	93.395	Trustees of Boston University	5U01CA265713-02	242,670	-
Cancer Treatment Research	93.395	ECOG-ACRIN Medical Research Foundation, Inc.	5U10CA180820-09	8,381	-
Cancer Treatment Research	93.395	ECOG-ACRIN Medical Research Foundation, Inc.	5U10CA180820-10	227,368	-
Cancer Treatment Research	93.395	University of Texas, MD Anderson Cancer Center	5R01CA260872-03	230,917	-
Cancer Treatment Research	93.395	H. Lee Moffitt Cancer Center & Research Institute Hospital, Inc.	1R01CA266803-01A1	127,111	-
Cancer Treatment Research	93.395	Transcode Therapeutics, Inc	1R44CA257093-01A1	455,605	-
Cancer Treatment Research	93.395	University of Maryland, Baltimore	5R01CA260340-03	513,821	-
Cancer Treatment Research	93.395	NRG Oncology	5U10CA180868-10	12,082	-
Cancer Treatment Research	93.395	University of California at San Francisco, Cardiovascular Research Institut	SU24CA215123-05	140,296	-
Cancer Treatment Research	93.395	Public Health Institute	U10CA180886	19,720	-
Cardiovascular Diseases Research	93.837	Africa Health Research Institute (AHRI)	5R01HL144848-03	233,262	-
Cardiovascular Diseases Research	93.837	Albany MedicalCollege	5R01HL153019-04	85,813	-
Cardiovascular Diseases Research	93.837	Albany MedicalCollege	R01HL141127	13,454	-
Cardiovascular Diseases Research	93.837	Augusta University	5R01HL157665-03	290,141	-
Cardiovascular Diseases Research	93.837	Baylor College of Medicine	5R01HL148050-04	340,576	197,731
Cardiovascular Diseases Research	93.837	Beckman Research Institute of the City of Hope	R01HL150069-04	17,581	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5R01HL129185-06	70,370	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5R01HL154744-02	(7,666)	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5R01HL158077-02	80,158	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	1R01HL161697-01A1	22,092	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5R01HL157991-03	83,206	-
Cardiovascular Diseases Research	93.837	Board of Trustees of the University of Alabama for the University of Alabama	5R35HL135816-06	(2,028)	-
Cardiovascular Diseases Research	93.837	Boston Medical Center	1R56HL157367-01A1	259,959	-
Cardiovascular Diseases Research	93.837	Boston University School of Medicine	5R01HL127564-07	161,359	-
Cardiovascular Diseases Research	93.837	Brigham and Women's Hospital, Inc.	1R01HL157457-01A1	133,800	-
Cardiovascular Diseases Research	93.837	Brigham and Women's Hospital, Inc.	1R01HL164409-01	114,659	-
Cardiovascular Diseases Research	93.837	Brigham and Women's Hospital, Inc.	1R01HL166487-01	11,776	-
Cardiovascular Diseases Research	93.837	Brigham and Women's Hospital, Inc.	1R56HL157457-01	(2,225)	-
Cardiovascular Diseases Research	93.837	Brigham and Women's Hospital, Inc.	5R01HL150401-04	148,476	-
Cardiovascular Diseases Research	93.837	Broad Institute, inc.	1R01HL159176-01	39,431	-
Cardiovascular Diseases Research	93.837	Broad Institute, inc.	5R01HL143295-04	326,640	-
Cardiovascular Diseases Research	93.837	Broad Institute, inc.	1OT3HL147154-13	19,199	-
Cardiovascular Diseases Research	93.837	Broad Institute, inc.	1R01HL142711-01A1	11,907	-
Cardiovascular Diseases Research	93.837	Broad Institute, inc.	1R01HL156991-01	7,884	-
Cardiovascular Diseases Research	93.837	Broad Institute, inc.	1R01HL157717-01A1	180,572	-
Cardiovascular Diseases Research	93.837	Broad Institute, inc.	231873	875	-
Cardiovascular Diseases Research	93.837	Broad Institute, inc.	240336	15,821	-
Cardiovascular Diseases Research	93.837	Broad Institute, inc.	2R01HL092577	3,482	-
Cardiovascular Diseases Research	93.837	Broad Institute, inc.	54000004030	20,109	-
Cardiovascular Diseases Research	93.837	Broad Institute, inc.	5R01HL148050-04	17,625	-
Cardiovascular Diseases Research	93.837	Broad Institute, inc.	5R01HL151152	16,591	-
Cardiovascular Diseases Research	93.837	Broad Institute, inc.	5R01HL151283-03	28,103	-
Cardiovascular Diseases Research	93.837	Broad Institute, inc.	R01HL143295	15,079	-
Cardiovascular Diseases Research	93.837	Cedar-Sinai Medical Center	5R01HL131532-05	(4,290)	-
Cardiovascular Diseases Research	93.837	Cedar-Sinai Medical Center	5R01HL151828-03	112,123	-
Cardiovascular Diseases Research	93.837	Cedars-Sinai Health System	1R01HL165840-01A1	344,453	-
Cardiovascular Diseases Research	93.837	Cedars-Sinai Health System	5R35HL161195-02	157,043	-
Cardiovascular Diseases Research	93.837	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL156362-03	132,423	-
Cardiovascular Diseases Research	93.837	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL159097-03	32,498	-
Cardiovascular Diseases Research	93.837	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL162367-02	165,150	-
Cardiovascular Diseases Research	93.837	Children's Hospital Corporation dba Boston Children's Hospital	5U01HL098147-13	137,850	-
Cardiovascular Diseases Research	93.837	Direct		65,880,943	12,664,017

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Cardiovascular Diseases Research	93.837	Duke University	1R21HL157856-01A1	25,293	-
Cardiovascular Diseases Research	93.837	Duke University	U01HL134679-02	1,801	-
Cardiovascular Diseases Research	93.837	Duke University	5R01HL146145-04	151,089	-
Cardiovascular Diseases Research	93.837	Emory University	5R01HL119798-09	4,090	-
Cardiovascular Diseases Research	93.837	Harvard Pilgrim Health Care	5R01HL150119-03	232,102	-
Cardiovascular Diseases Research	93.837	HealthCore	5R01HL141213-03	16,000	-
Cardiovascular Diseases Research	93.837	Icahn School of Medicine at Mount Sinai	5U01HL089842-16	93,040	-
Cardiovascular Diseases Research	93.837	Icahn School of Medicine at Mount Sinai	5R01HL144072-04	(602)	-
Cardiovascular Diseases Research	93.837	Johns Hopkins University	5R01HL159987-02	196,530	-
Cardiovascular Diseases Research	93.837	Joslin Diabetes Center	5R01HL161858-02	325,927	-
Cardiovascular Diseases Research	93.837	Joslin Diabetes Center	5R01HL161864-02	30,451	-
Cardiovascular Diseases Research	93.837	Joslin Diabetes Center	R01HL161864-01	56,791	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	1R01HL149516-01A1	8,082	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	1R01HL149647-02	22,195	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	1UG3HL164285-01	5,097	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL133149-05	3,412	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL140498-05	79,212	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL141053-04	(2,200)	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL141917-04	34,103	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL146267-04	41,254	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL151293-03	86,800	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL151293-04	50,502	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL151643-03	102,013	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL155301-03	6,120	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL163234-02	75,164	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5U01HL123336-04	40,512	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5U01HL123336-06	102,928	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5U01HL160278-03	187,372	-
Cardiovascular Diseases Research	93.837	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5R01HL153857-04	403,257	-
Cardiovascular Diseases Research	93.837	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5R01HL161069-02	272,897	-
Cardiovascular Diseases Research	93.837	Mayo Clinic Arizona	1R01HL165176-01	276,693	-
Cardiovascular Diseases Research	93.837	Minnesota Health Solutions	1R43HL160298-01	60,483	-
Cardiovascular Diseases Research	93.837	New England Research Institute, Inc. (NERI)	5U01HL107407-05	1,360	-
Cardiovascular Diseases Research	93.837	New York University Grossman School of Medicine	5R01HL157220-02	26,127	-
Cardiovascular Diseases Research	93.837	New York University Grossman School of Medicine	5R01HL161090-02	110,379	-
Cardiovascular Diseases Research	93.837	Ohio State University	1R01HL168892-01	102,171	-
Cardiovascular Diseases Research	93.837	Physical Sciences, Inc.	1R43HL156359-01A1	4,745	-
Cardiovascular Diseases Research	93.837	President and Fellows of Harvard College	1R03HL150412-01A1	11,507	-
Cardiovascular Diseases Research	93.837	President and Fellows of Harvard College	5R01HL035464-32	470,138	-
Cardiovascular Diseases Research	93.837	President and Fellows of Harvard College	5R01HL126896-06	140,087	-
Cardiovascular Diseases Research	93.837	President and Fellows of Harvard College	5U01HL145386-05	1,461,201	-
Cardiovascular Diseases Research	93.837	Regents of the University of California, San Francisco	1R01HL164337-01A1	76,193	-
Cardiovascular Diseases Research	93.837	Regents of the University of California, San Francisco	5R01HL152957-03	164,217	-
Cardiovascular Diseases Research	93.837	Regents of the University of California, San Francisco	5R33HL141047-05	65,401	-
Cardiovascular Diseases Research	93.837	Regents of the University of Michigan	5R01HL146619-04	6,137	-
Cardiovascular Diseases Research	93.837	Regents of the University of Michigan	5R01HL155834-03	61,958	-
Cardiovascular Diseases Research	93.837	Regents of the University of Michigan	4UG3HL159134-02	28,458	-
Cardiovascular Diseases Research	93.837	Regents of the University of Minnesota	5R01HL141288-04	43,558	-
Cardiovascular Diseases Research	93.837	Research Triangle Institute International	5R01HL149352-04	128,283	-
Cardiovascular Diseases Research	93.837	The Administrators of the Tulane Educational Fund d/b/a Tulane University	5R01HL157903-02	42,927	-
Cardiovascular Diseases Research	93.837	The Administrators of the Tulane Educational Fund d/b/a Tulane University	1R21HL161718-01A1	17,773	-
Cardiovascular Diseases Research	93.837	The University of Texas Health Science Center at Houston	5R01HL141824-04	(120,536)	-
Cardiovascular Diseases Research	93.837	The Washington University	5R01HL143421-04	77,057	-
Cardiovascular Diseases Research	93.837	Thomas Jefferson University	5R01HL136209-04	1,335	-
Cardiovascular Diseases Research	93.837	Trustees of Boston University	5R01HL141406-04	325	-
Cardiovascular Diseases Research	93.837	Trustees of Boston University	2R01HL098028-09	107,064	-
Cardiovascular Diseases Research	93.837	Trustees of Boston University	5R01HL098028-06	(251)	-
Cardiovascular Diseases Research	93.837	Trustees of Boston University	5R01HL156975-02	81,399	-
Cardiovascular Diseases Research	93.837	Trustees of the University of Pennsylvania	5R01HL148272-03	219,887	-
Cardiovascular Diseases Research	93.837	Tufts Medical Center, Inc.	7R01HL149999-02	35,222	-
Cardiovascular Diseases Research	93.837	University of Arizona	5U01HL133362-05	135,060	-
Cardiovascular Diseases Research	93.837	University of California at Davis	1R01HL157712-01A1	96,262	-
Cardiovascular Diseases Research	93.837	University of Massachusetts, Worcester	5R01HL137794-04	3,659	-
Cardiovascular Diseases Research	93.837	University of Michigan Medical School	5R01HL146619-04	59,056	-
Cardiovascular Diseases Research	93.837	University of North Carolina at Chapel Hill, The	1R01HL163262-01A1	10,217	-
Cardiovascular Diseases Research	93.837	University of Pittsburgh Of the Commonwealth System of Higher Education	1UG3HL153847-01A1	716	-
Cardiovascular Diseases Research	93.837	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01HL142932-05	7,380	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Cardiovascular Diseases Research	93.837	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01HL151386-03	144,110	-
Cardiovascular Diseases Research	93.837	University of Pittsburgh Of the Commonwealth System of Higher Education	1R01HL160326-01	(1,836)	-
Cardiovascular Diseases Research	93.837	University of Pittsburgh Of the Commonwealth System of Higher Education	5U3HL153847-03	945	-
Cardiovascular Diseases Research	93.837	University of Rochester	1R01HL160795-01	19,366	-
Cardiovascular Diseases Research	93.837	University of Rochester	5R01HL153390-03	162,448	-
Cardiovascular Diseases Research	93.837	University of Rochester	R01HL140588-04	88	-
Cardiovascular Diseases Research	93.837	University of Washington	1R01HL142834-04	9,606	-
Cardiovascular Diseases Research	93.837	University of Washington - Seattle	5R01HL158765-02	377,663	-
Cardiovascular Diseases Research	93.837	Vanderbilt University Medical Center	5R01HL159487-03	47,874	-
Cardiovascular Diseases Research	93.837	Vanderbilt University Medical Center	5R01HL161516-02	28,691	-
Cardiovascular Diseases Research	93.837	Vanderbilt University Medical Center	5R01HL164675-02	366,583	-
Cardiovascular Diseases Research	93.837	Vanderbilt University Medical Center	1R01HL161516-01	33,443	-
Cardiovascular Diseases Research	93.837	Washington University, The	1R21HL167126-01	11,675	-
Cardiovascular Diseases Research	93.837	Washington University, The	5R01HL156991-03	85,352	-
Cardiovascular Diseases Research	93.837	Washington University, The	1UG3HL162970-01	41,026	-
Cardiovascular Diseases Research	93.837	Yale University	5R01HL148819-03	29,051	-
Cardiovascular Diseases Research	93.837	George Washington University	5R01HL140977-04	51,119	-
Cardiovascular Diseases Research	93.837	Reveal Pharmaceuticals	1R43HL156713	7,000	-
Cardiovascular Diseases Research	93.837	Oklahoma Medical Research Foundation	1R01HL167656-01A1	8,998	-
Cardiovascular Diseases Research	93.837	LiquiGlide Inc.	1R43HL162196-01A1	13,998	-
Cardiovascular Diseases Research	93.837	Mount Sinai School of Medicine	5U01HL088942-16	176,729	-
Cardiovascular Diseases Research	93.837	Mount Sinai School of Medicine	5P01HL131478-05	103,372	-
Cardiovascular Diseases Research	93.837	Columbia University Irving Medical Center (CUIMC)	5R01HL157216-03	45,562	-
Cardiovascular Diseases Research	93.837	Board of Regents of the University of Oklahoma Health Sciences Center	5R01HL161008-02	129,616	-
Cardiovascular Diseases Research	93.837	Dynocardia, Inc.	5R44HL158374-02	98,103	-
Cardiovascular Diseases Research	93.837	Masonic Medical Research Institute	R01HL102368-09	9,298	-
Cardiovascular Diseases Research	93.837	Mercator MedSystems, Inc.	R41HL160434	612	-
Child Health and Human Development Extramural Research	93.865	Barrett Technology	1R43HD105546-01	170,470	-
Child Health and Human Development Extramural Research	93.865	Beth Israel Deaconess Medical Center	5R01HD108047-02	28,429	-
Child Health and Human Development Extramural Research	93.865	Bionic Skins LLC	1R44HD110327-01	23,490	-
Child Health and Human Development Extramural Research	93.865	BioSensics LLC	2R44HD084035-04	134,686	-
Child Health and Human Development Extramural Research	93.865	Board of Regents of the University of Wisconsin System, The	5R01HD094759-05	16,404	-
Child Health and Human Development Extramural Research	93.865	Boston College	5R01HD098421-03	164,404	-
Child Health and Human Development Extramural Research	93.865	Boston University School of Medicine	5R01HD086742-07	2,212	-
Child Health and Human Development Extramural Research	93.865	Brigham and Women's Hospital, Inc.	5R01HD093724-05	34,697	-
Child Health and Human Development Extramural Research	93.865	Brigham and Women's Hospital, Inc.	1R21HD105050-01A1	35,092	-
Child Health and Human Development Extramural Research	93.865	Brigham and Women's Hospital, Inc.	3R01HD093724-05	18,774	-
Child Health and Human Development Extramural Research	93.865	Brigham and Women's Hospital, Inc.	5R01HD107772-02	52,781	-
Child Health and Human Development Extramural Research	93.865	Broad Institute, inc.	U24HD090743	(11,210)	-
Child Health and Human Development Extramural Research	93.865	Brown University	5P2CHD101895-03	17,381	-
Child Health and Human Development Extramural Research	93.865	Cedar-Sinai Medical Center	1R01HD106096-01	(73,338)	-
Child Health and Human Development Extramural Research	93.865	Charles River Analytics, Inc.	1R43HD106834-01	83,784	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children's Hospital	1R21HD107515-01A1	18,410	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children's Hospital	5R01HD100009-04	23,501	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children's Hospital	1R03HD104891-02	8,893	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children's Hospital	5R01HD100009-05	111,201	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Los Angeles	5R21HD107983-02	14,412	-
Child Health and Human Development Extramural Research	93.865	Direct		35,017,327	7,910,326
Child Health and Human Development Extramural Research	93.865	Emma Pendleton Bradley Hospital	5R01HD103665-03	21,670	-
Child Health and Human Development Extramural Research	93.865	Emory University	1R01HD110480-01	15,875	-
Child Health and Human Development Extramural Research	93.865	Fenway Community Health Center	UM2HD111102	13,905	-
Child Health and Human Development Extramural Research	93.865	Fertility Inc.	6R44HD099040-03	(46)	-
Child Health and Human Development Extramural Research	93.865	Fred Hutchinson Cancer Research Center	1R21HD107577-01A1	105,264	-
Child Health and Human Development Extramural Research	93.865	Giner, Inc.	1R43HD098994-01	(141)	-
Child Health and Human Development Extramural Research	93.865	Harvard Pilgrim Health Care	5R01HD094150-05	68,922	-
Child Health and Human Development Extramural Research	93.865	Massachusetts General Hospital	1R01HD105266-02	46,412	-
Child Health and Human Development Extramural Research	93.865	Massachusetts General Hospital	5R01HD091067-05	207,110	-
Child Health and Human Development Extramural Research	93.865	Massachusetts General Hospital	5R01HD107064-02	365,960	-
Child Health and Human Development Extramural Research	93.865	Massachusetts General Hospital	5R61HD103099-02	(666)	-
Child Health and Human Development Extramural Research	93.865	Massachusetts General Hospital	R33HD103099-03	3,522	-
Child Health and Human Development Extramural Research	93.865	Mayo Clinic Jacksonville	7R01HD106096-03	124,205	-
Child Health and Human Development Extramural Research	93.865	Medical University of South Carolina	2P2CHD086844-08	11,955	-
Child Health and Human Development Extramural Research	93.865	Michigan State University	5R01HD094842-05	43,342	-
Child Health and Human Development Extramural Research	93.865	Michigan State University	5R01HD096033-05	464,406	-
Child Health and Human Development Extramural Research	93.865	Michigan State University	5R01HD107019-02	45,191	-
Child Health and Human Development Extramural Research	93.865	Myolyn, LLC	1R41HD102261-01A1	(9,358)	-
Child Health and Human Development Extramural Research	93.865	Northeastern University	5R37HD087089-07	216,950	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Child Health and Human Development Extramural Research	93.865	Oregon Health & Science University (OHSU)	5U54HD100982-04	134,224	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	1R01HD095766	13,192	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	1R13HD104440-01	563	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD093761-05	129,837	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD094725-04	186,160	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD095766-03	3,962	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD097778-04	278,180	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R21HD103052-02	18,921	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	1P01HD107670-02	34,001	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	3P01HD103133-03	4,434	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5P01HD103133-03	23,923	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5P01HD107670-02	154,408	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD095766-05	5,516	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD101351-03	114,277	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD102342-02	62,221	-
Child Health and Human Development Extramural Research	93.865	Regents of the University of California, San Francisco	5R01HD098978-04	222,976	-
Child Health and Human Development Extramural Research	93.865	Rush University Medical Center	1R01HD107348-01A1	32,558	-
Child Health and Human Development Extramural Research	93.865	St. Louis College of Pharmacy	4R33HD099748-04	321,283	-
Child Health and Human Development Extramural Research	93.865	The University of Texas Health Science Center at Houston	5R01HD099543-03	(2,849)	-
Child Health and Human Development Extramural Research	93.865	Trustees of Columbia University in the City of New York (The)	5R01HD094793-05	164,575	-
Child Health and Human Development Extramural Research	93.865	Tufts Medical Center, Inc.	1R01HD097081-03	(8,343)	-
Child Health and Human Development Extramural Research	93.865	Tufts Medical Center, Inc.	5R01HD088061-05	15,356	-
Child Health and Human Development Extramural Research	93.865	Tufts Medical Center, Inc.	1R01HD109206-01	10,624	-
Child Health and Human Development Extramural Research	93.865	University of Arizona	5R21HD099623-02	(93)	-
Child Health and Human Development Extramural Research	93.865	University of Cincinnati	5R01HD105818-02	62,160	-
Child Health and Human Development Extramural Research	93.865	University of Colorado at Denver	5R01HD108133-02	258,306	-
Child Health and Human Development Extramural Research	93.865	University of Florida Board of Trustees	5R01HD089939-05	(304)	-
Child Health and Human Development Extramural Research	93.865	University of Massachusetts at Lowell	5R00HD093814-05	65,973	-
Child Health and Human Development Extramural Research	93.865	University of Massachusetts Chan Medical School	7R01HD099543-05	37,584	-
Child Health and Human Development Extramural Research	93.865	University of Massachusetts Medical School	1R01HD104772-01A1	25,935	-
Child Health and Human Development Extramural Research	93.865	University of North Carolina at Chapel Hill, The	5R01HD092374-05	99,813	-
Child Health and Human Development Extramural Research	93.865	University of North Carolina at Chapel Hill, The	3U24HD089880-05S1	(9)	-
Child Health and Human Development Extramural Research	93.865	University of North Carolina at Chapel Hill, The	5U19HD089881-05	5,371	-
Child Health and Human Development Extramural Research	93.865	University of Pittsburgh Of the Commonwealth System of Higher Education	AWD00003188(417136-6)	1,360	-
Child Health and Human Development Extramural Research	93.865	University of Pittsburgh Of the Commonwealth System of Higher Education	AWD00003188(419326-12)	15,649	-
Child Health and Human Development Extramural Research	93.865	University of Pittsburgh Of the Commonwealth System of Higher Education	U24HD036801-26	285,133	-
Child Health and Human Development Extramural Research	93.865	Women and Infants Hospital of Rhode Island	7R01HD097081-04	276,060	-
Child Health and Human Development Extramural Research	93.865	Worcester Polytechnic Institute	1R15HD104169-01A1	27,949	-
Child Health and Human Development Extramural Research	93.865	MGH Institute of Health Professions	R01HD106122-01A1	26,873	-
Child Health and Human Development Extramural Research	93.865	University of Cape Town	1R21HD110305-01A1	9,422	-
Child Health and Human Development Extramural Research	93.865	Florida State University	1UM2HD111102-01	270,998	-
Child Health and Human Development Extramural Research	93.865	Mbarara University of Science and Technology	2R21HD107985-02	19,783	-
Child Health and Human Development Extramural Research	93.865	Auto IVF	4R44HD105529-02	187,235	-
Child Health and Human Development Extramural Research	93.865	Research Foundation for the State University Of New York (SUNY), Albany	5R01HD097331-03	17,987	-
Child Health and Human Development Extramural Research	93.865	Auburn University	5R21HD101964-03	153,747	-
Child Health and Human Development Extramural Research	93.865	Phoenix Children's Hospital	R01HD088528	(15,529)	-
Child Health and Human Development Extramural Research	93.865	Stellenbosch University	R61HD103093	4,498	-
COVID-19 Aging Research	93.866	COVID-19 Direct		1,886,302	349,555
COVID-19 Aging Research	93.866	COVID-19 Hebrew Senior Life	90103	(32,703)	-
COVID-19 Aging Research	93.866	COVID-19 Johns Hopkins University	5R01AG050515-04	13,240	-
COVID-19 Aging Research	93.866	COVID-19 President and Fellows of Harvard College	5R01AG075507-02	12,674	-
COVID-19 Aging Research	93.866	COVID-19 President and Fellows of Harvard College	3P01AG032952-12S1	5,308	-
COVID-19 Aging Research	93.866	COVID-19 President and Fellows of Harvard College	3P01AG032952-12S3	2,474	-
COVID-19 Aging Research	93.866	COVID-19 Regents of the University of California, San Francisco	5R24AG065175-04	24,640	-
COVID-19 Aging Research	93.866	COVID-19 Washington University, The	3U01AG052564-04S1	(83)	-
COVID-19 Aging Research	93.866	COVID-19 MASSACHUSETTS INSTITUTE OF TECHNOLOGY	3P30AG064190-02S1	51,019	-
COVID-19 Aging Research	93.866	COVID-19 University of Texas Health Science Center at San Antonio	1R56AG074467-01	9,000	-
COVID-19 Aging Research	93.866	COVID-19 Johns Hopkins Hospital	3R01AG050515-04S1	2,201	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Benaroya Research Institute at Virginia Mason	3UM1AI109565-08S1	(45,329)	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Broad Institute, inc.	3U19AI110818-08S1	499,632	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Broad Institute, inc.	5R21AI162662-02	16,705	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Broad Institute, inc.	3U19AI110818-08S2	148,349	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Broad Institute, inc.	3U19AI110818-08S3	218,137	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Children's Hospital Corporation dba Boston Children's Hospital	3U19AI118609-05S2	118	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Direct		7,584,222	2,905,723
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Emory University	3U19AI110483-08S4	458,873	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Fred Hutchinson Cancer Center	3UM1AI068614-17S2	28,881	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Fred Hutchinson Cancer Center	3UM1A1068614-17S5	530,941	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Fred Hutchinson Cancer Center	3UM1A1068614-17S4	(5,061)	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Fred Hutchinson Cancer Research Center	3UM1A1068614-14S1	138,752	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Fred Hutchinson Cancer Research Center	3UM1A1068614-15S2	(7,175)	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Johns Hopkins University	3U01A1138897-04S1	7,802	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Regents of the University of California, Los Angeles, The	3UM1A1068636-15S1	(28,810)	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Regents of the University of California, Los Angeles, The	UM1A1068636	352,213	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Washington University, The	1P01A1168347-01	294,765	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Brigham and Women's Hospital, Inc.	1P01A1165072-01	1,686,480	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Scripps Research Institute	2U19A1135995-06	19,719	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5U19A1167899-02	1,101,393	-
COVID-19 Arthritis, Musculoskeletal and Skin Diseases Research	93.846	COVID-19 Direct		213,489	82,546
COVID-19 Arthritis, Musculoskeletal and Skin Diseases Research	93.846	COVID-19 Northwestern University	5R01AR080089-02	449,822	-
COVID-19 Arthritis, Musculoskeletal and Skin Diseases Research	93.846	COVID-19 Brigham and Women's Hospital, Inc.	1R01AR080659-01A1	107,973	-
COVID-19 Biomedical Research and Research Training	93.859	COVID-19 Direct		664,381	-
COVID-19 Blood Diseases and Resources Research	93.839	COVID-19 Direct		196,178	5,539
COVID-19 Blood Diseases and Resources Research	93.839	COVID-19 Emory University	5R01HL138656-04	(185)	-
COVID-19 Cancer Cause and Prevention Research	93.393	COVID-19 Direct		325,243	65,690
COVID-19 Cancer Centers Support Grants	93.397	COVID-19 Trustees of Columbia University in the City of New York (The)	3R01CA240080-04S1	206,512	-
COVID-19 Cancer Detection and Diagnosis Research	93.394	COVID-19 Beth Israel Deaconess Medical Center	1U01CA260476-01	(3,764)	-
COVID-19 Cancer Detection and Diagnosis Research	93.394	COVID-19 Beth Israel Deaconess Medical Center	4U01CA260476-02	48,604	-
COVID-19 Cancer Treatment Research	93.395	COVID-19 Direct		811,725	-
COVID-19 Cardiovascular Diseases Research	93.837	COVID-19 Beth Israel Deaconess Medical Center	1R01HL160003-01A1	138,144	-
COVID-19 Cardiovascular Diseases Research	93.837	COVID-19 Direct		1,913,270	463,326
COVID-19 Cardiovascular Diseases Research	93.837	COVID-19 Duke University	10T2HL156812-01	16,711	-
COVID-19 Cardiovascular Diseases Research	93.837	COVID-19 Icahn School of Medicine at Mount Sinai	5U01HL088942-14	20,538	-
COVID-19 Cardiovascular Diseases Research	93.837	COVID-19 Icahn School of Medicine at Mount Sinai	7R01HL159433-02	128,753	-
COVID-19 Child Health and Human Development Extramural Research	93.865	COVID-19 Direct		258,324	9,792
COVID-19 Child Health and Human Development Extramural Research	93.865	COVID-19 Michigan State University	3R01HD094842-04S1	99,244	-
COVID-19 Child Health and Human Development Extramural Research	93.865	COVID-19 President and Fellows of Harvard College	3R01HD094725-02S1	224,469	-
COVID-19 Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	COVID-19 Direct		99,305	-
COVID-19 Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	COVID-19 Temple University - Of the Commonwealth System of Higher Education	3U01DK073975-15S2	(326)	-
COVID-19 Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	COVID-19 Direct		3,964,620	702,303
COVID-19 Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	COVID-19 Icahn School of Medicine at Mount Sinai	1R01EB031083-01	8,455	-
COVID-19 Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	COVID-19 Rensselaer Polytechnic Institute	3R21EB028001-02S1	(22)	-
COVID-19 Drug Abuse and Addiction Research Programs	93.279	COVID-19 Biobot Analytics, Inc.	3R44DA051106-02S1	35,051	-
COVID-19 Drug Abuse and Addiction Research Programs	93.279	COVID-19 Biobot Analytics, Inc.	4R44DA051106-02	193,622	-
COVID-19 Drug Abuse and Addiction Research Programs	93.279	COVID-19 Direct		623,521	9,331
COVID-19 Environmental Health	93.113	COVID-19 Direct		137,093	47,306
COVID-19 Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	COVID-19 Direct		363,155	-
COVID-19 Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	COVID-19 Trustees of Boston University	1R21NS123412-01	87,963	-
COVID-19 Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	COVID-19 Yale University	3U01NS106513-02S1	(3,242)	-
COVID-19 Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	COVID-19 Regents of the University of Minnesota	5R01NS124065-02	147,187	-
COVID-19 Human Genome Research	93.172	COVID-19 Direct		(160)	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Beth Israel Deaconess Medical Center	1OT2HL156812-01	148,808	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Beth Israel Deaconess Medical Center	3U01HL123009-06S1	(8,449)	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Direct		34,491,316	19,034,809
COVID-19 Lung Diseases Research	93.838	COVID-19 MaineHealth	OT2HL161847	23,038	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Massachusetts General Hospital	1OT2HL161841-01	1,558,746	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Massachusetts General Hospital	1R01HL162373-01A1	8,093	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Massachusetts General Hospital	3U01HL123009-06S2	(9,514)	-
COVID-19 Lung Diseases Research	93.838	COVID-19 National Jewish Health	OT2HL156812	14,344	-
COVID-19 Lung Diseases Research	93.838	COVID-19 New York University Grossman School of Medicine	1OT2HL161847-01	3,949,623	2,484,139
COVID-19 Lung Diseases Research	93.838	COVID-19 New York University Grossman School of Medicine	OT2HL161847	163,384	-
COVID-19 Lung Diseases Research	93.838	COVID-19 New York University Grossman School of Medicine	OT2HL161847-01	236,040	57,460
COVID-19 Lung Diseases Research	93.838	COVID-19 PARXEL International, LLC	OT2HL156812	28,345	-
COVID-19 Lung Diseases Research	93.838	COVID-19 The Administrators of the Tulane Educational Fund db/a Tulane University	3R01HL165265-01S1	11,122	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Trustees of Columbia University in the City of New York (The)	RT122-312-0217571-66178	15,062	-
COVID-19 Lung Diseases Research	93.838	COVID-19 University of Florida Board of Trustees	OT2HL161847-01	33,849	-
COVID-19 Lung Diseases Research	93.838	COVID-19 University of Pittsburgh Of the Commonwealth System of Higher Education	1OT2HL156812-01	1,885,011	627,330
COVID-19 Lung Diseases Research	93.838	COVID-19 Vanderbilt University Medical Center	1OT2HL156812-01	216,185	-
COVID-19 Lung Diseases Research	93.838	COVID-19 New York University School of Medicine	OT2HL156812	143,245	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Research Triangle Institute International	1OT2HL156812-01	2,292,411	174,316
COVID-19 Lung Diseases Research	93.838	COVID-19 Brigham and Women's Hospital, Inc.	OT2HL161847-01	1,529,532	-
COVID-19 Medical Library Assistance	93.879	COVID-19 Direct		95,749	-
COVID-19 Mental Health Research Grants	93.242	COVID-19 Direct		1,384,362	175,316
COVID-19 Minority Health and Health Disparities Research	93.307	COVID-19 Direct		26,044	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
COVID-19 National Center for Advancing Translational Sciences	93.350	COVID-19 Direct		246,081	-
COVID-19 National Center for Advancing Translational Sciences	93.350	COVID-19 New York University Grossman School of Medicine	3UL1TR001445-06A1S2	81,635	-
COVID-19 National Center for Advancing Translational Sciences	93.350	COVID-19 Vanderbilt University Medical Center	3UL1TR002243-04S3	9,954	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 Beth Israel Deaconess Medical Center	1OT2HL156812-01	13,727	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 Duke University	HHSO1002014000021	45,962	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 Leidos Biomedical Research Inc	75N91019D00024	918,374	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 University of Chicago	75N92020D00021	67,801	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 Global Genomic Medicine Collaborative (G2MC)	31342020-C	12,971	-
COVID-19 Nursing Research	93.361	COVID-19 Washington University, The	5U01NR020555-02	68,664	-
COVID-19 Oral Diseases and Disorders Research	93.121	COVID-19 University of Mississippi Medical Center	1R01DE031928-01A1	1,233	-
COVID-19 Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	COVID-19 Vanderbilt University Medical Center	1OT2HL156812-01	48,090	-
COVID-19 Trans-NIH Research Support	93.310	COVID-19 Direct		572,075	48,204
COVID-19 Trans-NIH Research Support	93.310	COVID-19 Duke University	4U24MD016258-03	101,851	-
COVID-19 Trans-NIH Research Support	93.310	COVID-19 Johns Hopkins University	3UH3A1133669-05S2	54,357	-
COVID-19 Trans-NIH Research Support	93.310	COVID-19 Johns Hopkins University	UH3A1133669	(91,363)	-
COVID-19 Trans-NIH Research Support	93.310	COVID-19 President and Fellows of Harvard College	3P50CA24433-02S1	(2,218)	-
COVID-19 Trans-NIH Research Support	93.310	COVID-19 President and Fellows of Harvard College	3P50CA24433-03S3	(6,855)	-
COVID-19 Trans-NIH Research Support	93.310	COVID-19 Mbarara University of Science and Technology	1U54TW012043-01	154,923	-
COVID-19 Vision Research	93.867	COVID-19 Rector and Visitors of the University of Virginia, The	2R01EY026171-05	5,304	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Albert Einstein College of Medicine	5R01DK115577-05	154,087	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Augusta University	5R01DK121003-05	201,154	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Augusta University	5R01DK133520-02	113,151	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Beth Israel Deaconess Medical Center	5R01DK081572-12	28,886	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Beth Israel Deaconess Medical Center	5R01DK124502-03	21,799	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Beth Israel Deaconess Medical Center	5R01DK125846-03	23,940	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Board of Trustees of the University of Illinois, The	5R01DK118736-04	(7,809)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Board of Trustees of the University of Illinois, The	5R01DK125782-04	13,571	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Boston Medical Center	3P30DK046200-29	(836)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Boston Medical Center	5P30DK046200-29	4,227	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Brigham and Women's Hospital, Inc.	1R01DK126685-01A1	116,178	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Brigham and Women's Hospital, Inc.	5R01DK102696-05	(1,260)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Brigham and Women's Hospital, Inc.	5R01DK125786-03	116,895	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	1U01DK137242	6,400	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	2P30DK043351-31	9,756	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	5R01DK099465-08	45,408	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	5R01DK129464-03	13,251	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	RC2DK114784	(106)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	U01DK123717	4,024	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	UWSC12163	(2,634)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	1R01DK127171-01A1	22,717	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	1RC2DK135492-01	3,526	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	2R01DK081572-11A1	3,416	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	2U01DK114907-06	10,913	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	2UM1DK105554-06	27,370	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	5119609/540001422	85,785	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	5400001498	21,546	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	5400001498/1061307	8,978	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	5400001512	13,431	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	5R01DK120485-03	5,096	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	5R01DK114784-05	397,350	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	FP068366-01A	77,792	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Brown University	5R01DK127585-03	257,464	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	5R01DK116723-02	14,422	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	5U01DK094157-11	(3,547)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	5U01DK094157-13	531,567	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	1R01DK126448-02	109,357	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	2P30DK034854-36	237,539	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	2R01DK048106-28	20,512	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	3P30DK034854-36S1	6,924	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5P30DK034854-37	46,343	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5R01DK125273-03	252,755	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5R01DK097112-07	21,997	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5RC2DK131963-02	453,118	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Cleveland Clinic Lerner College of Medicine of Case Western Reserve University	U01DK114156-05	17,314	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Dana Farber Cancer Institute	5R01DK124384-04	39,725	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Direct		50,718,115	8,339,558
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Georgia Institute of Technology	1R01DK133702-01	165,041	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Icahn School of Medicine at Mount Sinai	5U54DK083909-14	26,228	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joan & Sanford I. Weill Medical College of Cornell University	1R01DK132427-01	29,502	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Johns Hopkins University	5R01DK124782-04	309,730	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	2R01DK106193-05A1	75,799	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5R01DK106193-06	153,602	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5R01DK121995-05	15,774	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5U01DK114156-05	45,458	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5U01DK116102-04	5,149	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	R01DK122808	249,843	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	U01DK114156	40,280	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	1U01DK135095-01	225,287	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5R01DK125677-03	12,493	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5R01DK129318-02	1,680	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	1R01DK133364-01A1	4,978	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	1UM1NS132358-01	38,092	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	2P30DK040561-26	4,235	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	3R01DK124710-03S1A1	123,737	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5P30DK040561-24	(1,013)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5P30DK040561-25	(7,480)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5R01DK049302-24	(14)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5R01DK101495-08	121,396	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5R01DK124145-03	(2,452)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5R01DK124145-04	28,098	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5R01DK124223-03	7,614	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	McLean Hospital Corporation	3R01DK121240-02S1	15,810	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Medical University of South Carolina	1U01DK104833-03	17,454	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	New England Research Institute, Inc. (NERI)	5U01DK110377-03	26,245	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	New York University	1R01DK133871-01A1	6,873	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	North Carolina Agricultural and Technical State University	5R01DK131753-02	42,788	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northeastern University	1R21DK118449-01A1	8,760	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northern California Institute for Research and Education	R01DK120387	363,383	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	3U01DK123759-03S1	112,664	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	1U2CDK129670-03	31,234	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5R01DK120560-04	87,557	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5R01DK120870	9,686	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5R01DK120870-04	99,988	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5R01DK126698-03	43,403	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5U2CDK129670-02	32,737	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5U2CDK129670-03	436,862	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5UC2DK126023-04	313,039	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Rector and Visitors of the University of Virginia, The	3P50DK096373-10	423	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of California, Los Angeles, The	5RC2DK118640-02	22,230	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of California, Los Angeles, The	5R01DK108438-05	5,362	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of California, San Diego	5R01DK128803-04	103,953	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of California, San Diego	5R01DK124318-03	64,920	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of California, San Francisco	5R01DK114014-04	(9,468)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of Michigan	5R01DK106618-08	196,706	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of Michigan	5U01DK133090-02	78,877	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Rush University Medical Center	5R01DK124280-03	15,784	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Rush University Medical Center	5R01DK084195-10	74,339	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Administrators of the Tulane Educational Fund d/b/a Tulane University	1R01DK125782-01A1	(2,708)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Trustees of Boston University	1R01DK132576-01	128,331	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Trustees of Indiana University	R01DK112293-05	48,642	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Trustees of the University of Pennsylvania	5U01DK103225-07	18,945	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Trustees of the University of Pennsylvania	5U01DK126654-02	6,774	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Alabama, Birmingham	5R01DK115473-04	20,050	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Chicago	5R01DK118266-04	(1,058)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Chicago	5U54DK118612-05	117,753	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Cincinnati	5R01DK123330-04	287,435	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Massachusetts, Worcester	1R01DK127180-01	73,355	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Massachusetts, Worcester	1R01DK127207-01	81,029	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of North Carolina at Chapel Hill, The	5R01DK125831-03	97,157	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of North Carolina at Chapel Hill, The	5R01DK127365-03	165,131	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Southern California	5U24DK110814-05	178,214	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Utah	1U24DK126127-01	92	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Utah	5U24DK126127-04	33,105	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Washington	5U2CDK114886-05	(27,113)	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Vanderbilt University Medical Center	5R01DK127912-03	107,798	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Vanderbilt University Medical Center	5R01DK131129-02	289,310	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Vanderbilt University Medical Center	5U01DK112271-05	16,274	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK061230-16	(1,120)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK098246-10	190,915	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Reveal Pharmaceuticals	R44DK134295-01	106,204	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	MONTREAL HEART INSTITUTE	2U01DK062432-22	266,689	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	MONTREAL HEART INSTITUTE	5U01DK062432-19	(2,138)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Advent Health	3R01DK112700-02S1	31,350	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Advent Health	5R01DK112700-03	3,492	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Sylvatica Biotech, Inc	4R44DK124053-02	57,825	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Barrett Technology	2R44EB027525-02	(108,315)	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Board of Trustees of the Leland Stanford Junior University, The	1R01EB033206-01	13,327	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Brigham and Women's Hospital, Inc.	5R01EB032378-02	186,828	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Brigham and Women's Hospital, Inc.	5R01EB033866-02	66,406	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Cedars-Sinai Health System	5R01EB034586-02	199,414	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Children's Hospital Corporation dba Boston Children's Hospital	5R01EB032708-02	27,517	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Dana Farber Cancer Institute	R56EB027683	(436)	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Direct		34,067,058	5,657,034
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Duke University	5R01EB028143-04	176,565	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Icahn School of Medicine at Mount Sinai	5R01EB030549-02	2,114	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Massachusetts General Hospital	1R01EB031008-03	192,285	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Massachusetts General Hospital	1U54EB033650-01	81,836	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5R01EB000244-41	180,473	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	1R01EB031813-01A1	378,750	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5P41EB015871-35	46,150	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Physical Sciences, Inc.	1R43EB032676-01	67,246	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Regents of the University of Minnesota	5U01EB025153-05	31,265	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Trustees of Boston University	1R21EB029154-01	44,513	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Trustees of Boston University	5R21EB030197-03	19,644	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Trustees of the University of Pennsylvania	5U24EB028941-04	80,813	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Houston	R21EB030257-01	(22,433)	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Massachusetts Amherst	5R01EB027777-04	154,170	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Texas at Austin	7R21EB027506-03	78,819	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Yale University	5R01EB031114-02	452,806	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	North Carolina State University	1R01EB029829-01	41,662	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Regents of the University of California	5U01EB025162-05	149,916	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Superconducting Systems, Inc.	1R43EB030454	7,892	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Nalu Scientific, LLC	1R43EB032730-01	49,916	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Kitware, Inc	2R01EB014955-05	17,915	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Rensselaer Polytechnic Institute	R01EB031102	282,689	-
Drug Abuse and Addiction Research Programs	93.279	Biobot Analytics, Inc.	1R44DA051106-01	34,934	-
Drug Abuse and Addiction Research Programs	93.279	Biobot Analytics, Inc.	3R44DA051106-03S1	44,118	-
Drug Abuse and Addiction Research Programs	93.279	Board of Trustees of the University of Alabama for the University of Alabama	5R01DA044112-05	97,075	-
Drug Abuse and Addiction Research Programs	93.279	Boston Medical Center	5UM1DA049412-04	139,741	-
Drug Abuse and Addiction Research Programs	93.279	Brigham and Women's Hospital, Inc.	5R01DA044167-05	18,547	-
Drug Abuse and Addiction Research Programs	93.279	Brigham and Women's Hospital, Inc.	5R21DA056799-02	9,982	-
Drug Abuse and Addiction Research Programs	93.279	Brigham and Women's Hospital, Inc.	1U19NS130617-01	418,632	-
Drug Abuse and Addiction Research Programs	93.279	Broad Institute, inc.	1U01DA053631-01	65,602	-
Drug Abuse and Addiction Research Programs	93.279	Brown University	1R34DA052838-01A1	30,218	-
Drug Abuse and Addiction Research Programs	93.279	Brown University	5R01DA047975-04	29,168	-
Drug Abuse and Addiction Research Programs	93.279	Cessation Therapeutics, LLC	U01DA051071-01A1	(4,916)	-
Drug Abuse and Addiction Research Programs	93.279	Children's Hospital Corporation dba Boston Children's Hospital	5U01DA055353-03	82,251	-
Drug Abuse and Addiction Research Programs	93.279	Direct		23,681,650	3,092,710
Drug Abuse and Addiction Research Programs	93.279	Emory University	7R01DA043263-06	(2,837)	-
Drug Abuse and Addiction Research Programs	93.279	ExQor Technologies Inc	2R44DA044050-02A1	400,038	-
Drug Abuse and Addiction Research Programs	93.279	Fenway Community Health Center	1DP2DA055107-01	11,277	-
Drug Abuse and Addiction Research Programs	93.279	Fenway Community Health Center	5R01DA047045-05	12,417	-
Drug Abuse and Addiction Research Programs	93.279	Florida International University	U01DA040381	(1,104)	-
Drug Abuse and Addiction Research Programs	93.279	Massachusetts General Hospital	4R33DA047034-04	205,717	-
Drug Abuse and Addiction Research Programs	93.279	Massachusetts General Hospital	5R61DA047034-03	(6,792)	-
Drug Abuse and Addiction Research Programs	93.279	McLean Hospital Corporation	1R21DA056864-01	74,586	-
Drug Abuse and Addiction Research Programs	93.279	McLean Hospital Corporation	5R01DA045632-04	17,386	-
Drug Abuse and Addiction Research Programs	93.279	McLean Hospital Corporation	5R33DA042847-05	40,376	-
Drug Abuse and Addiction Research Programs	93.279	MindLight, LLC	2R44DA050358-02A1	111,552	-
Drug Abuse and Addiction Research Programs	93.279	New York University Grossman School of Medicine	5UG3CA261067-03	85,200	-
Drug Abuse and Addiction Research Programs	93.279	Nobilis Therapeutics	R41DA055403	48,238	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Drug Abuse and Addiction Research Programs	93.279	Northeastern University	5R01DA047130-05	247,667	-
Drug Abuse and Addiction Research Programs	93.279	Northeastern University	7U18DA052509-02	5,623	-
Drug Abuse and Addiction Research Programs	93.279	President and Fellows of Harvard College	1R01DA054601-01A1	22,492	-
Drug Abuse and Addiction Research Programs	93.279	President and Fellows of Harvard College	2P30DA035772-06A1	42,347	-
Drug Abuse and Addiction Research Programs	93.279	President and Fellows of Harvard College	5R01DA048533-04	15,998	-
Drug Abuse and Addiction Research Programs	93.279	President and Fellows of Harvard College	523D32028/36C24123C0030	53,846	-
Drug Abuse and Addiction Research Programs	93.279	Regents of the University of Minnesota	R01DA047287	30,337	-
Drug Abuse and Addiction Research Programs	93.279	Research Triangle Institute International	1UM1DA049394-01	472,025	-
Drug Abuse and Addiction Research Programs	93.279	Trustees of Boston University	5R33DA045148-05	250,480	-
Drug Abuse and Addiction Research Programs	93.279	University of Florida Board of Trustees	1R01DA055568-01A1	35,637	-
Drug Abuse and Addiction Research Programs	93.279	Vox Biomedical LLC	4R42DA049655-03	217,415	-
Drug Abuse and Addiction Research Programs	93.279	Wake Forest University Health Sciences	5R24DA055306-02	35,355	-
Drug Abuse and Addiction Research Programs	93.279	Yale University	3UG1DA015831-21S4	133,890	-
Drug Abuse and Addiction Research Programs	93.279	Yale University	5UG1DA015831-22	1,326,261	-
Drug Abuse and Addiction Research Programs	93.279	Yale University	2UG1DA015831-22	19,798	-
Drug Abuse and Addiction Research Programs	93.279	Yale University	3UG1DA015831-22	496,764	-
Drug Abuse and Addiction Research Programs	93.279	Hennepin Healthcare Research Institute	5UG1DA040316-09	270,772	-
Drug Abuse and Addiction Research Programs	93.279	Tulane University School of Medicine	1R01NS114286	6,546	-
Drug Abuse and Addiction Research Programs	93.279	George Mason University	1U2CDA050097	16,190	-
Drug Abuse and Addiction Research Programs	93.279	University of Texas Medical Branch at Galveston	3R01DA040621-07S1	29,044	-
Drug Abuse and Addiction Research Programs	93.279	Partnership to End Addiction	3R24DA051946-01S1	27,122	-
Drug Abuse and Addiction Research Programs	93.279	PASCALL Systems, Inc.	4R42DA053075-02	321,365	-
Drug Abuse and Addiction Research Programs	93.279	Achieve Life Sciences, Inc.	4R44DA054784-02	451,602	-
Drug Abuse and Addiction Research Programs	93.279	Board of Regents of the University of Nebraska for the University of Nebraska	5R01DA046852-05	109,207	-
Drug Abuse and Addiction Research Programs	93.279	Avera McKennan	5R01DA050696-04	158,086	-
Drug Abuse and Addiction Research Programs	93.279	Clear Scientific	U01DA053054-03	180,796	-
Environmental Health	93.113	Arizona State University	1R01ES033999-01A1	27,244	-
Environmental Health	93.113	Beth Israel Deaconess Medical Center	5R01ES028688-05	22,938	-
Environmental Health	93.113	Dartmouth-Hitchcock Clinic	1R01ES034133-01	66,098	-
Environmental Health	93.113	Direct		3,149,297	1,096,009
Environmental Health	93.113	Drexel University	5R01ES032469-03	130,617	-
Environmental Health	93.113	President and Fellows of Harvard College	1R01ES034038-01A1	54,125	-
Environmental Health	93.113	President and Fellows of Harvard College	1R01ES035106-01	17,226	-
Environmental Health	93.113	President and Fellows of Harvard College	1R56ES033185-01	(334)	-
Environmental Health	93.113	President and Fellows of Harvard College	2P30ES000002-58	3,100	-
Environmental Health	93.113	President and Fellows of Harvard College	5P30ES000002-58	23,140	-
Environmental Health	93.113	President and Fellows of Harvard College	5P30ES000002-59	36,116	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES014370-15	8,362	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES022981-08	64,826	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES028033-05	69,196	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES031943-04	2,195	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES033185-02	47,167	-
Environmental Health	93.113	President and Fellows of Harvard College	5R24ES028521-05	110,097	-
Environmental Health	93.113	President and Fellows of Harvard College	5U01ES029520-05	85,568	-
Environmental Health	93.113	President and Fellows of Harvard College	7R01ES028298-04	9,889	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES031657-04	130,144	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES032470-03	33,517	-
Environmental Health	93.113	Regents of the University of California, Irvine	5R01ES020454-10	(9,672)	-
Environmental Health	93.113	Regents of the University of Michigan	1R01ES031591-03	125,779	-
Environmental Health	93.113	University of California at Irvine	5R01ES031139-04	336,077	-
Environmental Health	93.113	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01ES033519-03	79,619	-
Environmental Health	93.113	University of Washington	5R01ES027696-04	1,779	-
Environmental Health	93.113	University of Washington	5R21ES033343-02	25,227	-
Environmental Health	93.113	Regents of the University of California	5R01ES023316-10	30,429	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	149Medical,inc.	4R42NS110337-02	20,723	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	5R01NS105844-05	247,091	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	1U01NS096835-04	(1)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	5U01NS096835-04	2,726	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	5U01NS102289-03	182,675	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	7R01NS102190-06	15,125	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Board of Trustees of the Leland Stanford Junior University, The	5U01NS123101-02	221,869	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Brigham and Women's Hospital, Inc.	1R01NS121096-03	35	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Brigham and Women's Hospital, Inc.	5R01NS115951-03	221,985	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Brigham and Women's Hospital, Inc.	5R01NS123557-02	33,128	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Broad Institute, inc.	5R01NS102371-05	1,355	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Broad Institute, inc.	5400001617,GR105126,80001623	12,928	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Brown University	5R01NS113141-04	129,600	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Brown University	5R01NS079533-10	49,137	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital Corporation dba Boston Children's Hospital	5R01NS080833-11	34,859	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital Corporation dba Boston Children's Hospital	1R61NS126792-02	76,345	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital Corporation dba Boston Children's Hospital	5R21NS121735-02	24,963	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital of Philadelphia (The)	5U01NS111671-04	32,230	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital of Philadelphia (The)	5U54NS115052-04	1,633	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital of Philadelphia (The)	5U54NS115052-05	101,797	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Direct		105,592,191	17,092,911
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	1DP2NS127291-01	73,382	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	7R01NS113541-03	146,083	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Highland Instruments	5R44NS110237-03	146,467	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Icahn School of Medicine at Mount Sinai	1U01NS125580-01	51,023	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Icahn School of Medicine at Mount Sinai	5R01NS115957-04	126,043	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Icahn School of Medicine at Mount Sinai	1RF1NS115268-01	81,964	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Icahn School of Medicine at Mount Sinai	1RF1NS128961-01	191,501	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Icahn School of Medicine at Mount Sinai	5U01NS107016-05	123,292	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Jackson Laboratory, The	1R01NS125742-01	128,507	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Joan & Sanford I. Weill Medical College of Cornell University	5UH3NS095554-05	25,991	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1OT2NS122680-01	30,715	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1R61NS117210-01A1	22,576	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1R1NS128741-01	11,317	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	2R01NS093870-06A1	80,611	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5R01NS062092-08	55,395	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5R01NS102574-05	17,817	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5R01NS103924-05	167,905	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5U19NS115388-05	135,333	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5U24NS107154-05	124,321	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5U24NS107243-05	10,401	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5U24NS113850-05	198,227	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	U01NS114001	69,489	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	U01NS120901	19,752	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	1U01NS121471-03	756,956	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5R01NS121073-02	167,652	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5R01NS121078-03	450,613	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic	5R01NS076491-12	244,623	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic	5UH3NS103870-05	300,058	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic Jacksonville	5P01NS084974-08	126,790	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic Jacksonville	5U01NS080168-09	55,830	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Michigan State University	1RF1NS128611-01	245,797	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Neuropace, Inc.	5UH3NS109557-02	78,430	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Neuropace, Inc.	1UH3NS109557-01A1	124,548	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Northeastern University	1UF1NS107694-01	3,220	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Northwestern University	5R01NS085770-07	73,291	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Ohio State University	5UG3NS117844-02	85,417	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	PathMaker Neurosystems Inc.	1U44NS104138-01	312,843	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	President and Fellows of Harvard College	1R01NS126248-02	295,625	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	President and Fellows of Harvard College	5R01NS104143-05	79,366	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	President and Fellows of Harvard College	5R01NS126260-02	61,554	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	President and Fellows of Harvard College	1R01NS124017-01	68,625	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	President and Fellows of Harvard College	1R01NS126260-01	19,291	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	President and Fellows of Harvard College	5R01NS111952-04	15,481	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of California, San Diego	5UG3NS123723-02	232,098	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of California, San Francisco	1RF1NS128217-01A1	11,897	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of California, San Francisco	5R01NS111166-04	18,039	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of Michigan	1U01NS099046-01A1	33,369	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of Michigan	1UG3HL145269-01A1	2,994	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	ReNeuX Bio, Inc.	1R44NS118974-01	(4,815)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Schepens Eye Research Institute, Inc.	1RF1NS110048-01	26,359	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Sentiomed, Inc.	R43NS127733	13,542	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Soterya, Inc.	1R43NS120394-01A1	66,988	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Stanford University Medical Center	5U01NS038455-20	64,400	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	1R01NS125307-01A1	223,514	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	5R01NS121419-02	46,694	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	5U01NS093334-07	72,183	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	1U19NS128613-01	77,819	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	5R01NS110669-05	155,739	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	5U19NS123717-03	631,029	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Columbia University in the City of New York (The)	5R01NS084142-10	63,645	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Columbia University in the City of New York (The)	5U54NS078059-11	61,581	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of the University of Pennsylvania	5U01NS114140-03	21,317	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Chicago	5R01NS116262-03	78,439	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS102289-01A1	19,824	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS069763-08	736,654	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS095869-02	26,693	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS099043-01A1	31,607	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS110772-01	10,844	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS120910-01	1,085	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS106513-02	5,185	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS110728-02	570	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	7U01NS100699-03	4,496	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Florida Board of Trustees	1U01NS124613-01A1	27,140	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Florida Board of Trustees	5U01NS119562-03	17,175	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Maryland	5R01NS122980-03	130,272	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Massachusetts at Lowell	5R01NS097723-06	3,904	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Massachusetts, Worcester	5R01NS108769-04	357,983	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Massachusetts, Worcester	5U01NS114098-04	282,543	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Miami	2U54NS092091-06	(10,480)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Miami	5U54NS092091-09	26,576	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pittsburgh Of the Commonwealth System of Higher Education	U24NS115708	9,946	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Southern California	5U54NS100064-05	6,531	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Texas at San Antonio	1R01NS113516-02	(26,810)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Texas Health Science Center at San Antonio	5R01NS017950-37	41,666	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Texas Southwestern Medical Center	5R01NS108115-05	203,626	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Utah	5U01NS120901-02	1,165,761	278,110
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Vanderbilt University Medical Center	1R01NS123281-01A1	20,618	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Virginia Commonwealth University	5U01NS095388-03	(648)	(648)
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Yale University	1R01NS130189-01	127,724	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Yale University	5R01NS110721-05	3,935	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Yale University	5R01NS117904-03	262,187	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Yale University	5U01NS106513-02	1,721	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of California, Davis	R01NS058949-11	(7,647)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	George Washington University	5U54NS115054-04	2,212	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	MGH Institute of Health Professions	1R21NS120186-01A1	1,390	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Hillhurst Biopharmaceuticals, Inc.	1R41NS122576-01	226,579	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Buffalo	5R01NS058949-13	136,451	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Temple University - Of the Commonwealth System of Higher Education	5R01NS070267-14	8,450	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Cook Children's Health Care System	5R01NS104116-05	114,197	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Lovelace Biomedical Research Institute (LBRI)	5R01NS112808-06	25,215	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	The Methodist Hospital Research Institute	5U01NS104326-05	(6,206)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	State University of New York at Buffalo, The	7R01NS058949-12	266,650	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	NF Bio, Inc.	R41NS120338	(5,133)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Loxagen, Inc.	R43NA124491-01A1	78,203	-
Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.077	Direct		301,431	152,157
Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.077	University of Southern California	5R01CA260459-02	105,363	-
Human Genome Research	93.172	Brigham and Women's Hospital, Inc.	1R01HG012810-01	13,882	-
Human Genome Research	93.172	Brigham and Women's Hospital, Inc.	2U01HG008685-05	227,996	-
Human Genome Research	93.172	Brigham and Women's Hospital, Inc.	5U01HG012009-02	36,051	-
Human Genome Research	93.172	Brigham and Women's Hospital, Inc.	9U01NS134357-09	36,640	-
Human Genome Research	93.172	Broad Institute, inc.	1U01HG011755-01	39,999	-
Human Genome Research	93.172	Broad Institute, inc.	5U01HG011723-03	39,301	-
Human Genome Research	93.172	Broad Institute, inc.	5U24HG006934	43,352	-
Human Genome Research	93.172	Broad Institute, inc.	1U01HG011723-01	16,628	-
Human Genome Research	93.172	Broad Institute, inc.	1U24HG011450-01	313,184	-
Human Genome Research	93.172	Broad Institute, inc.	1U01HG011986-01	(1)	-
Human Genome Research	93.172	Broad Institute, inc.	54000001295/1U01HG011723	7,990	-
Human Genome Research	93.172	Broad Institute, inc.	54000001487/1U01HG011755	32,253	-
Human Genome Research	93.172	Broad Institute, inc.	5400000947	(12,118)	-
Human Genome Research	93.172	Broad Institute, inc.	5400001294/1U01HG011723-01	8,959	-
Human Genome Research	93.172	Broad Institute, inc.	5U01HG011755-03	624,577	-
Human Genome Research	93.172	Broad Institute, inc.	5U24HG011025-03	15,079	-
Human Genome Research	93.172	Broad Institute, inc.	5U01HG011986-02	663	-
Human Genome Research	93.172	Broad Institute, inc.	R01HG009141	(9,540)	-
Human Genome Research	93.172	Broad Institute, inc.	R01HG010647	47,487	-
Human Genome Research	93.172	Broad Institute, inc.	U01HG011723	40,579	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Human Genome Research	93.172	Broad Institute, inc.	U24HG006934-08	75,397	-
Human Genome Research	93.172	Broad Institute, inc.	U24HG010262	6,826	-
Human Genome Research	93.172	Broad Institute, inc.	U24HG012090	10,864	-
Human Genome Research	93.172	Broad Institute, inc.	U41HG006994	(9,578)	-
Human Genome Research	93.172	Children's Hospital Medical Center	5R01HG010730-03	68	-
Human Genome Research	93.172	Dana Farber Cancer Institute	5U24HG004059-19	252,589	-
Human Genome Research	93.172	Direct		9,189,094	2,514,762
Human Genome Research	93.172	Jackson Laboratory, The	5U24HG011735-02	101,946	-
Human Genome Research	93.172	Jackson Laboratory, The	5U24HG007497-08	69,601	-
Human Genome Research	93.172	Johns Hopkins University	5U24HG010263-05	144,196	-
Human Genome Research	93.172	Massachusetts General Hospital	5UM1HG012010-03	259,248	-
Human Genome Research	93.172	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5R01HG008754-04	(1,428)	-
Human Genome Research	93.172	President and Fellows of Harvard College	3U01HG009088-04S2	(132)	-
Human Genome Research	93.172	President and Fellows of Harvard College	3U01HG009088-04S3	(19)	-
Human Genome Research	93.172	President and Fellows of Harvard College	3U01HG009088-04S4	49	-
Human Genome Research	93.172	University of North Carolina at Chapel Hill, The	2U24HG009650-05	79,142	-
Human Genome Research	93.172	Whitehead Institute for Biomedical Research	2RM1HG0009490-06	682,467	-
Human Genome Research	93.172	University of California at Berkeley	5RM1HG0009490-05	(25,665)	-
International Research and Research Training	93.989	Direct		55,629	16,279
International Research and Research Training	93.989	President and Fellows of Harvard College	2D43TW009610-11	5,553	-
International Research and Research Training	93.989	President and Fellows of Harvard College	3D43TW010543-05S4	32,646	-
International Research and Research Training	93.989	University of Arizona	5R21TW011222-02	(57)	-
Lung Diseases Research	93.838	Beth Israel Deaconess Medical Center	3U01HL123009-07S1	30,864	-
Lung Diseases Research	93.838	Beth Israel Deaconess Medical Center	5U01HL123009-07	14,828	-
Lung Diseases Research	93.838	Beth Israel Deaconess Medical Center	5R01HL149422-04	71,040	-
Lung Diseases Research	93.838	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL118455-07	95,843	-
Lung Diseases Research	93.838	Children's Hospital Medical Center	5U01HL148856-04	104,114	-
Lung Diseases Research	93.838	Cincinnati Children's Hospital Medical Center	1R61HL165366-01	426,693	-
Lung Diseases Research	93.838	Cincinnati Children's Hospital Medical Center	5U24HL148865-03	(245)	-
Lung Diseases Research	93.838	Cincinnati Children's Hospital Medical Center	5U24HL148865-04	62,872	-
Lung Diseases Research	93.838	Cleveland Clinic Lerner College of Medicine	4U01HL125177-06	6,838	-
Lung Diseases Research	93.838	Direct		40,261,281	12,000,392
Lung Diseases Research	93.838	Fred Hutchinson Cancer Center	5UH3HL147011-04	32	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	1R61HL153011-01	(1,276)	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	2P01HL114501-06A1	82,545	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	4R33HL153011-02	249,838	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	5P01HL114501-07	696,875	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	5P01HL114501-08	541,570	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	1R61HL158540-01A1	34,209	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	4UH3HL154944-02	2,157	-
Lung Diseases Research	93.838	Johns Hopkins University	5R01HL160008-02	203,796	-
Lung Diseases Research	93.838	Massachusetts General Hospital	5R01HL154549-03	20,453	-
Lung Diseases Research	93.838	Massachusetts General Hospital	5UG3HL140177-03	(21,164)	-
Lung Diseases Research	93.838	National Jewish Health	5R01HL109557-11	138,225	-
Lung Diseases Research	93.838	National Jewish Health	5U01HL089897-14	(12,518)	-
Lung Diseases Research	93.838	Northwestern University	5R01HL122477-09	230,068	-
Lung Diseases Research	93.838	Northwestern University	5R01HL159250-02	51,122	-
Lung Diseases Research	93.838	Northwestern University	5U01HL146408-05	346,048	-
Lung Diseases Research	93.838	President and Fellows of Harvard College	5R01HL150520-04	241,972	-
Lung Diseases Research	93.838	Rector and Visitors of the University of Virginia, The	5R01HL153248-02	265,552	-
Lung Diseases Research	93.838	Regents of the University of California, San Diego	1R01HL161362-01	111,164	-
Lung Diseases Research	93.838	Regents of the University of California, San Diego	5R01HL162570-05	104,663	-
Lung Diseases Research	93.838	Regents of the University of Michigan	5U24HL145265-04	22,222	-
Lung Diseases Research	93.838	The University of Texas Health Science Center at Houston	5R01HL145025-05	480,722	-
Lung Diseases Research	93.838	Trustees of Boston University	1R01HL159644-01A1	217,667	-
Lung Diseases Research	93.838	Trustees of Columbia University in the City of New York (The)	5R01HL137234-04	99,122	-
Lung Diseases Research	93.838	Trustees of Columbia University in the City of New York (The)	7UH3HL140177-04	275,539	-
Lung Diseases Research	93.838	Trustees of Columbia University in the City of New York (The)	7R01HL121228-08	119,213	-
Lung Diseases Research	93.838	University of Cincinnati	5U01HL131755-05	4,873	-
Lung Diseases Research	93.838	University of Cincinnati	7R01HL146541-05	25,988	-
Lung Diseases Research	93.838	University of Colorado at Denver	5R01HL152735-04	94,783	-
Lung Diseases Research	93.838	University of Florida Board of Trustees	7R01HL157879-02	159,746	-
Lung Diseases Research	93.838	University of North Carolina at Chapel Hill, The	5U24HL138998-06	260,762	-
Lung Diseases Research	93.838	University of Pittsburgh Of the Commonwealth System of Higher Education	1R01HL157879-01	(4,867)	-
Lung Diseases Research	93.838	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01HL149719-04	13,858	-
Lung Diseases Research	93.838	University of Vermont and State Agricultural College	1R01HL161220-01A1	23,624	-
Lung Diseases Research	93.838	Vanderbilt University Medical Center	5R01HL146588-03	10,847	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Lung Diseases Research	93.838	Vanderbilt University Medical Center	5R01HL163960-02	96,667	-
Lung Diseases Research	93.838	Regents of the University of California, Davis	R01HL148715	11,720	-
Lung Diseases Research	93.838	Columbia University Irving Medical Center (CUIMC)	1R01HL159675-03	108,000	-
Medical Library Assistance	93.879	Dana Farber Cancer Institute	5R01LM013352-03	20,829	-
Medical Library Assistance	93.879	Direct		1,069,093	260,662
Medical Library Assistance	93.879	Northeastern University	1R01LM013772-01A1	88,172	-
Medical Library Assistance	93.879	Northwestern University	1R01LM013337-03	39,155	-
Medical Library Assistance	93.879	President and Fellows of Harvard College	5R01LM013614-02	35,453	-
Medical Library Assistance	93.879	President and Fellows of Harvard College	5R01LM013614-03	30,419	-
Medical Library Assistance	93.879	University of Cincinnati	5R21LM013683-03	11,294	-
Medical Library Assistance	93.879	University of Massachusetts Amherst	5R01LM013444-03	19,700	-
Medical Library Assistance	93.879	Cornell University	5R01LM012719-04	(112)	-
Mental Health Research Grants	93.242	Baylor College of Medicine	5R01MH115793-05	48,730	-
Mental Health Research Grants	93.242	Beth Israel Deaconess Medical Center	5R01MH116170-05	77,341	-
Mental Health Research Grants	93.242	Beth Israel Deaconess Medical Center	5R01MH107579-05	(2)	-
Mental Health Research Grants	93.242	Board of Trustees of the Leland Stanford Junior University, The	5R01MH116173-05	212,693	-
Mental Health Research Grants	93.242	Board of Trustees of the University of Alabama for the University of Alabama	R34RMH118044A	40,540	-
Mental Health Research Grants	93.242	Boston University School of Medicine	5R01MH128377-02	66,976	-
Mental Health Research Grants	93.242	Boston VA Research Institute Inc	4R33MH113751-03	151,177	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5U01MH109977-04	(4,016)	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5U24MH124629-04	788,101	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	1R01MH130666-01	61,152	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5R01MH101244-09	(136,835)	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5R01MH113929-08	196,416	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5R01MH125860-03	232,365	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5U24MH124629-03	929,100	-
Mental Health Research Grants	93.242	Broad Institute, inc.	R01MH130675	23,212	-
Mental Health Research Grants	93.242	Broad Institute, inc.	1R01MH130675-01	62,436	-
Mental Health Research Grants	93.242	Broad Institute, inc.	1RF1MH124598-01	22,251	-
Mental Health Research Grants	93.242	Broad Institute, inc.	1U01MH121499-01	1,354	-
Mental Health Research Grants	93.242	Broad Institute, inc.	1U01MH124602-01	31,256	-
Mental Health Research Grants	93.242	Broad Institute, inc.	1UM1MH130966-01	130,100	-
Mental Health Research Grants	93.242	Broad Institute, inc.	5R01MH106595-07	5,557	-
Mental Health Research Grants	93.242	Broad Institute, inc.	5R01MH107649-08	171,233	-
Mental Health Research Grants	93.242	Broad Institute, inc.	5R01MH115957-04	400,280	-
Mental Health Research Grants	93.242	Broad Institute, inc.	5R01MH116037-03	2,778	-
Mental Health Research Grants	93.242	Broad Institute, inc.	5R01MH120642-05	23,470	-
Mental Health Research Grants	93.242	Broad Institute, inc.	5R01MH129722-02	45,996	-
Mental Health Research Grants	93.242	Broad Institute, inc.	5R21MH125358-02	30,803	-
Mental Health Research Grants	93.242	Broad Institute, inc.	5R37MH107649-08	25,335	-
Mental Health Research Grants	93.242	Broad Institute, inc.	5U01MH111660-05	(980)	-
Mental Health Research Grants	93.242	Broad Institute, inc.	5U01MH119689-05	5,557	-
Mental Health Research Grants	93.242	Broad Institute, inc.	5U01MH125047-03	149,257	-
Mental Health Research Grants	93.242	Broad Institute, inc.	7R01MH104964-09	75,959	-
Mental Health Research Grants	93.242	Broad Institute, inc.	GR111001CON-8000267	4,037	-
Mental Health Research Grants	93.242	Broad Institute, inc.	R01MH111813	92,657	-
Mental Health Research Grants	93.242	Broad Institute, inc.	R01MH115957	25,076	-
Mental Health Research Grants	93.242	Broad Institute, inc.	R01MH120642	24,280	-
Mental Health Research Grants	93.242	Broad Institute, inc.	U01MH115727	(561)	-
Mental Health Research Grants	93.242	Broad Institute, inc.	U01MH119689	48,434	-
Mental Health Research Grants	93.242	Broad Institute, inc.	U19MH114821	8,128	-
Mental Health Research Grants	93.242	Butler Hospital	5R01MH112674-04	(387)	-
Mental Health Research Grants	93.242	Cambridge Health Alliance	P50MH126283-03	128,534	-
Mental Health Research Grants	93.242	Children's Hospital Corporation dba Boston Children's Hospital	1R01MH126977-01A1	152,324	-
Mental Health Research Grants	93.242	Children's Hospital Corporation dba Boston Children's Hospital	1RF1MH122967-01	27,829	-
Mental Health Research Grants	93.242	Cleveland Clinic Lerner College of Medicine of Case Western Reserve University	5R01MH125214-02	320,449	-
Mental Health Research Grants	93.242	Dartmouth-Hitchcock Clinic	5R01MH110965-05	1	-
Mental Health Research Grants	93.242	Direct		66,825,074	15,829,965
Mental Health Research Grants	93.242	Emory University	R01MH131434-01	44,090	-
Mental Health Research Grants	93.242	London School of Hygiene & Tropical Medicine	5R01MH115504-03	24,620	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	1R01MH128246-01A1	186,423	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	2R56MH091448-11A1	197,924	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	5R01MH102279-05	1,198	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	5R01MH113930-05	(619)	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	5R01MH113930-07	20,827	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	5R01MH116205-05	172,653	-
Mental Health Research Grants	93.242	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	1RF1MH121885-01A1	298,185	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Mental Health Research Grants	93.242	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	SU01MH117072-05	63,233	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	1R56MH125995-01	(290)	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5R01MH117012-05	141,843	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5R01MH122427-04	543,954	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	1P50MH115846-03	79,966	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5P50MH115846-03	109,909	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5P50MH115846-04	119,901	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5P50MH119467-04	653,132	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5R01MH120991-04	70,999	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5R37MH068376-18	85,404	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5R61MH121640-02	314,361	-
Mental Health Research Grants	93.242	National Network of Depression Centers	1R01MH121542-01	19,080	-
Mental Health Research Grants	93.242	New York University School of Medicine	5R01MH126981-02	68,806	-
Mental Health Research Grants	93.242	New York University School of Medicine	5R61MH122647-02	(41,578)	-
Mental Health Research Grants	93.242	Northeastern University	1R21MH129902-01	15,852	-
Mental Health Research Grants	93.242	Northeastern University	5R01MH113234-05	162,351	-
Mental Health Research Grants	93.242	Ocean State Research Institute, Inc.	1U01MH123427-02	25,287	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	1R01MH131414-01	17,724	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	3R01MH101269-08	24,068	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH101269-08	308,174	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH112829-06	34,415	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH121632-02	85,649	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R21MH121704-02	16,841	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	R01MH121191-04	21,186	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	T32MH017119	(5,065)	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	1R01MH121191-04	8,880	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	1R1MH128861-01	204,786	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH101244-12	313,203	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH120642-04	44,333	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH124004-03	82,192	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	SU01MH116928-04	122,747	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	7R01MH101244-10	176,270	-
Mental Health Research Grants	93.242	RAND Corporation	5R01MH117760-04	58,738	-
Mental Health Research Grants	93.242	RAND Corporation	5R34MH126478-03	10,683	-
Mental Health Research Grants	93.242	Regents of the University of California, San Diego	5R01MH106595-08	74,744	-
Mental Health Research Grants	93.242	Regents of the University of California, San Diego	1R1MH117155-01	(4,684)	-
Mental Health Research Grants	93.242	Regents of the University of Michigan	5R01MH110872-04	59,687	-
Mental Health Research Grants	93.242	Research Foundation for Mental Hygiene, Inc.	5R33MH116089-05	51,304	-
Mental Health Research Grants	93.242	Trustees of Boston University	1R01MH128280-01A1	31,622	-
Mental Health Research Grants	93.242	Trustees of Boston University	5R01MH121397-03	16,033	-
Mental Health Research Grants	93.242	Trustees of Boston University	5R01MH125703-02	39,982	-
Mental Health Research Grants	93.242	Trustees of Boston University	7R01MH111359-05	42	-
Mental Health Research Grants	93.242	University of Delaware	1R01MH126196-01A1	66,432	-
Mental Health Research Grants	93.242	University of Florida Board of Trustees	R01MH117114	119,842	-
Mental Health Research Grants	93.242	University of Massachusetts Amherst	5R01MH122371-04	112,784	-
Mental Health Research Grants	93.242	University of Massachusetts Chan Medical School	1R01MH128275-01A1	67,148	-
Mental Health Research Grants	93.242	University of Massachusetts, Worcester	5R01MH128904-02	135,325	-
Mental Health Research Grants	93.242	University of Miami	R01MH118043	65,312	-
Mental Health Research Grants	93.242	University of Miami	R01MH128868	6,514	-
Mental Health Research Grants	93.242	University of Mississippi Medical Center	1R01MH125833-01A1	43,080	-
Mental Health Research Grants	93.242	University of North Carolina at Chapel Hill, The	SU01MH110925-05	20,115	-
Mental Health Research Grants	93.242	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01MH115754-05	30,003	-
Mental Health Research Grants	93.242	University of Rochester	5P50MH106435-07	1,003,153	-
Mental Health Research Grants	93.242	University of Rochester	5R01MH045573-32	117,720	-
Mental Health Research Grants	93.242	University of Rochester	2P50MH106435-06A1	44,422	-
Mental Health Research Grants	93.242	University of Texas at Austin	R01MH120219	107,679	-
Mental Health Research Grants	93.242	University of Washington	5R01MH124465-02	26,125	-
Mental Health Research Grants	93.242	Vanderbilt University Medical Center	5R01MH113478-05	60,436	-
Mental Health Research Grants	93.242	Vanderbilt University Medical Center	R56MH120736	(1,076)	-
Mental Health Research Grants	93.242	Virginia Commonwealth University	1R01MH125938-01A1	(9,105)	-
Mental Health Research Grants	93.242	Yale University	5R01MH120080-05	63,977	-
Mental Health Research Grants	93.242	Yale University	5R01MH123155-03	323,997	-
Mental Health Research Grants	93.242	Yale University	5R01MH127259-02	91,981	-
Mental Health Research Grants	93.242	Trace-Ability, Inc.	1R44MH119110-01A1	(2,957)	-
Mental Health Research Grants	93.242	Paradromics, Inc.	1R44MH125700-01A1	178,086	-
Mental Health Research Grants	93.242	Huntington Medical Research Institute	2R01MH110438-06A1	308,855	-
Mental Health Research Grants	93.242	Rhode Island Hospital	5P50MH106435-07	23,199	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Mental Health Research Grants	93.242	King's College London	5R01MH114708-05	237,860	-
Mental Health Research Grants	93.242	Rutgers, the State University of New Jersey	5R01MH124899-03	46,651	-
Mental Health Research Grants	93.242	Rutgers, the State University of New Jersey	5R34MH113757-03	30,807	-
Mental Health Research Grants	93.242	Allen Institute	SUM1MH130981-02	305,315	-
Mental Health Research Grants	93.242	Palo Alto Veterans Institute for Research (PAVIR)	R01MH112628	774	-
Mental Health Research Grants	93.242	eMRI System LLP	R43MH128138	64,359	-
Mental Health Research Grants	93.242	NOUS Imaging Inc.	R44MH124567	219,760	-
Minority Health and Health Disparities Research	93.307	Children's Hospital Corporation dba Boston Children's Hospital	5R01MD015031-02	20,924	-
Minority Health and Health Disparities Research	93.307	Direct		3,337,248	1,108,755
Minority Health and Health Disparities Research	93.307	Environment and Health Group, Inc.	1R43MD018244-01	27,507	-
Minority Health and Health Disparities Research	93.307	Harvard Pilgrim Health Care	5R01MD015256-04	139,086	-
Minority Health and Health Disparities Research	93.307	Michigan State University	5R01MD015763-02	30,311	-
Minority Health and Health Disparities Research	93.307	Northern Arizona University	5R01MD013352-04	7,786	-
Minority Health and Health Disparities Research	93.307	President and Fellows of Harvard College	5R01MD012793-05	32,654	-
Minority Health and Health Disparities Research	93.307	President and Fellows of Harvard College	5R01MD014304-04	29,617	-
Minority Health and Health Disparities Research	93.307	President and Fellows of Harvard College	5R01MD017747-02	90,302	-
Minority Health and Health Disparities Research	93.307	Regents of the University of California, Los Angeles, The	5R01MD013913-04	28,132	-
Minority Health and Health Disparities Research	93.307	Regents of the University of California, Los Angeles, The	5R21MD017499-02	98,554	-
Minority Health and Health Disparities Research	93.307	Trustees of Boston University	5R01MD014312-03	40,097	-
Minority Health and Health Disparities Research	93.307	Tufts University	1R01MD016026-01	35,996	-
Minority Health and Health Disparities Research	93.307	University of California at Irvine	5R01MD015186-03	84,886	-
Minority Health and Health Disparities Research	93.307	University of North Carolina at Chapel Hill, The	1R01MD016755-01A1	35,443	-
Minority Health and Health Disparities Research	93.307	AltaMed Health Services Corporation	1R01MD013837-01A1	33,678	-
National Center for Advancing Translational Sciences	93.350	Boston Medical Center	SU01TR002070-05	126,588	-
National Center for Advancing Translational Sciences	93.350	Brigham and Women's Hospital, Inc.	5UH3TR002155-05	914	-
National Center for Advancing Translational Sciences	93.350	Broad Institute, inc.	125846/5400001597	6,413	-
National Center for Advancing Translational Sciences	93.350	Direct		3,663,017	1,061,853
National Center for Advancing Translational Sciences	93.350	Ohio State University	5R21TR003191-02	(9)	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	1UM1TR004408-01	622,623	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	5UL1TR002541-04	(82,344)	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	5UL1TR002541-05	1,391,821	-
National Center for Advancing Translational Sciences	93.350	Tufts University School of Medicine	5UL1TR002544	11,151	-
National Center for Advancing Translational Sciences	93.350	University of Pittsburgh Of the Commonwealth System of Higher Education	1U24TR004111-01	259,471	-
National Center on Sleep Disorders Research	93.233	Beth Israel Deaconess Medical Center	1R21NS149815-01	1,442	-
National Center on Sleep Disorders Research	93.233	Beth Israel Deaconess Medical Center	5P01HL149630-03	221,194	-
National Center on Sleep Disorders Research	93.233	Beth Israel Deaconess Medical Center	5R01HL136310-05	4,670	-
National Center on Sleep Disorders Research	93.233	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL137192-04	219,528	-
National Center on Sleep Disorders Research	93.233	Children's Hospital of Philadelphia (The)	4R33HL151253-04	19,113	-
National Center on Sleep Disorders Research	93.233	Children's Hospital of Philadelphia (The)	5R33HL151253-03S1	70,237	-
National Center on Sleep Disorders Research	93.233	Direct		9,737,849	737,539
National Center on Sleep Disorders Research	93.233	Icahn School of Medicine at Mount Sinai	5R01HL147328-05	52,708	-
National Center on Sleep Disorders Research	93.233	Ohio State University	5UH3HL140144-03	13,806	-
National Center on Sleep Disorders Research	93.233	Regents of the University of Michigan	1R01HL164755-01A1	15,902	-
National Center on Sleep Disorders Research	93.233	Stanford University Medical Center	5R01HL148704-03	568,244	-
National Institutes of Health Contracts	93.RD1	Altec, Inc.	SA-75N95023C00005	9,320	-
National Institutes of Health Contracts	93.RD1	Children's Hospital Corporation dba Boston Children's Hospital	75N93019C00044	(7,270)	-
National Institutes of Health Contracts	93.RD1	Children's Hospital Corporation dba Boston Children's Hospital	75N93020C00038	12,382	-
National Institutes of Health Contracts	93.RD1	Direct		7,102,889	8,171
National Institutes of Health Contracts	93.RD1	Duke University	75N93019C00050	413,960	-
National Institutes of Health Contracts	93.RD1	Duke University	HHSN2752010000031	1,858	-
National Institutes of Health Contracts	93.RD1	Duke University	HHSN2752018000031	25,996	-
National Institutes of Health Contracts	93.RD1	ExQor Technologies Inc	2R44MH108481-03	13,391	-
National Institutes of Health Contracts	93.RD1	Leidos Biomedical Research Inc	75N91019D000024	896,777	-
National Institutes of Health Contracts	93.RD1	Leidos Biomedical Research Inc	HHSN261200800001E	2,652,144	1,424,077
National Institutes of Health Contracts	93.RD1	Leidos Biomedical Research Inc	20X013	161,945	9,271
National Institutes of Health Contracts	93.RD1	Leidos Biomedical Research Inc	20X013F	845,690	-
National Institutes of Health Contracts	93.RD1	Leidos Biomedical Research Inc	HHSN261201500003/HHSN26100068	80,874	-
National Institutes of Health Contracts	93.RD1	President and Fellows of Harvard College	75N93019C00071	1,427,616	-
National Institutes of Health Contracts	93.RD1	Research Foundation for The SUNY on behalf of University of Buffalo	75N92021D00002-P00003	172,503	-
National Institutes of Health Contracts	93.RD1	Social and Scientific Systems, Inc.	HHSN273201600003/HHSN27300017	126,126	-
National Institutes of Health Contracts	93.RD1	Social and Scientific Systems, Inc.	HHSN612014000101	(65,013)	-
National Institutes of Health Contracts	93.RD1	University of Georgia Research Foundation, Inc. (UGARF)	75N93019C00052	166,290	-
National Institutes of Health Contracts	93.RD1	University of Mississippi Medical Center	HHSN2682018000111	68,927	-
National Institutes of Health Contracts	93.RD1	Westat, Inc.	HHSN261201300028I	244,023	-
National Institutes of Health Contracts	93.RD1	Westat, Inc.	HHSN261201800043C	54,715	-
National Institutes of Health Contracts	93.RD1	Public Health Institute	HSN261201500003I	5,161	-
National Institutes of Health Contracts	93.RD1	Robin Medical, Inc.	75N91019C00009	17,087	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
National Institutes of Health Contracts	93.RD1	Aethlon Medical, Inc.	75N91019C00042	87,315	-
National Institutes of Health Contracts	93.RD1	Seattle Children's Hospital	75N93021C00029	17,506	-
National Institutes of Health Contracts	93.RD1	Cure Systems, LLC	75N93022C00021	14,304	-
National Institutes of Health Contracts	93.RD1	Battelle, Columbus Division	HHSN2722018000131	330,528	-
National Institutes of Health Contracts	93.RD1	Duke Clinical Research Institute	HHSN2752018000031	1,442	-
NIEHS Superfund Hazardous Substances, Basic Research and Education	93.143	President and Fellows of Harvard College	5P42ES030990-03	29,225	-
NIEHS Superfund Hazardous Substances, Basic Research and Education	93.143	President and Fellows of Harvard College	5P42ES030990-04	82,381	-
NIEHS Superfund Hazardous Substances, Basic Research and Education	93.143	University of Rhode Island	5P42ES027706-07	43,227	-
Nursing Research	93.361	Brigham and Women's Hospital, Inc.	1R01NR020765-02	147,327	-
Nursing Research	93.361	Case Western Reserve University	5R56NR019306-02	30,493	-
Nursing Research	93.361	Columbia University Medical Center	5R01NR016941-06	43,288	-
Nursing Research	93.361	Direct		3,203,107	765,438
Nursing Research	93.361	etedRx, Inc.	1R43NR020289-01A1	24,256	-
Nursing Research	93.361	Fenway Community Health Center	1R43NR020289-01	6,723	-
Nursing Research	93.361	Umass Memorial Medical Center, Inc.	1R01NR020439-01	23,561	-
Nursing Research	93.361	University of Colorado at Denver	5U2CNR014637-10	204,241	-
Nursing Research	93.361	University of Massachusetts Medical School	5R01NR020439-02	50,743	-
Nursing Research	93.361	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01NR020031-02	94,672	-
Nursing Research	93.361	University of Rochester	2R01NR016037-06	17,810	-
Nursing Research	93.361	Yale University School of Medicine	5R01NR018335-05	27,069	-
Oral Diseases and Disorders Research	93.121	AtriumHealth	1UG3DE031250-01	17,758	-
Oral Diseases and Disorders Research	93.121	Board of Trustees of the University of Illinois, The	3R21DE026582-02S1	20,538	-
Oral Diseases and Disorders Research	93.121	Carolinas Health Care System	5U01DE022939-10	197,662	-
Oral Diseases and Disorders Research	93.121	Cincinnati Children's Hospital Medical Center	4UH3DE030401-02	15,527	-
Oral Diseases and Disorders Research	93.121	Dana Farber Cancer Institute	5R01DE027736-05	56,993	-
Oral Diseases and Disorders Research	93.121	Direct		4,487,269	975,591
Oral Diseases and Disorders Research	93.121	Emory University	5R01DE030342-03	95,011	-
Oral Diseases and Disorders Research	93.121	Forsyth Institute, The	5R01DE025020-09	89,041	-
Oral Diseases and Disorders Research	93.121	Massachusetts General Hospital	1R01DE027989-01A1	11,416	-
Oral Diseases and Disorders Research	93.121	Massachusetts General Hospital	1R01DE030464-02	45,784	-
Oral Diseases and Disorders Research	93.121	Massachusetts General Hospital	1UG3DE031920-01	115,364	-
Oral Diseases and Disorders Research	93.121	Massachusetts General Hospital	4UH3DE031920-02	72,234	-
Oral Diseases and Disorders Research	93.121	Ohio State University	5R01DE032334-02	22,983	-
Oral Diseases and Disorders Research	93.121	Ohio State University	7R01DE028565-02	100,162	-
Oral Diseases and Disorders Research	93.121	Stanford University	5R01DE024971-05	(3,432)	-
Oral Diseases and Disorders Research	93.121	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01DE026155-05	14,974	-
Oral Diseases and Disorders Research	93.121	University of Pittsburgh Of the Commonwealth System of Higher Education	5U01DE029759-04	107,964	-
Oral Diseases and Disorders Research	93.121	Wake Forest University Health Sciences	5R01DE031285-02	95,587	-
Oral Diseases and Disorders Research	93.121	University of Illinois at Urbana Champaign	R01DE027989	262,665	10,783
Oral Diseases and Disorders Research	93.121	SingleO2 Therapeutics LLC	R44DE026083	83,231	-
Oral Diseases and Disorders Research	93.121	Hennepin Healthcare Research Institute	UH3DE029973-04	22,391	-
Oral Diseases and Disorders Research	93.213	Aitec, Inc.	5R43AT012003-02	45,802	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	1R01AT012072-01	24,507	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	R34AT009354	(980)	-
Research and Training in Complementary and Integrative Health	93.213	Direct		7,321,059	1,497,527
Research and Training in Complementary and Integrative Health	93.213	Duke University	5U24AT009150-08	127,272	-
Research and Training in Complementary and Integrative Health	93.213	Massachusetts General Hospital	5P01AT009965-05	530,806	-
Research and Training in Complementary and Integrative Health	93.213	Massachusetts General Hospital	5R33AT009306-05	297,772	-
Research and Training in Complementary and Integrative Health	93.213	New York University Grossman School of Medicine	4UG3AT009844-05	29,334	-
Research and Training in Complementary and Integrative Health	93.213	President and Fellows of Harvard College	5R01AT009708-04	1,342	-
Research and Training in Complementary and Integrative Health	93.213	RAND Corporation	3R01AT010402-03S1	76,769	-
Research and Training in Complementary and Integrative Health	93.213	Spaulding Rehabilitation Hospital	1R21AT011918-01A1	6,787	-
Research and Training in Complementary and Integrative Health	93.213	Trustees of Boston University	5R01AT011429-02	262,356	-
Research and Training in Complementary and Integrative Health	93.213	University of Alabama, Birmingham	1U24AT011969-01	18,858	-
Research and Training in Complementary and Integrative Health	93.213	University of Kentucky	5R34AT010370-03	45	-
Research Infrastructure Programs	93.351	Direct		3,313,183	111,549
Research Related to Deafness and Communication Disorders	93.173	Board of Trustees of the Leland Stanford Junior University, The	5R01DC014034-08	147,824	-
Research Related to Deafness and Communication Disorders	93.173	Board of Trustees of the Leland Stanford Junior University, The	5U01DC019430-02	159,809	-
Research Related to Deafness and Communication Disorders	93.173	Brigham and Women's Hospital, Inc.	1R01DC020965-01	33,874	-
Research Related to Deafness and Communication Disorders	93.173	Brigham and Women's Hospital, Inc.	5R01DC015052-04	8,135	-
Research Related to Deafness and Communication Disorders	93.173	Brown University	5U01DC017844-03	201,041	-
Research Related to Deafness and Communication Disorders	93.173	Children's Hospital Corporation dba Boston Children's Hospital	2R01DC008853-11A1	87,930	-
Research Related to Deafness and Communication Disorders	93.173	Direct		25,481,092	3,885,683
Research Related to Deafness and Communication Disorders	93.173	Massachusetts Eye and Ear Infirmary	1P50DC019900-02	102,172	-
Research Related to Deafness and Communication Disorders	93.173	Massachusetts Eye and Ear Infirmary	1U01DC019279-03	125,477	-
Research Related to Deafness and Communication Disorders	93.173	Massachusetts Eye and Ear Infirmary	5R01DC011805-11	(1,238)	-
Research Related to Deafness and Communication Disorders	93.173	Massachusetts Eye and Ear Infirmary	5R01DC011805-13	129,808	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Research Related to Deafness and Communication Disorders	93.173	Massachusetts Eye and Ear Infirmary	5U01DC019279-02	75,832	-
Research Related to Deafness and Communication Disorders	93.173	Massachusetts General Hospital	1R01DC019916-01A1	102,372	-
Research Related to Deafness and Communication Disorders	93.173	Massachusetts General Hospital	242793	26,955	-
Research Related to Deafness and Communication Disorders	93.173	Modality AI, Inc.	4R42DC019877-02	187,342	-
Research Related to Deafness and Communication Disorders	93.173	President and Fellows of Harvard College	5R01DC017717-03	72,338	-
Research Related to Deafness and Communication Disorders	93.173	President and Fellows of Harvard College	5R01DC016932-05	26,222	-
Research Related to Deafness and Communication Disorders	93.173	Sunnybrook Research Institute	1R01DC017291-05	133,346	-
Research Related to Deafness and Communication Disorders	93.173	Trustees of Boston University	4500004411	183,354	-
Research Related to Deafness and Communication Disorders	93.173	Trustees of Boston University	1R01DC020867-01	44,262	-
Research Related to Deafness and Communication Disorders	93.173	University of Miami	1R01DC019404-01A1	208,832	-
Research Related to Deafness and Communication Disorders	93.173	Worcester Polytechnic Institute	1R15DC018667-01	8,223	-
Research Related to Deafness and Communication Disorders	93.173	Yale University	5R21DC018098-03	(2,240)	-
Research Related to Deafness and Communication Disorders	93.173	MGH Institute of Health Professions	1R15DC018944-01A1	21,909	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	Direct		948,628	351,984
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	President and Fellows of Harvard College	5R01HL149912-03	3,388	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	President and Fellows of Harvard College	5R01HL149912-04	51,420	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	Wits Reproductive Health and HIV Institute (WRHI)	4UH3HL156388-03	16,762	-
Trans-NIH Research Support	93.310	Board of Regents of the University of Wisconsin System, The	5UH3OD023282-07	315,118	-
Trans-NIH Research Support	93.310	Board of Trustees of the University of Illinois, The	5UH3OD023272-07	43,345	-
Trans-NIH Research Support	93.310	Brigham and Women's Hospital, Inc.	1U01HL166060-02	218,845	-
Trans-NIH Research Support	93.310	Brigham and Women's Hospital, Inc.	3U01HG007690-08S1	45,229	-
Trans-NIH Research Support	93.310	Brigham and Women's Hospital, Inc.	5U01HG007690-08	3,570	-
Trans-NIH Research Support	93.310	Brigham and Women's Hospital, Inc.	U01HG007690-08S2	28,064	-
Trans-NIH Research Support	93.310	Broad Institute, inc.	5DP5OD024582-05	(732)	-
Trans-NIH Research Support	93.310	Broad Institute, inc.	U24HD090743	13,825	-
Trans-NIH Research Support	93.310	Carnegie Mellon University	3OT2OD033759-01S1	162,186	-
Trans-NIH Research Support	93.310	Children's Hospital Corporation dba Boston Children's Hospital	1U01OD033248-01	204,849	-
Trans-NIH Research Support	93.310	Direct		29,329,354	10,673,042
Trans-NIH Research Support	93.310	International Agency for Research on Cancer	7U19CA203654	35,478	-
Trans-NIH Research Support	93.310	Massachusetts General Hospital	1UF1NS131791-01	79,395	-
Trans-NIH Research Support	93.310	Massachusetts General Hospital	3OT2OD026553-01S4	3,362,656	-
Trans-NIH Research Support	93.310	Massachusetts General Hospital	5U01DK127587-04	147,737	-
Trans-NIH Research Support	93.310	Michigan State University	5UH3OD023285-07	99,586	-
Trans-NIH Research Support	93.310	President and Fellows of Harvard College	1UM1DA058230-01	33,007	-
Trans-NIH Research Support	93.310	President and Fellows of Harvard College	5UG3OD023286-07	8,581	-
Trans-NIH Research Support	93.310	President and Fellows of Harvard College	5UH3OD023282-07	73,044	-
Trans-NIH Research Support	93.310	President and Fellows of Harvard College	5U01HG007530-08	(31,496)	-
Trans-NIH Research Support	93.310	Regents of the University of California, San Diego	5UG3CA241687	34,868	-
Trans-NIH Research Support	93.310	The Medical College of Wisconsin, Inc.	5U24HG010423-04	198,689	-
Trans-NIH Research Support	93.310	Tufts University	UG1HD107691	108,827	-
Trans-NIH Research Support	93.310	Tufts University	5UG1HD107691-02	511,922	-
Trans-NIH Research Support	93.310	University of Texas Health Science Center at San Antonio	1U54AG075941-01	23,368	-
Trans-NIH Research Support	93.310	Ludwig Institute for Cancer Research	5R01NS112503-03	125,905	-
Vision Research	93.867	AfaSci Research Laboratories	2R44EY025913-02	(16,902)	-
Vision Research	93.867	Brigham and Women's Hospital, Inc.	5R24EY028767-04	171,638	-
Vision Research	93.867	Brown University	5R01EY030569-03	37,503	-
Vision Research	93.867	Children's Hospital Corporation dba Boston Children's Hospital	1U01EY034686-01	132,279	-
Vision Research	93.867	Children's Hospital Corporation dba Boston Children's Hospital	2R01EY025794-06A1	51,507	-
Vision Research	93.867	Direct		29,392,014	3,826,396
Vision Research	93.867	Icahn School of Medicine at Mount Sinai	1R21EY032522-01	33,225	-
Vision Research	93.867	Icahn School of Medicine at Mount Sinai	5R01EY015473-17	68,114	-
Vision Research	93.867	Icahn School of Medicine at Mount Sinai	5R01EY032559-02	244,456	-
Vision Research	93.867	Jaeb Center for Health Research	1UG1EY030030-01A1	9,501	-
Vision Research	93.867	Johns Hopkins University	1UG1EY033293-01	(1,060)	-
Vision Research	93.867	Johns Hopkins University	7UG1EY028096-02	(1,030)	-
Vision Research	93.867	Massachusetts Eye and Ear Infirmary	1R21EY032953-02	32,574	-
Vision Research	93.867	Massachusetts Eye and Ear Infirmary	2R01EY020928-10	215,554	-
Vision Research	93.867	Massachusetts Eye and Ear Infirmary	5R01EY028269-02	(73)	-
Vision Research	93.867	Massachusetts Eye and Ear Infirmary	5R01EY031708-03	44,515	-
Vision Research	93.867	Massachusetts Eye and Ear Infirmary	5R01EY019703-12	5,185	-
Vision Research	93.867	Massachusetts Eye and Ear Infirmary	5R01EY031300-04	42,103	-
Vision Research	93.867	Massachusetts General Hospital	5R01EY029544-03	179,487	-
Vision Research	93.867	Massachusetts General Hospital	7R01EY030877-04	18,944	-
Vision Research	93.867	Massachusetts General Hospital	R01EY034857	3,751	-
Vision Research	93.867	New York University School of Medicine	3U10EY026869-05S3	14,100	-
Vision Research	93.867	New York University School of Medicine	5U10EY026869-03	(5,342)	-
Vision Research	93.867	Northeastern University	7R01EY027857-05	11,741	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures	
Research and Development Continued						
Vision Research	93.867	Oregon Health & Science University (OHSU)	8R01EY019474-10	(3,320)	-	
Vision Research	93.867	Pennsylvania State University	SUG1EY023533-08	41,571	-	
Vision Research	93.867	Regents of the University of California, San Francisco	5R01EY032041-02	(1,801)	-	
Vision Research	93.867	Research Foundation for The SUNY on behalf of University of Buffalo	1R01EY028553-01	(2,869)	-	
Vision Research	93.867	Schepens Eye Research Institute, Inc.	1R01EY031696-01A1	60,083	-	
Vision Research	93.867	Schepens Eye Research Institute, Inc.	5R01EY019470-14	19,189	-	
Vision Research	93.867	Scripps Research Institute	2R01EY026202-06A1	59,330	-	
Vision Research	93.867	Tufts Medical Center, Inc.	5R01EY029602-05	34,033	-	
Vision Research	93.867	University of New England	1U01EY034709-01	307,347	-	
Vision Research	93.867	University of New Mexico Health Sciences Center	7R01EY013124-22	89,206	-	
Vision Research	93.867	University of Pittsburgh Of the Commonwealth System of Higher Education	SUG1EY031651-02	57,066	-	
Vision Research	93.867	University of Tennessee Health Science Center	1R21EY031725-01	(1,569)	-	
Vision Research	93.867	Vanderbilt University Medical Center	1R21EY032592-01	51,802	-	
Vision Research	93.867	Vanderbilt University Medical Center	U24EY029893-03	507,062	-	
Vision Research	93.867	Intelton Optics	2R42EY028820-02	72,718	-	
Vision Research	93.867	Montana State University	R21EY031130	(5)	-	
				<u>Subtotal</u>	<u>1,227,143,893</u>	<u>235,591,333</u>
National Science Foundation, National Science Foundation						
Biological Sciences	47.074	Direct		506,368	254,079	
Biological Sciences	47.074	Regents of the University of California, Riverside	2211661	57,369	-	
Computer and Information Science and Engineering	47.070	Direct		288,892	-	
Computer and Information Science and Engineering	47.070	Research Foundation for The SUNY Stony Brook University, The	IIS1926781	289,435	-	
Computer and Information Science and Engineering	47.070	University of Massachusetts Amherst	1915481	52,064	-	
COVID-19 Biological Sciences	47.074	COVID-19 Direct		16,654	-	
COVID-19 Social, Behavioral, and Economic Sciences	47.075	COVID-19 Claremont McKenna College	2027694	34	-	
COVID-19 Social, Behavioral, and Economic Sciences	47.075	COVID-19 University of California at Davis	2116859	23,914	-	
Engineering	47.041	Direct		608,016	-	
Engineering	47.041	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	2124319	(49,103)	-	
Engineering	47.041	President and Fellows of Harvard College	EFMA-1830896	(362)	-	
Engineering	47.041	Regents of the University of Minnesota	2220611	20,271	-	
Engineering	47.041	Regents of the University of Minnesota	EEC-194153	1,999,975	-	
Engineering	47.041	George Washington University	1830941	5,393	-	
Engineering	47.041	Vulcan Biologics, Inc.	2126838	156,867	-	
Integrative Activities	47.083	University of Iowa	2040532	(56)	-	
Mathematical and Physical Sciences	47.049	Children's Hospital Corporation dba Boston Children's Hospital	1707865	12,707	-	
Mathematical and Physical Sciences	47.049	Direct		572	-	
Mathematical and Physical Sciences	47.049	President and Fellows of Harvard College	2127882	95,196	-	
Mathematical and Physical Sciences	47.049	Virginia Polytechnic Institute and State University	DMS-2229819	18,338	-	
Office of International Science and Engineering	47.079	President and Fellows of Harvard College	59-0210-6-004(OISA-9531011)	10,366	-	
Social, Behavioral, and Economic Sciences	47.075	Direct		133,095	-	
Social, Behavioral, and Economic Sciences	47.075	Regents of the University of California, San Diego	1932619	108,656	-	
STEM Education (formerly Education and Human Resources)	47.076	Direct		843,224	55,491	
				<u>Subtotal</u>	<u>5,197,885</u>	<u>309,570</u>
Office of Elementary and Secondary Education, Education, Department of Education Innovation and Research (formerly Investing in Innovation (I3) Fund)						
	84.411	United Way of Massachusetts Bay, Inc.	U411C170195	16,772	-	
				<u>Subtotal</u>	<u>16,772</u>	<u>-</u>
Office of Justice Programs, Justice, Department of Opioid Affected Youth Initiative Services for Trafficking Victims U.S. Department of Justice Contracts						
	16.842	Direct		281,867	-	
	16.320	Beth Israel Deaconess Medical Center	2019-VT-BX-K012	73,598	-	
	93.RD3	Direct		918	-	
				<u>Subtotal</u>	<u>356,383</u>	<u>-</u>
Office of The Secretary of Defense, Dept of Defense Basic, Applied, and Advanced Research in Science and Engineering						
Basic, Applied, and Advanced Research in Science and Engineering	12.300	Direct		516	-	
Basic, Applied, and Advanced Research in Science and Engineering	12.300	Ohio State University	N000142012163	283,351	-	
Basic, Applied, and Advanced Research in Science and Engineering	12.300	Regents of the University of Michigan	N00014-20-1-2479	286,612	-	
Basic, Applied, and Advanced Research in Science and Engineering	12.630	Terasaki Institute for Biomedical Innovation	W911NF1730003	(82)	-	
Basic, Applied, and Advanced Research in Science and Engineering	12.630	Advanced Regenerative Manufacturing Institute	22-01	107,479	-	
				<u>Subtotal</u>	<u>677,876</u>	<u>-</u>
Office of The Secretary, Transportation, Department of U.S. Department of Transportation Contracts						
	93.RD12	Direct		211,581	-	
				<u>Subtotal</u>	<u>211,581</u>	<u>-</u>

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development Continued					
Office of The Under Secretary for Public Diplomacy and Public Affairs, State, Department of Public Diplomacy Programs	19.040	Direct		26,161	-
				<u>26,161</u>	<u>-</u>
State, Department of, State, Department of U.S. Department of State Contracts	93.RD6	Direct		52,870	-
				<u>52,870</u>	<u>-</u>
Substance Abuse and Mental Health Services Administration, Health and Human Services, Department of Block Grants for Community Mental Health Services Opioid STR	93.958	University of Puerto Rico Medical Sciences Campus	2022951719	93,538	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.788	American Academy of Addiction Psychiatry (AAAP)	5H79TI083343-NCE	185,877	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	Direct		16	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	Victory Programs, Inc.	1H79SP083251-01	64,538	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	American Academy of Addiction Psychiatry (AAAP)	1H79TI085588-01	174,211	-
				<u>518,180</u>	<u>-</u>
Uniformed Services University of The Health Sciences (USUHS), Dept of Defense COVID-19 Uniformed Services University Medical Research Projects	12.750	COVID-19 Henry M Jackson Foundation for the Advancement of Military Medicine, Inc.	HU00012120089	560,916	-
Uniformed Services University Medical Research Projects	12.750	Geneva Foundation, The	HU00011920056	62,128	-
Uniformed Services University Medical Research Projects	12.750	Geneva Foundation, The	HU00011920009	277,334	-
Uniformed Services University Medical Research Projects	12.750	Geneva Foundation, The	HU00012020011	599,251	-
Uniformed Services University Medical Research Projects	12.750	Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	HU00011720023	72,405	-
Uniformed Services University Medical Research Projects	12.750	Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	HU00011820015	(36,926)	-
Uniformed Services University Medical Research Projects	12.750	Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	HU00011820018	5,368	-
Uniformed Services University Medical Research Projects	12.750	Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	HU00012320020	27,823	-
Uniformed Services University Medical Research Projects	12.750	Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	HU00012320021	21,317	-
Uniformed Services University Medical Research Projects	12.750	Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	HU00011720009	(72,114)	-
Uniformed Services University Medical Research Projects	12.750	Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	HU00011720009	(5,227)	-
Uniformed Services University Medical Research Projects	12.750	President and Fellows of Harvard College	HU00012020031	17,928	-
Uniformed Services University Medical Research Projects	12.750	The Geneva Foundation	HU00011920000	(8,579)	-
				<u>1,521,624</u>	<u>-</u>
VA Health Administration Center, Veterans Affairs, Department of Department of Veterans Affairs Contracts	93.RD2	Direct		1,951,845	-
Department of Veterans Affairs Contracts	93.RD2	President and Fellows of Harvard College	36C24E18D0048	28,514	-
Research and Development	64.054	Direct		838	-
				<u>1,981,197</u>	<u>-</u>
				\$ 1,318,554,173	\$ 242,016,724

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research Training					
Agency for Healthcare Research and Quality, Health and Human Services, Department of					
COVID-19 Research on Healthcare Costs, Quality and Outcomes	93.226	COVID-19 Direct		\$ 10,611	\$ -
Research on Healthcare Costs, Quality and Outcomes	93.226	Children's Hospital Corporation dba Boston Children's Hospital	5T32HS000063-28	13,405	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Direct		226,623	-
				<u>250,639</u>	<u>-</u>
Subtotal					
Dept of The Army, Dept of Defense					
Military Medical Research and Development	12.420	Direct		157,014	-
				<u>157,014</u>	<u>-</u>
Subtotal					
Health Resources and Services Administration, Health and Human Services, Department of					
Maternal and Child Health Federal Consolidated Programs	93.110	President and Fellows of Harvard College	6T76MC00001670	10,867	-
Mental and Behavioral Health Education and Training Grants	93.732	Direct		1,610,847	152,767
Mental and Behavioral Health Education and Training Grants	93.732	Massachusetts General Hospital	5T25HP37602-04-00	100,394	-
Mental and Behavioral Health Education and Training Grants	93.732	MGH Institute of Health Professions	1M01HP41980-02-00	3,335	-
Mental and Behavioral Health Education and Training Grants	93.732	MGH Institute of Health Professions	5M01HP41980-02	23,240	-
National Research Service Award in Primary Care Medicine	93.186	Beth Israel Deaconess Medical Center	5T32HP42013-02	19,899	-
National Research Service Award in Primary Care Medicine	93.186	Beth Israel Deaconess Medical Center	6T32HP42013-01-01	118,511	-
National Research Service Award in Primary Care Medicine	93.186	Direct		5,937	-
Nurse Education, Practice Quality and Retention Grants	93.359	Direct		463,687	15,000
Nurse Education, Practice Quality and Retention Grants	93.359	MGH Institute of Health Professions	5UK1HP46057-02-00	13,331	-
				<u>2,370,048</u>	<u>167,767</u>
Subtotal					
National Institutes of Health, Health and Human Services, Department of					
Aging Research	93.866	Beth Israel Deaconess Medical Center	3K24AG065525-03S1	5,871	-
Aging Research	93.866	Direct		5,538,521	6,003
Aging Research	93.866	Hebrew Senior Life	T32AG023480-17	28,671	-
Aging Research	93.866	Massachusetts General Hospital	5K23AG061276-04	4,479	-
Aging Research	93.866	President and Fellows of Harvard College	2T32AG000222-31	141,423	-
Aging Research	93.866	President and Fellows of Harvard College	5T32AG000222-28	16,955	-
Aging Research	93.866	President and Fellows of Harvard College	5T32AG000222-30	81,677	-
Alcohol Research Programs	93.273	Direct		1,197,315	40,617
Allergy and Infectious Diseases Research	93.855	Boston Medical Center	2T32AI052074-17	64,296	-
Allergy and Infectious Diseases Research	93.855	Boston Medical Center	5T32AI052074-16A1	65,292	-
Allergy and Infectious Diseases Research	93.855	Boston Medical Center	5T32AI052074-17	16,499	-
Allergy and Infectious Diseases Research	93.855	Dana Farber Cancer Institute	5T32AI07386-29	64,521	-
Allergy and Infectious Diseases Research	93.855	Direct		6,626,931	120,572
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5P30AI060354-19	104,297	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5T32AI07245-38	4,337	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5T32AI07245-39	107,176	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	CFAR-MGH-21-2-STANTON	2,215	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Direct		4,482,837	20,276
Biomedical Research and Research Training	93.859	Direct		1,958,015	-
Blood Diseases and Resources Research	93.839	Beth Israel Deaconess Medical Center	5T32HL007917-22	54,355	-
Blood Diseases and Resources Research	93.839	Beth Israel Deaconess Medical Center	5T32HL007917-24	63,492	-
Blood Diseases and Resources Research	93.839	Brigham and Women's Hospital, Inc.	5K12HL141953-05	133,751	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	5T32HL066987-19	60,705	-
Blood Diseases and Resources Research	93.839	Direct		1,808,145	461,532
Cancer Cause and Prevention Research	93.393	Dana Farber Cancer Institute	5UE5CA246746-03	4,306	-
Cancer Cause and Prevention Research	93.393	Direct		394,797	-
Cancer Research Manpower	93.398	Beth Israel Deaconess Medical Center	5K08CA248473-04	15,981	-
Cancer Research Manpower	93.398	Dana Farber Cancer Institute	5K08CA219504-05	(2)	-
Cancer Research Manpower	93.398	Dana Farber Cancer Institute	5R25CA181000-09	73,365	-
Cancer Research Manpower	93.398	Dana Farber Cancer Institute	5T32CA092203	40,573	-
Cancer Research Manpower	93.398	Dana Farber Cancer Institute	5T32CA092203-20	46,569	-
Cancer Research Manpower	93.398	Dana Farber Cancer Institute	T32CA092203	112,006	-
Cancer Research Manpower	93.398	Direct		9,641,504	111,472
Cancer Research Manpower	93.398	Massachusetts General Hospital	5K12CA090354-22	6,830	-
Cancer Research Manpower	93.398	President and Fellows of Harvard College	1K22CA258960-01	155,165	-
Cancer Research Manpower	93.398	President and Fellows of Harvard College	5T32CA009001-46	15,195	-
Cancer Research Manpower	93.398	President and Fellows of Harvard College	5T32CA009001-47	48,328	-
Cancer Research Manpower	93.398	President and Fellows of Harvard College	5T32CA009001-48	56,292	-
Cancer Research Manpower	93.398	President and Fellows of Harvard College	5T32CA057711-29	69,828	-
Cancer Research Manpower	93.398	Regents of the University of Michigan	2T32CA009672-31A1	78,471	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5T32HL007734-28	80,816	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5T32HL155020-03	1,400	-
Cardiovascular Diseases Research	93.837	Direct		9,079,380	18,405
Cardiovascular Diseases Research	93.837	President and Fellows of Harvard College	5T32HL098048-14	70,013	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research Training Continued					
Cardiovascular Diseases Research	93.837	Trustees of Boston University	5T32HL125232-06	(1)	-
Cardiovascular Diseases Research	93.837	University of North Carolina at Chapel Hill, The	1OT3HL147154-01	(20,025)	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children's Hospital	3T32DK007726-38S1	61,992	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children's Hospital	5K08HD100595-03	17,893	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children's Hospital	5T32HD040128-19	55,282	-
Child Health and Human Development Extramural Research	93.865	Direct		2,706,547	149,857
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	T32HD104612	62,775	-
COVID-19 Cancer Research Manpower	93.388	COVID-19 President and Fellows of Harvard College	5T32CA009001-47	68,190	-
COVID-19 Child Health and Human Development Extramural Research	93.865	COVID-19 Brigham and Women's Hospital, Inc.	5K12HD103096-03	136,669	-
COVID-19 Alcohol Research Programs	93.273	COVID-19 Direct		10,799	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Direct		381,971	90,000
COVID-19 Biomedical Research and Research Training	93.859	COVID-19 Direct		64,706	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5T32007477-38	11,525	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Direct		8,820,988	12,563
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5T32DK007260-46	58,637	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5T32DK007703-28	63,037	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Direct		1,663,396	-
Drug Abuse and Addiction Research Programs	93.279	American Academy of Child and Adolescent Psychiatry	K12DA000357	141,458	-
Drug Abuse and Addiction Research Programs	93.279	Boston Medical Center	2R25DA013582-21	14,246	-
Drug Abuse and Addiction Research Programs	93.279	Direct		2,130,438	95,336
Environmental Health	93.113	Direct		582,559	40,265
Environmental Health	93.113	President and Fellows of Harvard College	5T32ES007069-42	(4,545)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Direct		6,123,515	136,827
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Kennedy Krieger Institute	5K12NS098482-05	(5,845)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Kennedy Krieger Institute Inc	5K12NS098482-06	184,655	-
Human Genome Research	93.172	Direct		1,151,635	-
International Research and Research Training	93.989	American University of Beirut	2D43TW009118-06	7,146	-
International Research and Research Training	93.989	Direct		441,819	133,915
International Research and Research Training	93.989	Mbarara University of Science and Technology	5D43TW011632-03	46,507	-
Lung Diseases Research	93.838	Direct		7,541,861	6,174
Lung Diseases Research	93.838	University of Colorado at Denver	1F32HL162230-01	20,572	-
Medical Library Assistance	93.879	President and Fellows of Harvard College	2T15LM007092-31	65,903	-
Medical Library Assistance	93.879	President and Fellows of Harvard College	2T15LM7092-31	71,600	-
Mental Health Research Grants	93.242	Boston Medical Center	5T32MH116140-03	(7,771)	-
Mental Health Research Grants	93.242	Boston Medical Center	5T32MH116140-05	94,471	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5K24MH110807-05	26,762	-
Mental Health Research Grants	93.242	Children's Hospital Corporation dba Boston Children's Hospital	2T32MH112510-07	76,842	-
Mental Health Research Grants	93.242	Direct		7,651,266	221,932
Mental Health Research Grants	93.242	Judge Baker Children's Center	5T32MH016259-41	61,459	-
Mental Health Research Grants	93.242	Judge Baker Children's Center	5T32MH016259-42	100,292	-
Mental Health Research Grants	93.242	Northeastern University	7K23MH113805-05	96,289	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5T32MH17119-36	54,840	-
Minority Health and Health Disparities Research	93.307	Direct		406,537	-
National Center for Advancing Translational Sciences	93.350	Harvard Catalyst - The Harvard Clinical and Translational Science Center	1K12TR004381-01	70,847	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	1K12TR004381-01	10,578	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	5KL2TR002542-05	946,921	-
National Center on Sleep Disorders Research	93.233	Direct		1,216,501	-
National Institutes of Health Contracts	93.RD1	Westat, Inc.	75N92021F00229-P00002-0-1	86,534	-
National Institutes of Health Contracts	93.RD1	Westat, Inc.	75N92021Q0072	49,469	-
Oral Diseases and Disorders Research	93.121	Direct		497,758	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	5T32AT000051-23	143,128	-
Research and Training in Complementary and Integrative Health	93.213	Direct		721,192	-
Research Related to Deafness and Communication Disorders	93.173	Direct		1,685,534	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	Direct		204,492	-
Vision Research	93.867	Direct		1,779,401	-
				<u>91,273,830</u>	<u>1,665,746</u>
Substance Abuse and Mental Health Services Administration, Health and Human Services, Department of					
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	American Academy of Addiction Psychiatry (AAAP)	5H79TI081358-03	1,839	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	American Academy of Addiction Psychiatry (AAAP)	5H79TI081358-04	58,317	-
				<u>60,156</u>	<u>-</u>
				Total Research Training	\$ 94,111,687
				Total Research and Development and Research Training	\$ 1,412,665,860
					\$ 243,850,237

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Student Financial Aid					
Health Resources and Services Administration, Health and Human Services, Department of					
Nurse Faculty Loan Program (NFLP)	93.264	Nurse Faculty Loan Program (NFLP) FY22 Outstanding Loans	Direct	\$ 137,708	\$ -
Nurse Faculty Loan Program (NFLP)	93.264	Nurse Faculty Loan Program (NFLP) New Loans Issued During FY23	Direct	13,656	-
				Subtotal	-
				151,364	-
Office of Federal Student Aid, Education, Department of					
Federal Direct Student Loans	84.268	Department of Education	Direct	39,966,646	-
				Subtotal	-
				39,966,646	-
				Total Student Financial Aid	\$ -
				\$ 40,118,010	\$ -

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Food Distribution Cluster					
Food and Nutrition Service, Agriculture, Department of Emergency Food Assistance Program (Food Commodities)	10.569	Direct	Agency2273	\$ 92,256	\$ -
				Subtotal	-
				92,256	-
SNAP Cluster					
Food and Nutrition Service, Agriculture, Department of State Administrative Matching Grants for the Supplemental Nutrition Assistance Program	10.561	University of Massachusetts Medical Center	OutreachPartnerAmendment1-4-2016	20	-
				Subtotal	-
				20	-
Special Supplemental Nutrition Program for Women, Infant, and Children					
Food and Nutrition Service, Agriculture, Department of WIC Special Supplemental Nutrition Program for Women, Infants, and Children	10.557	Massachusetts Department of Public Health	INTF3502M03162726104	893,175	-
WIC Special Supplemental Nutrition Program for Women, Infants, and Children	10.557	Massachusetts Department of Public Health	INTF3502M03162726128	814,055	-
WIC Special Supplemental Nutrition Program for Women, Infants, and Children	10.557	Massachusetts Department of Public Health	WICvoucher	4,862,363	-
				Subtotal	-
				6,569,593	-
Economic Development Cluster					
Economic Development Administration, Commerce, Department of Economic Adjustment Assistance	11.307	Massachusetts Technology Park Corporation	ED21HDQ3070023	122,418	-
				Subtotal	-
				122,418	-
Highway Safety Cluster					
National Highway Traffic Safety Administration, Transportation, Department of National Highway Traffic Safety Administration (NHTSA) Discretionary Safety Grants and Cooperative Agreements	20.614	KEA Technologies, Inc.	DTNH22-13-H-00433	155,438	-
				Subtotal	-
				155,438	-
Coronavirus Relief Fund					
Departmental Offices, Treasury, Department of the COVID-19 Coronavirus Relief Fund	21.019	COVID-19 Foundation for Healthy Communities	CoronavirusReliefFundGrant	(7,270)	-
COVID-19 Coronavirus State and Local Fiscal Recovery Funds	21.027	COVID-19 COMMONWEALTH OF MASSACHUSETTS	CTDOE22CT96EAASESWFMCLEAN	(37)	-
				Subtotal	-
				(7,307)	-
Aging Cluster					
Administration for Community Living (ACL), Health and Human Services, Department of National Family Caregiver Support, Title III, Part E	93.052	Highland Valley Elder Services	NUMBER NOT AVAILABLE	4,000	-
				Subtotal	-
				4,000	-
Administration for Community Living (ACL), Health and Human Services, Department of Special Programs for the Aging, Title III, Part B, Grants for Supportive Services and Senior Centers	93.044	Highland Valley Elder Services	NUMBER NOT AVAILABLE	4,119	-
Special Programs for the Aging, Title III, Part B, Grants for Supportive Services and Senior Centers	93.044	Mystic Valley Elder Services	TitleIII-E	(2,973)	-
				Subtotal	-
				1,146	-
Other Programs					
Administration for Children and Families, Health and Human Services, Department of Title V State Sexual Risk Avoidance Education (Title V State SRAE) Program	93.235	Massachusetts Department of Public Health	INTF3211MM3W19020007	47,523	11,400
				Subtotal	11,400
				47,523	11,400
Agency for International Development, Agency for International Development Foreign Assistance to American Schools and Hospitals Abroad (ASHA)	98.006	Direct	72ASHA19GR00002	114,698	-
				Subtotal	-
				114,698	-
Agency for International Development, Agency for International Development USAID Development Partnerships for University Cooperation and Development	98.012	Yale University	7200AA21CA00010	10,942	-
				Subtotal	-
				10,942	-
Agency for International Development, Agency for International Development USAID Foreign Assistance for Programs Overseas	98.001	Direct	720FDA20CA00084	904,804	687,868
USAID Foreign Assistance for Programs Overseas	98.001	Direct	AID-440-A-16-00002	1,163,380	734,498
USAID Foreign Assistance for Programs Overseas	98.001	Direct	7200AA18CA00002	34,918	-
USAID Foreign Assistance for Programs Overseas	98.001	Eastern Virginia Medical School	7200AA20CA00019	30,776	-
USAID Foreign Assistance for Programs Overseas	98.001	Fenway Community Health Center	72038619CA00001	23,537	-
USAID Foreign Assistance for Programs Overseas	98.001	International AIDS Vaccine Initiative (IAVI)	A09867	99,325	-
USAID Foreign Assistance for Programs Overseas	98.001	International AIDS Vaccine Initiative (IAVI)	AID-0AA-A-16-00032	160,174	-
USAID Foreign Assistance for Programs Overseas	98.001	Invisible Children	7260518CA000001	7,997	-
USAID Foreign Assistance for Programs Overseas	98.001	National Opinion Research Center	GS-10F-0033M/7200AA18M00016	27,009	-
USAID Foreign Assistance for Programs Overseas	98.001	President and Fellows of Harvard College	7200AA19AP500003	324,718	-
USAID Foreign Assistance for Programs Overseas	98.001	President and Fellows of Harvard College	720FDA20GR000043	225,765	-
USAID Foreign Assistance for Programs Overseas	98.001	SSG Advisors, LLC d/b/a Resonance	7200AA18C00072	14,347	5,002
USAID Foreign Assistance for Programs Overseas	98.001	The KonTerra Group	7200AA20M000001	1,066	-
USAID Foreign Assistance for Programs Overseas	98.001	The KonTerra Group	GS-10F-0418Y/7200AA20M00001	109,170	-
				Subtotal	1,427,368
				3,126,986	1,427,368

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Other Programs Continued					
Assistant Secretary for Community Planning and Development, Housing and Urban Development, Department of Continuum of Care Program	14.267	Community Action of Pioneer Valley	MA0401L1T072110	116,099	-
	14.267	Massachusetts Department of Public Health	INTF4944MM3181926016	18,454	-
				Subtotal	-
Assistant Secretary for Community Planning and Development, Housing and Urban Development, Department of Housing Opportunities for Persons with AIDS	14.241	Direct	20210144	292,841	-
				Subtotal	-
CDC National Center for Chronic Disease Prevention and Health Promotion, Health and Human Services, Department of Drug-Free Communities Support Program Grants	93.276	Direct	2NH28CE002705-06-00	138,223	-
				Subtotal	-
Centers for Disease Control and Prevention, Health and Human Services, Department of Birth Defects and Developmental Disabilities - Prevention and Surveillance	93.073	Massachusetts Department of Public Health	5U01DD001224-03	53,614	-
	93.073	Massachusetts Department of Public Health	INTF3122HH4300522044	11,757	-
				Subtotal	-
Centers for Disease Control and Prevention, Health and Human Services, Department of COVID-19 Community Health Workers for Public Health Response and Resilient	93.495	COVID-19 Massachusetts Department of Public Health	INTF4207M03225031014	138,830	17,172
				Subtotal	17,172
Centers for Disease Control and Prevention, Health and Human Services, Department of COVID-19 Immunization Cooperative Agreements	93.268	COVID-19 Massachusetts Department of Public Health	INTF4207M03225031014	134,849	-
				Subtotal	-
Centers for Disease Control and Prevention, Health and Human Services, Department of COVID-19 Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security	93.318	COVID-19 Direct	6NU50CK000611-02-01	427,775	-
				Subtotal	-
Centers for Disease Control and Prevention, Health and Human Services, Department of COVID-19 Sexually Transmitted Diseases (STD) Prevention and Control Grants	93.977	COVID-19 Massachusetts Department of Public Health	INTF5264HH2500224074	65,047	-
				Subtotal	-
Centers for Disease Control and Prevention, Health and Human Services, Department of Disabilities Prevention	93.184	University of Alabama, Birmingham	1NU27DD000022-01-00	93,510	-
				Subtotal	-
Centers for Disease Control and Prevention, Health and Human Services, Department of Epidemiologic Research Studies of Acquired Immunodeficiency Syndrome (AIDS) and Human Immunodeficiency Virus (HIV) Infection in Selected Population Groups	93.943	Massachusetts Department of Public Health	INTF5180HH2W40199011	5	-
				Subtotal	-
Centers for Disease Control and Prevention, Health and Human Services, Department of HIV Prevention Activities Health Department Based	93.940	Massachusetts Department of Public Health	INTF4944MM3181926038	1,344,886	-
				Subtotal	-
Centers for Disease Control and Prevention, Health and Human Services, Department of Hospital Preparedness Program (HPP) and Public Health Emergency Preparedness (PHEP) Aligned Cooperative Agreements	93.074	Boston Public Health Commission, City of Boston	FY17017746	476	-
				Subtotal	-
Centers for Disease Control and Prevention, Health and Human Services, Department of Public Health Emergency Preparedness	93.069	BOSTON PUBLIC HEALTH COMMISSION	FY19020002	1,225	-
				Subtotal	-
Centers for Disease Control and Prevention, Health and Human Services, Department of Sexually Transmitted Diseases (STD) Prevention and Control Grants	93.977	Massachusetts Department of Public Health	INTF5290HH2500224014	65,937	-
				Subtotal	-
Centers for Disease Control and Prevention, Health and Human Services, Department of Sexually Transmitted Diseases (STD) Provider Education Grants	93.978	Massachusetts Department of Public Health	6NU62PS924585	121,863	-
	93.978	Massachusetts Department of Public Health	INTF5291HH4300522040	32,335	-
				Subtotal	-
Centers for Disease Control and Prevention, Health and Human Services, Department of Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	Direct	5NU50CK000622-02-00	1,175,181	445,951
				Subtotal	445,951

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Other Programs Continued					
Education, Department of, Education, Department of	84.425	COVID-19 Direct	P425E202204	13,603	-
COVID-19 Education Stabilization Fund	84.425	COVID-19 Direct	P425F202849	227,269	-
				<u>240,872</u>	<u>-</u>
Health Resources and Services Administration, Health and Human Services, Department of					
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153	Dimock Community Health Center	2H12HA24846-06-00	95,719	-
				<u>95,719</u>	<u>-</u>
Health Resources and Services Administration, Health and Human Services, Department of					
Ending the HIV Epidemic: A Plan for America — Ryan White HIV/AIDS Program Parts A and B	93.686	BOSTON PUBLIC HEALTH COMMISSION	6UT8HA33922-02-03	5,225	-
				<u>5,225</u>	<u>-</u>
Health Resources and Services Administration, Health and Human Services, Department of					
Health Systems Strengthening and HIV/AIDS Prevention, Care and Treatment under the President's Emergency Plan for AIDS Relief	93.266	Direct	5UH6HA30738-05-17	119,751	83,113
				<u>119,751</u>	<u>83,113</u>
Health Resources and Services Administration, Health and Human Services, Department of					
HIV Care Formula Grants	93.917	Massachusetts Department of Public Health	INTF4944MM3181926016	429,456	-
				<u>429,456</u>	<u>-</u>
Health Resources and Services Administration, Health and Human Services, Department of					
HIV Emergency Relief Project Grants	93.914	BOSTON PUBLIC HEALTH COMMISSION	6H89HA00011-32-02	96,528	-
HIV Emergency Relief Project Grants	93.914	BOSTON PUBLIC HEALTH COMMISSION	H89HA00011	342,896	-
				<u>439,424</u>	<u>-</u>
Health Resources and Services Administration, Health and Human Services, Department of					
Maternal and Child Health Federal Consolidated Programs	93.110	COMMONWEALTHOFMASSACHUSETTS	INTF3000H78W23011288	192,725	-
Maternal and Child Health Federal Consolidated Programs	93.110	Icahn School of Medicine at Mount Sinai	5H30MC24048-10	17,399	-
Maternal and Child Health Federal Consolidated Programs	93.110	Massachusetts Department of Public Health	INTF3121M04W16082022	(36,204)	2,230
Maternal and Child Health Federal Consolidated Programs	93.110	Massachusetts Department of Public Health	INTF3121MM3W23005040	1,204	-
Maternal and Child Health Federal Consolidated Programs	93.110	University of Colorado at Denver	2UA6MC31101-06-00	46,142	-
				<u>221,266</u>	<u>2,230</u>
Health Resources and Services Administration, Health and Human Services, Department of					
Maternal, Infant and Early Childhood Home Visiting Grant	93.870	Massachusetts Department of Public Health	INTF3617MM3220226202	336,425	-
Maternal, Infant and Early Childhood Home Visiting Grant	93.870	Massachusetts Department of Public Health	INTF3617MM3220226207	192,897	-
				<u>529,322</u>	<u>-</u>
Health Resources and Services Administration, Health and Human Services, Department of					
State Rural Hospital Flexibility Program	93.241	Massachusetts Department of Public Health	UW33294	14,533	-
				<u>14,533</u>	<u>-</u>
Health Resources and Services Administration, Health and Human Services, Department of					
Telehealth Programs	93.211	Direct	4P13RH33168-01-03	193,510	-
				<u>193,510</u>	<u>-</u>
Health Resources and Services Administration, Health and Human Services, Department of					
COVID-19 Ending the HIV Epidemic: A Plan for America — Ryan White HIV/AIDS Program Parts A and B	93.686	COVID-19 BOSTON PUBLIC HEALTH COMMISSION	6UT8HA33922-02-03	53,792	-
				<u>53,792</u>	<u>-</u>
Immed Office of The Secretary of Health and Human Services, Health and Human Services, Department of					
COVID-19 Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	COVID-19 Direct	5U3REP220683-02-00	707,012	-
COVID-19 Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	COVID-19 Direct	INTF6208PP1W20166284	8,667	-
COVID-19 Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	COVID-19 Massachusetts Department of Public Health	INTF6207PP1W16005812	953	-
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	Direct	INTF6207PP1W16052809	(2,674)	-
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	Direct	6HITEP180042-01-18	1,377,768	243,294
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	Direct	6HITEP180042-01-19	481	-
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	Massachusetts Department of Public Health	INTF6208PP1W22146333	110,522	-
				<u>2,202,729</u>	<u>243,294</u>
Immed Office of The Secretary of Health and Human Services, Health and Human Services, Department of					
National Bioterrorism Hospital Preparedness Program	93.889	Massachusetts Department of Public Health	INTF6207PP12042155071	(1,309)	-
				<u>(1,309)</u>	<u>-</u>
National Institutes of Health, Health and Human Services, Department of					
Drug Abuse and Addiction Research Programs	93.279	Salem Board of Health	5UM1DA049412-02	624	-
				<u>624</u>	<u>-</u>

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2023

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Other Programs Continued					
Office of Justice Programs, Justice, Department of Crime Victim Assistance	16.575	COMMONWEALTH OF MASSACHUSETTS	VC6000166374	107,060	-
Crime Victim Assistance	16.575	COMMONWEALTH OF MASSACHUSETTS	VOCA2021MGHI00000000	(32,778)	-
Crime Victim Assistance	16.575	COMMONWEALTHOFMASSACHUSETTS	VOCA2021BRIGPASS0000	(4,334)	-
Crime Victim Assistance	16.575	COMMONWEALTHOFMASSACHUSETTS	VOCA2021BRIGVRP00000	(11,658)	-
				<u>Subtotal</u>	<u>-</u>
Office of Justice Programs, Justice, Department of Crime Victim Assistance/Discretionary Grants	16.582	Direct	2018-V3-GX-K036	(12,900)	-
				<u>Subtotal</u>	<u>-</u>
Office of Justice Programs, Justice, Department of U.S. Department of Justice Contracts	93.UO1	COMMONWEALTHOFMASSACHUSETTS	24VOCAVWA	40,386	-
				<u>Subtotal</u>	<u>-</u>
Substance Abuse and Mental Health Services Administration, Health and Human Services, Department of Block Grants for Prevention and Treatment of Substance Abuse	93.959	Massachusetts Department of Public Health	INTF2351M03183626051	266,175	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	Massachusetts Department of Public Health	INTF2351M03183626053	185,176	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	Massachusetts Department of Public Health	INTF2351M03183626061	241,966	-
				<u>Subtotal</u>	<u>-</u>
Substance Abuse and Mental Health Services Administration, Health and Human Services, Department of Opioid STR	93.788	New Hampshire Department of Health and Human Services	05-95-92-7040-500731	1,034,617	-
				<u>Subtotal</u>	<u>-</u>
Substance Abuse and Mental Health Services Administration, Health and Human Services, Department of Substance Abuse and Mental Health Services Administration	93.UO2	City of Chelsea	2023-162	182,887	-
				<u>Subtotal</u>	<u>-</u>
Federal Emergency Management Agency, Homeland Security, Department of Disaster Grants - Public Assistance (Presidentially Declared Disasters)	97.036	Direct		134,464,310	-
				<u>Subtotal</u>	<u>-</u>
				Total Other Programs	\$ 2,230,528
				Total Federal Expenditures	\$ 1,608,260,311

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Notes to Schedule of Expenditures of Federal Awards

September 30, 2023

1. Organization

Mass General Brigham Incorporated (the Company) is the parent organization and sole corporate member of numerous organizations whose financial condition and operations are described in the consolidated financial statements. The terms Mass General Brigham, We, Our or Us as used herein, unless otherwise stated or indicated by context, refer collectively to the Company and its affiliated organizations.

Mass General Brigham operates academic medical centers, community acute care hospitals, inpatient and outpatient mental health services facilities, urgent care centers, facilities that provide rehabilitation medicine and long-term care services, physician organizations, home health services, nursing homes and a graduate level program for health professions. Our mission is to provide world class health care services to the local communities in which we operate as well as to patients across the United States and the world. In addition, we are a nonuniversity-based nonprofit private medical research enterprise and a principal teaching affiliate of the medical and dental schools of Harvard University. Our licensed, not-for-profit managed care organization (Mass General Brigham Health Plan, Inc.) and licensed, for-profit insurance company (Mass General Brigham Health Plan) (collectively referred to as Mass General Brigham Health Plan) provide health insurance products and administrative services to the Massachusetts Medicaid program (MassHealth), ConnectorCare (a state subsidized program for adults who meet income and immigration guidelines) and commercial populations.

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the Schedule) includes the Federal award activity of Mass General Brigham and is recorded on the accrual basis of accounting.

The information in the Schedule is presented in accordance with Title 2 U.S. Code of Federal Regulations (CFR) 200 Uniform Administrative Requirements Cost Principles and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in or used in the preparation of the basic consolidated financial statements. Negative amounts represent adjustments to amounts reported as expenditures in prior years in the normal course of business. Assistance Listing Number (ALN) and pass-through award numbers are provided where available. The Schedule combines expenditures of The Brigham and Women's Hospital, Inc., The General Hospital Corporation d/b/a The Massachusetts General Hospital (MGH), Massachusetts Eye and Ear Infirmary, including Schepens Eye Research Institute, Inc., The McLean Hospital Corporation, The MGH Institute of Health Professions, Inc., The Spaulding Rehabilitation Hospital Corporation, including Spaulding Hospital-Cambridge, Inc. and Spaulding Nursing and Therapy Center Brighton, Inc., Cooley Dickinson Hospital, Inc., North Shore Medical Center, Inc. d/b/a Salem Hospital, Newton-Wellesley Hospital, Brigham and Women's Faulkner Hospital, Inc., Martha's Vineyard Hospital, Inc., Nantucket Cottage Hospital, Mass General Brigham Community Physicians, Inc., Wentworth-Douglass Hospital, and Mass General Brigham. These entities are all affiliates of Mass General Brigham.

Mass General Brigham Incorporated and Affiliates

Notes to Schedule of Expenditures of Federal Awards

September 30, 2023

Federal expenditures for Research and Development and Research and Development Training for Brigham and Women's Hospital, Massachusetts General Hospital, McLean, Massachusetts Eye and Ear Infirmary, Schepens Eye Research Institute, Spaulding Rehabilitation Hospital and the MGH Institute of Health Professions include facilities and administrative cost recoveries and fringe benefit cost recoveries in the amounts reported in the Schedule based on rates negotiated and awarded with the DHHS Division of Cost Allocation. These rates are based on financial information submitted utilizing the methods prescribed in Principles for Determining Costs Applicable to Research and Development Under Grants and Contracts with Hospitals, contained in the Code of Federal Regulation, Title 45, Part 74, Appendix E (OASC-3). The predetermined facilities and administrative cost rates for IHP are based on financial information submitted utilizing the simplified method for small institutions prescribed in Indirect (F&A) Costs Identification and Assignment, and Rate Determination for Institutions of Higher Education (IHEs), contained in the Code of Federal Regulation, Title 2, Part 200, Appendix III. Expenditures reported in Training and Other include the maximum facilities and administrative recoveries approved by the sponsor. The 10% de-minimis rate is not utilized on Research and Development or Research and Development Training by Mass General Brigham because they have approved negotiated rate agreements. The 10% de-minimis rate is used for Other awards where allowed.

2. Federal Student Loan Programs

The amounts reported in the Student Financial Aid Cluster of the Schedule represent the beginning balances and newly issued loans in fiscal year 2023. As of September 30, 2023, the MGH Institute of Health Professions (IHP) had loans outstanding of \$119,940 for loans issued as part of the Nurse Faculty Loan Program (ALN 93.264). IHP had Direct Loans issued by the Department of Education of \$39,966,646 as of September 30, 2023 for ALN 84.268.

3. Federal Emergency Management Agency (FEMA) Public Assistance

Mass General Brigham applied for reimbursement of certain expenses related to the COVID-19 pandemic under Assistance Listing #97.036, FEMA Public Assistance through the Commonwealth of Massachusetts. Expenditures are reflected in the Schedule of Federal Expenditures (SEFA) in the year in which a project application is obligated. The Schedule thus includes \$134,464,310 of expenditures incurred in fiscal years 2020, 2021 and 2022, which were obligated in fiscal year 2023 and represents a reconciling item between the federal expenses in Mass General Brigham's financial statements and the amount included on the Schedule.

Part II
Reports on Compliance and Internal Control



Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards

To the Board of Directors of
Mass General Brigham Incorporated

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Mass General Brigham Incorporated (the "Company") and its affiliates, which comprise the consolidated balance sheets as of September 30, 2023 and 2022, and the related consolidated statements of operations, of changes in net assets and of cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial statements"), and have issued our report thereon dated December 8, 2023.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the Company and its affiliates' internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Company and its affiliates' internal control. Accordingly, we do not express an opinion on the effectiveness of the Company and its affiliates' internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Company and its affiliates' consolidated financial statements are free from material misstatement, we performed tests of its compliance with



certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Company and its affiliates' internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Company and its affiliates' internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Boston, Massachusetts
December 8, 2023



Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance

To the Board of Directors of
Mass General Brigham Incorporated

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Mass General Brigham Incorporated (the “Company”) and its affiliates’ compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Company and its affiliates’ major federal programs for the year ended September 30, 2023. The Company and its affiliates’ major federal programs are identified in the summary of auditor’s results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Company and its affiliates complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended September 30, 2023.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (US GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors’ Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Company and its affiliates and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Company and its affiliates’ compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Company and its affiliates’ federal programs.



Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Company and its affiliates' compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Company and its affiliates' compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Company and its affiliates' compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Company and its affiliates' internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Company and its affiliates' internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type



of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Boston, Massachusetts
December 8, 2023

Part III
Federal Award Findings and Questioned Cost

Mass General Brigham Incorporated and Affiliates

Schedule of Findings and Questioned Costs

Fiscal Year Ended September 30, 2023

1. Summary of Auditor's Results

Financial Statements

Type of auditor's report issued

Internal control over financial reporting

Unmodified

Material weakness(es) identified?

yes no

Significant deficiency(ies) identified that are not considered to be material weaknesses?

yes none reported

Noncompliance material to financial statements noted?

yes no

Federal Awards

Internal control over major programs

Material weakness(es) identified?

yes no

Significant deficiency(ies) identified that are not considered to be material weaknesses?

yes none reported

Type of auditor's report issued on compliance for major programs Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200, 516(a)

yes no

Identification of Major Programs

Name of Federal Program or Cluster

Various Assistance Listing Numbers

Research and Development,
Research Training Cluster

10.557

Food and Nutrition Services
Department of Agriculture

93.940

HIV Prevention Activities
Health Department Based

97.036

Federal Emergency Management Agency
Department of Homeland Security

Dollar Threshold used to distinguish between Type A and Type B programs

\$4,824,781

Auditee qualified as low-risk auditee?

yes no

2. Financial Statement Findings

No findings to report.

3. Federal Findings and Questioned Costs

No findings to report.

Mass General Brigham Incorporated and Affiliates
Summary Schedule of Prior Audit Findings and Status
Fiscal Year Ended September 30, 2023

No findings noted in the prior year which required follow ups in the current year.